[{"id": 119001, "ingredient1": "Irinotecan", "ingredient2": "Boceprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119139/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 119002, "ingredient1": "Irinotecan", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119140/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "updated_at": 1767369485}, {"id": 119003, "ingredient1": "Irinotecan", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119141/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119004, "ingredient1": "Irinotecan", "ingredient2": "Frangula purshiana bark", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119142/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119005, "ingredient1": "Irinotecan", "ingredient2": "Castor oil", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119143/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 119006, "ingredient1": "Irinotecan", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119144/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119007, "ingredient1": "Irinotecan", "ingredient2": "Cinoxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119145/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119008, "ingredient1": "Irinotecan", "ingredient2": "Coccidioides immitis spherule", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119146/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119009, "ingredient1": "Irinotecan", "ingredient2": "Doxacurium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119147/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119010, "ingredient1": "Irinotecan", "ingredient2": "Echinacea", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119148/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Topotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119011, "ingredient1": "Irinotecan", "ingredient2": "Efalizumab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119149/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119012, "ingredient1": "Irinotecan", "ingredient2": "Enoxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119150/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119013, "ingredient1": "Irinotecan", "ingredient2": "Entrectinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119151/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Etoposide, Cabazitaxel", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119014, "ingredient1": "Irinotecan", "ingredient2": "Enzalutamide", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119152/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119015, "ingredient1": "Irinotecan", "ingredient2": "Eslicarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119153/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119016, "ingredient1": "Irinotecan", "ingredient2": "Etanercept", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119154/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119017, "ingredient1": "Irinotecan", "ingredient2": "Etacrynic acid", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119155/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119018, "ingredient1": "Irinotecan", "ingredient2": "Etravirine", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119156/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 119019, "ingredient1": "Irinotecan", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119157/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119020, "ingredient1": "Irinotecan", "ingredient2": "Felbamate", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119158/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119021, "ingredient1": "Irinotecan", "ingredient2": "Filgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119159/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119022, "ingredient1": "Irinotecan", "ingredient2": "Fingolimod", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119160/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119023, "ingredient1": "Irinotecan", "ingredient2": "Fluconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119161/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Caspofungin, Micafungin, Amphotericin B, Flucytosine, More", "alternatives_b": "Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119024, "ingredient1": "Irinotecan", "ingredient2": "Fluvoxamine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119162/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "Topotecan, Teniposide, Cabazitaxel", "updated_at": 1767369485}, {"id": 119025, "ingredient1": "Irinotecan", "ingredient2": "Fosamprenavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119163/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 119026, "ingredient1": "Irinotecan", "ingredient2": "Fosaprepitant", "severity": "Moderate", "effect": "Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.", "source": "DDInter", "management_text": "Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119164/", "reference_text": "[1] Charasson V, Haaz MC, Robert J \"Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan.\" Drug Metab Dispos 30 (2002): 731-733[2] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[3] Clarke SJ, Rivory LP \"Clinical pharmacokinetics of docetaxel.\" Clin Pharmacokinet 36 (1999): 99-114[4] \"Product Information. Emend (aprepitant).\" Merck & Company Inc, West Point, PA.[5] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Company Inc, West Point, PA.[6] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30", "alternatives_a": "Topotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119027, "ingredient1": "Irinotecan", "ingredient2": "Fosphenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119165/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119028, "ingredient1": "Irinotecan", "ingredient2": "Fostamatinib", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119166/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals, South San Francisco, CA.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119029, "ingredient1": "Irinotecan", "ingredient2": "Fostemsavir", "severity": "Moderate", "effect": "Coadministration with fostemsavir may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). Temsavir, the active moiety of fostemsavir, is an inhibitor of OATP 1B1 and 1B3. Additionally, temsavir and two metabolites are inhibitors of BCRP.", "source": "DDInter", "management_text": "Caution is advised when fostemsavir is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostemsavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostemsavir is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119167/", "reference_text": "[1] \"Product Information. Rukobia (fostemsavir).\" ViiV Healthcare, Research Triangle Park, NC.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 119030, "ingredient1": "Irinotecan", "ingredient2": "Furosemide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119168/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119031, "ingredient1": "Irinotecan", "ingredient2": "Ganciclovir", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119169/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119032, "ingredient1": "Irinotecan", "ingredient2": "Gatifloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119170/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 119033, "ingredient1": "Irinotecan", "ingredient2": "Gemfibrozil", "severity": "Major", "effect": "Coadministration with strong inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with strong inhibitors of CYP450 3A4 and/or UGT1A1 should generally be avoided. If coadministration is required, patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with strong inhibitors of CYP450 3A4 and/or UGT1A1 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119171/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[6] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[7] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Lovastatin, Cholestyramine, Clofibrate, Cerivastatin, More", "updated_at": 1767369485}, {"id": 119034, "ingredient1": "Irinotecan", "ingredient2": "Gemifloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119172/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119035, "ingredient1": "Irinotecan", "ingredient2": "Glasdegib", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119173/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Docetaxel", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 119036, "ingredient1": "Irinotecan", "ingredient2": "Glycerin", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119174/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 119037, "ingredient1": "Irinotecan", "ingredient2": "Goldenseal", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119175/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119038, "ingredient1": "Irinotecan", "ingredient2": "Golimumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119176/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119039, "ingredient1": "Irinotecan", "ingredient2": "Grepafloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119177/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119040, "ingredient1": "Irinotecan", "ingredient2": "Griseofulvin", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119178/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Terbinafine, Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Clotrimazole, Chlorphenesin", "alternatives_b": "Topotecan, Teniposide, Etoposide", "updated_at": 1767369485}, {"id": 119041, "ingredient1": "Irinotecan", "ingredient2": "Hepatitis A Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119179/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119042, "ingredient1": "Irinotecan", "ingredient2": "Hepatitis B Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119180/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119043, "ingredient1": "Irinotecan", "ingredient2": "Human papillomavirus type 11 L1 capsid protein antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119181/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119044, "ingredient1": "Irinotecan", "ingredient2": "Hydroflumethiazide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119182/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "updated_at": 1767369485}, {"id": 119045, "ingredient1": "Irinotecan", "ingredient2": "Idelalisib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119183/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119046, "ingredient1": "Irinotecan", "ingredient2": "Imatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119184/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Teniposide", "updated_at": 1767369485}, {"id": 119047, "ingredient1": "Irinotecan", "ingredient2": "Indapamide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119185/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Felodipine, Moexipril, Perindopril, Bisoprolol, Benazepril, Trandolapril, Captopril, Fosinopril, Tinidazole, Ascorbic acid, Simeprevir, More", "updated_at": 1767369485}, {"id": 119048, "ingredient1": "Irinotecan", "ingredient2": "Indinavir", "severity": "Major", "effect": "Coadministration with strong inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with strong inhibitors of CYP450 3A4 and/or UGT1A1 should generally be avoided. If coadministration is required, patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with strong inhibitors of CYP450 3A4 and/or UGT1A1 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119186/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[6] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[7] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Topotecan, Teniposide, Etoposide", "updated_at": 1767369485}, {"id": 119049, "ingredient1": "Irinotecan", "ingredient2": "Infliximab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119187/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119050, "ingredient1": "Irinotecan", "ingredient2": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119188/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119051, "ingredient1": "Irinotecan", "ingredient2": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119189/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119052, "ingredient1": "Isavuconazonium", "ingredient2": "Irinotecan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119190/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119053, "ingredient1": "Isoniazid", "ingredient2": "Irinotecan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119191/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "updated_at": 1767369485}, {"id": 119054, "ingredient1": "Isosorbide", "ingredient2": "Irinotecan", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119192/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119055, "ingredient1": "Itraconazole", "ingredient2": "Irinotecan", "severity": "Major", "effect": "Coadministration with certain azole antifungal agents may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with ketoconazole or itraconazole is considered contraindicated. Ketoconazole should be discontinued for at least one week before initiation of treatment with irinotecan, and itraconazole should be discontinued for up to two weeks before. Some authorities consider concomitant administration of irinotecan to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with ketoconazole or itraconazole is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119193/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[3] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[4] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Nizoral (ketoconazole).\" Janssen Pharmaceutica, Titusville, NJ. (1992):[8] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 119056, "ingredient1": "Irinotecan", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119194/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 119057, "ingredient1": "Irinotecan", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with certain azole antifungal agents may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with ketoconazole or itraconazole is considered contraindicated. Ketoconazole should be discontinued for at least one week before initiation of treatment with irinotecan, and itraconazole should be discontinued for up to two weeks before. Some authorities consider concomitant administration of irinotecan to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with ketoconazole or itraconazole is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119195/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[3] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[4] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Nizoral (ketoconazole).\" Janssen Pharmaceutica, Titusville, NJ. (1992):[8] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "updated_at": 1767369485}, {"id": 119058, "ingredient1": "Irinotecan", "ingredient2": "Lactitol", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119196/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 119059, "ingredient1": "Irinotecan", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119197/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119060, "ingredient1": "Irinotecan", "ingredient2": "Lactulose", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119198/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119061, "ingredient1": "Irinotecan", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119199/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Vinorelbine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119062, "ingredient1": "Irinotecan", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119200/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Cabazitaxel", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119063, "ingredient1": "Irinotecan", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119201/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Teniposide, Trabectedin", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More", "updated_at": 1767369485}, {"id": 119064, "ingredient1": "Irinotecan", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119202/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Topotecan", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, More", "updated_at": 1767369485}, {"id": 119065, "ingredient1": "Irinotecan", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119203/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119066, "ingredient1": "Irinotecan", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119204/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "updated_at": 1767369485}, {"id": 119067, "ingredient1": "Irinotecan", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119205/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 119068, "ingredient1": "Irinotecan", "ingredient2": "Levofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119206/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cabazitaxel", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Tinidazole, Tetracycline, More", "updated_at": 1767369485}, {"id": 119069, "ingredient1": "Irinotecan", "ingredient2": "Lomefloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119207/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 119070, "ingredient1": "Irinotecan", "ingredient2": "Lomitapide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119208/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Teniposide, Etoposide", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Lovastatin, Cholestyramine, Clofibrate, Cerivastatin, More", "updated_at": 1767369485}, {"id": 119071, "ingredient1": "Irinotecan", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119209/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119072, "ingredient1": "Irinotecan", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119210/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119073, "ingredient1": "Irinotecan", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119211/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119074, "ingredient1": "Irinotecan", "ingredient2": "Magnesium citrate", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119212/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium aspartate, More", "updated_at": 1767369485}, {"id": 119075, "ingredient1": "Irinotecan", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119213/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 119076, "ingredient1": "Irinotecan", "ingredient2": "Mannitol", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119214/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Sorbitol, Sulfamethizole, Sodium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vincristine, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119077, "ingredient1": "Irinotecan", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119215/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119078, "ingredient1": "Irinotecan", "ingredient2": "Meningococcal polysaccharide vaccine group C", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119216/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119079, "ingredient1": "Irinotecan", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119217/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119080, "ingredient1": "Irinotecan", "ingredient2": "Methazolamide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119218/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "updated_at": 1767369485}, {"id": 119081, "ingredient1": "Irinotecan", "ingredient2": "Metocurine", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119219/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119082, "ingredient1": "Irinotecan", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119220/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "updated_at": 1767369485}, {"id": 119083, "ingredient1": "Irinotecan", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119221/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 119084, "ingredient1": "Irinotecan", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119222/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 119085, "ingredient1": "Irinotecan", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with midostaurin may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and/or organic anion transporting polypeptide (OATP) 1B1 transporters. The proposed mechanism, based on in vitro data, is decreased clearance due to midostaurin-mediated inhibition of P-gp, BCRP, and/or OATP1B1 transport proteins.", "source": "DDInter", "management_text": "Caution is advised if midostaurin is used concomitantly with drugs that are substrates of P-gp, BCRP, and/or OATP1B1 transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever midostaurin is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if midostaurin is used concomitantly with drugs that are substrates of P-gp, BCRP, and/or OATP1B1 transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119223/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Teniposide, Trabectedin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119086, "ingredient1": "Irinotecan", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119224/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 119087, "ingredient1": "Irinotecan", "ingredient2": "Mineral oil", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119225/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 119088, "ingredient1": "Irinotecan", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119226/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine", "updated_at": 1767369485}, {"id": 119089, "ingredient1": "Irinotecan", "ingredient2": "Mivacurium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119227/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119090, "ingredient1": "Irinotecan", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119228/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Topotecan", "updated_at": 1767369485}, {"id": 119091, "ingredient1": "Irinotecan", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119229/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119092, "ingredient1": "Irinotecan", "ingredient2": "Moxifloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119230/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Gentamicin, More", "alternatives_b": "Cabazitaxel", "updated_at": 1767369485}, {"id": 119093, "ingredient1": "Irinotecan", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119231/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119094, "ingredient1": "Irinotecan", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119232/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "updated_at": 1767369485}, {"id": 119095, "ingredient1": "Irinotecan", "ingredient2": "Nalidixic acid", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119233/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119096, "ingredient1": "Irinotecan", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119234/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119097, "ingredient1": "Irinotecan", "ingredient2": "Nefazodone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119235/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 119098, "ingredient1": "Irinotecan", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119236/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119099, "ingredient1": "Irinotecan", "ingredient2": "Neratinib", "severity": "Moderate", "effect": "Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein. There are no clinical data regarding the use of neratinib with BCRP substrates.", "source": "DDInter", "management_text": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Others", "recommendation": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119237/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119100, "ingredient1": "Irinotecan", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119238/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Topotecan", "updated_at": 1767369485}, {"id": 119101, "ingredient1": "Irinotecan", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119239/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119102, "ingredient1": "Irinotecan", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.", "source": "DDInter", "management_text": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119240/", "reference_text": "[1] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119103, "ingredient1": "Irinotecan", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119241/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "updated_at": 1767369485}, {"id": 119104, "ingredient1": "Irinotecan", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119242/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119105, "ingredient1": "Irinotecan", "ingredient2": "Ofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119243/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "updated_at": 1767369485}, {"id": 119106, "ingredient1": "Irinotecan", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119244/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119107, "ingredient1": "Irinotecan", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119245/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119108, "ingredient1": "Irinotecan", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119246/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119109, "ingredient1": "Irinotecan", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with osimertinib may increase the exposure of breast cancer resistance protein (BCRP) transporter substrates. In vitro studies have shown that osimertinib is a competitive inhibitor of BCRP.", "source": "DDInter", "management_text": "Caution is recommended if osimertinib is used in combination with drugs that are substrates of the BCRP transporter, particularly those with a narrow therapeutic index. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever osimertinib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is recommended if osimertinib is used in combination with drugs that are substrates of the BCRP transporter, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119247/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Trabectedin, Cabazitaxel, Paclitaxel, Teniposide, Etoposide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119110, "ingredient1": "Irinotecan", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Several case reports have suggested that coadministration of oxaliplatin may increase the incidence and/or severity of irinotecan-induced cholinergic syndrome. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for cholinergic symptoms (e.g., rhinitis, miosis, lacrimation, hypersalivation, diaphoresis, flushing, abdominal cramps, and diarrhea). Subcutaneous atropine has been used to prevent and treat symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for cholinergic symptoms (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119248/", "reference_text": "[1] Cvitkovic E, Marty M, Wasserman E, Cuvier C, Goldwasser F, Misset JL \"Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.\" J Natl Cancer Inst 90 (1998): 1016-7[2] Dodds HM, Bishop JF, Rivory LP \"More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.\" J Natl Cancer Inst 91 (1999): 91-2[3] Valencak J, Raderer M, Kornek GV, Henja MH, Scheithauer W \"Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.\" J Natl Cancer Inst 90 (1998): 160", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119111, "ingredient1": "Irinotecan", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119249/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119112, "ingredient1": "Irinotecan", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119250/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119113, "ingredient1": "Irinotecan", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119251/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Teniposide, Etoposide, Cabazitaxel", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119114, "ingredient1": "Irinotecan", "ingredient2": "Palifermin", "severity": "Moderate", "effect": "INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.", "source": "DDInter", "management_text": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "mechanism_text": "Others", "recommendation": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119252/", "reference_text": "[1] \"Product Information. Kepivance (palifermin).\" Shire US Inc, Florence, KY.", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119115, "ingredient1": "Irinotecan", "ingredient2": "Bromotheophylline", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119253/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 119116, "ingredient1": "Irinotecan", "ingredient2": "Pancuronium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119254/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119117, "ingredient1": "Irinotecan", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with pazopanib may increase the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. The proposed mechanism is pazopanib inhibition of UGT1A1 and CYP450 3A4, the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism. Pazopanib is a potent inhibitor of UGT1A1 and weak inhibitor of CYP450 3A4 in vitro. However, its potential effects on the pharmacokinetics of irinotecan have not been studied.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with pazopanib. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with pazopanib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119255/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119118, "ingredient1": "Irinotecan", "ingredient2": "Pegfilgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119256/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119119, "ingredient1": "Irinotecan", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119257/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "updated_at": 1767369485}, {"id": 119120, "ingredient1": "Irinotecan", "ingredient2": "Pexidartinib", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119258/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan, Etoposide, Vinblastine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119121, "ingredient1": "Irinotecan", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119259/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 119122, "ingredient1": "Irinotecan", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119260/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Ketoprofen, Piroxicam, Meclofenamic acid, Sulindac, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, Naproxen, Esomeprazole, More", "updated_at": 1767369485}, {"id": 119123, "ingredient1": "Irinotecan", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119261/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "alternatives_b": "Topotecan", "updated_at": 1767369485}, {"id": 119124, "ingredient1": "Irinotecan", "ingredient2": "Pipecuronium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119262/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119125, "ingredient1": "Irinotecan", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Coadministration with pitolisant may reduce plasma concentrations of substrates of CYP450 2C, P-glycoprotein (P-gp), and uridine diphosphate glucuronosyltransferases (UGTs). Based on in vitro data, pitolisant and its main metabolites may induce CYP450 2C, P-gp, and UGTs.", "source": "DDInter", "management_text": "Caution is recommended if pitolisant is used in combination with substrates of CYP450 2C, P-gp, and/or UGTs. Clinical and laboratory monitoring may be appropriate for some drugs whenever pitolisant is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if pitolisant is used in combination with substrates of CYP450 2C, P-gp, and/or UGTs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119263/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Trabectedin, Cabazitaxel, Paclitaxel, Topotecan, Teniposide, Docetaxel", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine", "updated_at": 1767369485}, {"id": 119126, "ingredient1": "Irinotecan", "ingredient2": "Polyethylene glycol (3350)", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119264/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119127, "ingredient1": "Irinotecan", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119265/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "updated_at": 1767369485}, {"id": 119128, "ingredient1": "Irinotecan", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119266/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 119129, "ingredient1": "Irinotecan", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119267/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Topotecan", "alternatives_b": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "updated_at": 1767369485}, {"id": 119130, "ingredient1": "Irinotecan", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119268/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119131, "ingredient1": "Irinotecan", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119269/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Alprostadil, Indomethacin, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Topotecan, Teniposide, Etoposide, Paclitaxel", "updated_at": 1767369485}, {"id": 119132, "ingredient1": "Irinotecan", "ingredient2": "Rapacuronium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119270/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119133, "ingredient1": "Irinotecan", "ingredient2": "Regorafenib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119271/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119134, "ingredient1": "Irinotecan", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119272/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119135, "ingredient1": "Irinotecan", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119273/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "updated_at": 1767369485}, {"id": 119136, "ingredient1": "Irinotecan", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119274/", "reference_text": "[1] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[2] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[3] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[5] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[6] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[7] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[8] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[9] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[10] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[11] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9", "alternatives_a": "Topotecan", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "updated_at": 1767369485}, {"id": 119137, "ingredient1": "Irinotecan", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119275/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119138, "ingredient1": "Irinotecan", "ingredient2": "Rocuronium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119276/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "updated_at": 1767369485}, {"id": 119139, "ingredient1": "Irinotecan", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119277/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119140, "ingredient1": "Irinotecan", "ingredient2": "Rolapitant", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.", "source": "DDInter", "management_text": "Caution is advised when rolapitant is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Distribution", "recommendation": "Caution is advised when rolapitant is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119278/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel", "alternatives_b": "Scopolamine, Nabilone, Dronabinol", "updated_at": 1767369485}, {"id": 119141, "ingredient1": "Irinotecan", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119279/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Cabazitaxel", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 119142, "ingredient1": "Irinotecan", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119280/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Cabazitaxel, Paclitaxel, Topotecan, Teniposide, Vinorelbine", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119143, "ingredient1": "Irinotecan", "ingredient2": "Sacituzumab govitecan", "severity": "Major", "effect": "Coadministration of sacituzumab govitecan with irinotecan may increase the risk of adverse effects, such as severe neutropenia, nausea, vomiting, and diarrhea. The proposed mechanism involves increased exposure to SN-38, a potent topoisomerase I inhibitor. SN-38 is the pharmacologically active metabolite of irinotecan, and considered to be approximately 1000 times more potent than irinotecan. However, SN-38 is also delivered to Trop-2-expressing cancer cells via the Trop-2-directed antibody drug conjugate sacituzumab govitecan-hziy. SN-38 is covalently attached to sacituzumab govitecan, which binds to Trop-2-expressing cancer cells and allows for internalization of SN-38 into these cells to interact with topoisomerase I.", "source": "DDInter", "management_text": "Sacituzumab govitecan should not be substituted for or used with other drugs containing irinotecan or the active metabolite SN-38.", "mechanism_text": "Synergism", "recommendation": "Sacituzumab govitecan should not be substituted for or used with other drugs containing irinotecan or the active metabolite SN-38.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119281/", "reference_text": "[1] \"Product Information. Trodelvy (sacituzumab govitecan).\" Immunomedics, Morris Plains, NJ.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 119144, "ingredient1": "Irinotecan", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "Coadministration with safinamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to intestinal BCRP-inhibition by safinamide.", "source": "DDInter", "management_text": "Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever safinamide is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119282/", "reference_text": "[1] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[2] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More", "updated_at": 1767369485}, {"id": 119145, "ingredient1": "Irinotecan", "ingredient2": "Samarium (153Sm) lexidronam", "severity": "Major", "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119283/", "reference_text": "[1] \"Product Information. Quadramet (samarium sm 153 lexidronam)\" Berlex Laboratories, Richmond, CA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119146, "ingredient1": "Irinotecan", "ingredient2": "Sargramostim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119284/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119147, "ingredient1": "Irinotecan", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119285/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119148, "ingredient1": "Irinotecan", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119286/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Topotecan, Teniposide, Etoposide", "updated_at": 1767369485}, {"id": 119149, "ingredient1": "Irinotecan", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119287/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119150, "ingredient1": "Irinotecan", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119288/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119151, "ingredient1": "Irinotecan", "ingredient2": "Sipuleucel-T", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119289/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119152, "ingredient1": "Irinotecan", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119290/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Topotecan, Teniposide, Trabectedin", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, More", "updated_at": 1767369485}, {"id": 119153, "ingredient1": "Irinotecan", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119291/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119154, "ingredient1": "Irinotecan", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119292/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119155, "ingredient1": "Irinotecan", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119293/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 119156, "ingredient1": "Irinotecan", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119294/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 119157, "ingredient1": "Irinotecan", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119295/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Topotecan", "updated_at": 1767369485}, {"id": 119158, "ingredient1": "Irinotecan", "ingredient2": "Sorafenib", "severity": "Moderate", "effect": "Coadministration with sorafenib may increase the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. The proposed mechanism is sorafenib inhibition of CYP450 3A4 and UGT1A1, the enzymes responsible for the metabolic clearance of irinotecan and SN-38, respectively.", "source": "DDInter", "management_text": "Sorafenib product labeling recommends caution during coadministration with irinotecan. High plasma levels of irinotecan and SN-38 may result in increased toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "mechanism_text": "Metabolism", "recommendation": "Sorafenib product labeling recommends caution during coadministration with irinotecan.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119296/", "reference_text": "[1] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Mross K, Steinbild S, Baas F, et al. \"Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.\" Int J Clin Pharmacol Ther 41 (2003): 618-9[3] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Teniposide", "updated_at": 1767369485}, {"id": 119159, "ingredient1": "Irinotecan", "ingredient2": "Sparfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119297/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119160, "ingredient1": "Irinotecan", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "St. John's wort may significantly reduce the antineoplastic effectiveness of irinotecan. The mechanism is induction of CYP450 3A4, the isoenzyme that is partially responsible for the metabolic clearance of irinotecan.", "source": "DDInter", "management_text": "The use of St. John's wort should be avoided before and during the entire course of chemotherapy. It is not known how much time should elapse between the discontinuation of St. John's wort and initiation of chemotherapy.", "mechanism_text": "Metabolism", "recommendation": "The use of St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119298/", "reference_text": "[1] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Topotecan", "alternatives_b": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 119161, "ingredient1": "Irinotecan", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119299/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Vincristine, Vinblastine", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 119162, "ingredient1": "Irinotecan", "ingredient2": "Strontium chloride Sr-89", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119300/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119163, "ingredient1": "Irinotecan", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119301/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Lesinurad, Febuxostat, Colchicine, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 119164, "ingredient1": "Irinotecan", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119302/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "updated_at": 1767369485}, {"id": 119165, "ingredient1": "Irinotecan", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119303/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Topotecan, Teniposide, Trabectedin", "alternatives_b": "Minoxidil, Deoxycholic acid, Pimecrolimus, Calcium gluconate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, More", "updated_at": 1767369485}, {"id": 119166, "ingredient1": "Irinotecan", "ingredient2": "Tafamidis", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations. The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein.", "source": "DDInter", "management_text": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119304/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. Vyndaqel (tafamidis).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine", "updated_at": 1767369485}, {"id": 119167, "ingredient1": "Irinotecan", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119305/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119168, "ingredient1": "Irinotecan", "ingredient2": "Tazemetostat", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119306/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan, Docetaxel", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 119169, "ingredient1": "Irinotecan", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119307/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 119170, "ingredient1": "Irinotecan", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119308/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan", "alternatives_b": "Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 119171, "ingredient1": "Irinotecan", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119309/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Topotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119172, "ingredient1": "Irinotecan", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119310/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Topotecan, Teniposide, Trabectedin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 119173, "ingredient1": "Irinotecan", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119311/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119174, "ingredient1": "Irinotecan", "ingredient2": "Thalidomide", "severity": "Major", "effect": "Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism. The exact mechanism is unknown but likely multifactorial.", "source": "DDInter", "management_text": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119312/", "reference_text": "[1] Fine HA, Wen PY, Maher EA, et al. \"Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas.\" J Clin Oncol 21 (2003): 2299-304[2] Zangari M, Siegel E, Barlogie B, et al \"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.\" Blood 100 (2002): 1168-71[3] Figg WD, Arlen P, Gulley J, et al. \"A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.\" Semin Oncol 28(4 Suppl 15) (2001): 62-6[4] Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM \"A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.\" Cancer 95 (2002): 1629-36[5] Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J \"Thromboembolic events during treatment with thalidomide.\" Blood 99 (2002): 4247-8[6] Lee CK, Barlogie B, Munshi N, et al \"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.\" J Clin Oncol 21 (2003): 2732-9[7] Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R \"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.\" J Clin Oncol 21 (2003): 16-9[8] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[9] Cavo M, Zamagni E, Cellini C, et al. \"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.\" Blood 100 (2002): 2272-3[10] Bennett CL, Nebeker JR, Samore MH, et al \"The Research on Adverse Drug Events and Reports (RADAR) project.\" JAMA 293 (2005): 2131-40[11] Zangari M, Anaissie E, Barlogie B, et al \"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.\" Blood 98 (2001): 1614-5[12] Rajkumar SV, Hayman S, Gertz MA, et al. \"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.\" J Clin Oncol 20 (2002): 4319-23[13] Osman K, Comenzo R, Rajkumar SV \"Deep venous thrombosis and thalidomide therapy for multiple myeloma.\" N Engl J Med 344 (2001): 1951-2[14] Zangari M, Barlogie B, Anaissie E, et al \"Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.\" Br J Haematol 126 (2004): 715-21[15] Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A \"Thalidomide and venous thrombosis.\" Ann Intern Med 136 (2002): 711[16] Bennett CL, Schumock GT, Desai AA, et al \"Thalidomide-associated deep vein thrombosis and pulmonary embolism.\" Am J Med 113 (2002): 603-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119175, "ingredient1": "Irinotecan", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119313/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Etoposide, Paclitaxel", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "updated_at": 1767369485}, {"id": 119176, "ingredient1": "Irinotecan", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119314/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119177, "ingredient1": "Irinotecan", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119315/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Topotecan", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Teniposide, Irinotecan", "updated_at": 1767369485}, {"id": 119178, "ingredient1": "Irinotecan", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119316/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119179, "ingredient1": "Irinotecan", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119317/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "updated_at": 1767369485}, {"id": 119180, "ingredient1": "Irinotecan", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119318/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "updated_at": 1767369485}, {"id": 119181, "ingredient1": "Irinotecan", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119319/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119182, "ingredient1": "Irinotecan", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119320/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Topotecan, Teniposide, Etoposide, Vinorelbine", "updated_at": 1767369485}, {"id": 119183, "ingredient1": "Irinotecan", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119321/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 119184, "ingredient1": "Irinotecan", "ingredient2": "Trovafloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119322/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119185, "ingredient1": "Irinotecan", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119323/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119186, "ingredient1": "Irinotecan", "ingredient2": "Tubocurarine", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119324/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119187, "ingredient1": "Irinotecan", "ingredient2": "Tucatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119325/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119188, "ingredient1": "Irinotecan", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119326/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119189, "ingredient1": "Irinotecan", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119327/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119190, "ingredient1": "Irinotecan", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119328/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119191, "ingredient1": "Irinotecan", "ingredient2": "Ustekinumab", "severity": "Moderate", "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119329/", "reference_text": "[1] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119192, "ingredient1": "Irinotecan", "ingredient2": "Valganciclovir", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119330/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119193, "ingredient1": "Irinotecan", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119331/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119194, "ingredient1": "Irinotecan", "ingredient2": "Vecuronium", "severity": "Minor", "effect": "Theoretically, irinotecan may antagonize the pharmacologic effect of nondepolarizing neuromuscular blocking agents due to its anticholinesterase activity, resulting in increased dosage requirements for adequate skeletal muscle relaxation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119332/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119195, "ingredient1": "Irinotecan", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119333/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Vinblastine, Teniposide, Vinorelbine, Etoposide", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "updated_at": 1767369485}, {"id": 119196, "ingredient1": "Irinotecan", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119334/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119197, "ingredient1": "Irinotecan", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119335/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin", "alternatives_b": "Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 119198, "ingredient1": "Irinotecan", "ingredient2": "Voxelotor", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119336/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 119199, "ingredient1": "Irinotecan", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119337/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119200, "ingredient1": "Irinotecan", "ingredient2": "Zafirlukast", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119338/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Topotecan", "updated_at": 1767369485}, {"id": 119201, "ingredient1": "Iron", "ingredient2": "Iron Dextran", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119339/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119202, "ingredient1": "Iron Dextran", "ingredient2": "Ferrous fumarate", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119340/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119203, "ingredient1": "Iron Dextran", "ingredient2": "Ferrous gluconate", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119341/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119204, "ingredient1": "Iron Dextran", "ingredient2": "Ferrous sulfate anhydrous", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119342/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119205, "ingredient1": "Iron Dextran", "ingredient2": "Fosinopril", "severity": "Major", "effect": "Limited data suggest that ACE inhibitors may increase the risk of systemic adverse effects associated with the use of iron dextran. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from parenteral iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions. Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran. Such reactions occur most often within the first several minutes of administration and are generally characterized by sudden onset of respiratory difficulty and/or cardiovascular collapse. The extent of risk for anaphylactic-type reactions following exposure to any specific iron dextran product is unknown, but may vary among the products due to differences in chemical characteristics.", "source": "DDInter", "management_text": "Patients should be closely monitored during and after parenteral administration of iron dextran, regardless of whether they are being treated with an ACE inhibitor. This is particularly important in patients with a history of drug allergy or multiple drug allergies or an immune/inflammatory condition such as systemic lupus erythematosus or rheumatoid arthritis. Resuscitation techniques and personnel trained in the detection and treatment of anaphylactic-type reactions should be readily available. Prior to the first therapeutic dose, a test dose corresponding to 25 mg iron should be injected gradually. Although anaphylactic reactions are usually evident within a few minutes, observe patients for at least one hour before administering the remainder of the therapeutic dose. Administration must be stopped immediately if signs of an anaphylactoid reaction are observed. Patients should also be closely monitored during each subsequent administration of iron dextran. Fatal reactions have occurred following the test dose and also in situations where the test dose was tolerated. According to some studies, non-dextran parenteral iron formulations may be associated with a lower risk of adverse effects, especially death and life-threatening reactions such as anaphylaxis, cardiac arrest, and respiratory depression.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored during and after parenteral administration of iron dextran, regardless of whether they are being treated with an ACE inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119343/", "reference_text": "[1] Bailie GR, Clark JA, Lane CE, Lane PL \"Hypersensitivity reactions and deaths associated with intravenous iron preparations.\" Nephrol Dial Transplant 20 (2005): 1443-9[2] Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J \"On the relative safety of parenteral iron formulations.\" Nephrol Dial Transplant 19 (2004): 1571-5[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J \"Update on adverse drug events associated with parenteral iron.\" Nephrol Dial Transplant 21 (2006): 378-82[5] Faich G, Strobos J \"Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans.\" Am J Kidney Dis 33 (1999): 464-70[6] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[7] Fishbane S, Kowalski EA \"The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.\" Semin Dial 13 (2000): 381-4[8] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[9] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[10] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[11] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[12] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119206, "ingredient1": "Iron Dextran", "ingredient2": "Gallium chloride Ga-67", "severity": "Moderate", "effect": "The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.", "source": "DDInter", "management_text": "Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119344/", "reference_text": "[1] \"Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga)).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119207, "ingredient1": "Iron protein succinylate", "ingredient2": "Iron Dextran", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119345/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119208, "ingredient1": "Iron Dextran", "ingredient2": "Ramipril", "severity": "Major", "effect": "Limited data suggest that ACE inhibitors may increase the risk of systemic adverse effects associated with the use of iron dextran. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from parenteral iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions. Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran. Such reactions occur most often within the first several minutes of administration and are generally characterized by sudden onset of respiratory difficulty and/or cardiovascular collapse. The extent of risk for anaphylactic-type reactions following exposure to any specific iron dextran product is unknown, but may vary among the products due to differences in chemical characteristics.", "source": "DDInter", "management_text": "Patients should be closely monitored during and after parenteral administration of iron dextran, regardless of whether they are being treated with an ACE inhibitor. This is particularly important in patients with a history of drug allergy or multiple drug allergies or an immune/inflammatory condition such as systemic lupus erythematosus or rheumatoid arthritis. Resuscitation techniques and personnel trained in the detection and treatment of anaphylactic-type reactions should be readily available. Prior to the first therapeutic dose, a test dose corresponding to 25 mg iron should be injected gradually. Although anaphylactic reactions are usually evident within a few minutes, observe patients for at least one hour before administering the remainder of the therapeutic dose. Administration must be stopped immediately if signs of an anaphylactoid reaction are observed. Patients should also be closely monitored during each subsequent administration of iron dextran. Fatal reactions have occurred following the test dose and also in situations where the test dose was tolerated. According to some studies, non-dextran parenteral iron formulations may be associated with a lower risk of adverse effects, especially death and life-threatening reactions such as anaphylaxis, cardiac arrest, and respiratory depression.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored during and after parenteral administration of iron dextran, regardless of whether they are being treated with an ACE inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119346/", "reference_text": "[1] Bailie GR, Clark JA, Lane CE, Lane PL \"Hypersensitivity reactions and deaths associated with intravenous iron preparations.\" Nephrol Dial Transplant 20 (2005): 1443-9[2] Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J \"On the relative safety of parenteral iron formulations.\" Nephrol Dial Transplant 19 (2004): 1571-5[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J \"Update on adverse drug events associated with parenteral iron.\" Nephrol Dial Transplant 21 (2006): 378-82[5] Faich G, Strobos J \"Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans.\" Am J Kidney Dis 33 (1999): 464-70[6] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[7] Fishbane S, Kowalski EA \"The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.\" Semin Dial 13 (2000): 381-4[8] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[9] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[10] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[11] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[12] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Simvastatin, Atorvastatin, Lovastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119209, "ingredient1": "Iron Dextran", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.", "source": "DDInter", "management_text": "Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119347/", "reference_text": "[1] Melhorn DK, Gross S \"Relationships between iron-dextran and vitamin E in iron deficiency anemia in children.\" J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA \"The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction.\" J Pediatr 90 (1977): 282-4", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119210, "ingredient1": "Iron sucrose", "ingredient2": "Iron", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119348/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More", "updated_at": 1767369485}, {"id": 119211, "ingredient1": "Iron sucrose", "ingredient2": "Ferrous fumarate", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119349/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 119212, "ingredient1": "Iron sucrose", "ingredient2": "Ferrous gluconate", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119350/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 119213, "ingredient1": "Iron sucrose", "ingredient2": "Ferrous sulfate anhydrous", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119351/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119214, "ingredient1": "Iron sucrose", "ingredient2": "Fosinopril", "severity": "Moderate", "effect": "Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from intravenous iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions.", "source": "DDInter", "management_text": "No specific intervention is necessary to avert a potential interaction. However, patients should be closely monitored during and after parenteral iron treatment.", "mechanism_text": "Others", "recommendation": "No specific intervention is necessary to avert a potential interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119352/", "reference_text": "[1] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.[2] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[5] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[6] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, More", "updated_at": 1767369485}, {"id": 119215, "ingredient1": "Iron sucrose", "ingredient2": "Gallium chloride Ga-67", "severity": "Moderate", "effect": "The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.", "source": "DDInter", "management_text": "Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119353/", "reference_text": "[1] \"Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga)).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Cyanocobalamin, Folic acid, Ferric maltol, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119216, "ingredient1": "Iron sucrose", "ingredient2": "Iron protein succinylate", "severity": "Moderate", "effect": "Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.", "source": "DDInter", "management_text": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.", "mechanism_text": "Absorption", "recommendation": "Parenteral iron preparations should not be administered concomitantly with oral iron preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119354/", "reference_text": "[1] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[2] \"Product Information. Feraheme (ferumoxytol).\" Alza Pharmaceuticals, Mountain View, CA.[3] \"Product Information. Venofer (iron sucrose)\" American Regent Laboratories Inc, Shirley, NY.[4] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 119217, "ingredient1": "Iron sucrose", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from intravenous iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions.", "source": "DDInter", "management_text": "No specific intervention is necessary to avert a potential interaction. However, patients should be closely monitored during and after parenteral iron treatment.", "mechanism_text": "Others", "recommendation": "No specific intervention is necessary to avert a potential interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119355/", "reference_text": "[1] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.[2] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[5] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[6] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Simvastatin, Atorvastatin, Lovastatin, More", "alternatives_b": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, More", "updated_at": 1767369485}, {"id": 119218, "ingredient1": "Iron sucrose", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from intravenous iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions.", "source": "DDInter", "management_text": "No specific intervention is necessary to avert a potential interaction. However, patients should be closely monitored during and after parenteral iron treatment.", "mechanism_text": "Others", "recommendation": "No specific intervention is necessary to avert a potential interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119356/", "reference_text": "[1] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.[2] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[5] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[6] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, More", "updated_at": 1767369485}, {"id": 119219, "ingredient1": "Iron sucrose", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from intravenous iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions.", "source": "DDInter", "management_text": "No specific intervention is necessary to avert a potential interaction. However, patients should be closely monitored during and after parenteral iron treatment.", "mechanism_text": "Others", "recommendation": "No specific intervention is necessary to avert a potential interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119357/", "reference_text": "[1] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.[2] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[5] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[6] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Iron, Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 119220, "ingredient1": "Iron sucrose", "ingredient2": "Ramipril", "severity": "Moderate", "effect": "Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron. The exact mechanism of interaction is unclear. Certain systemic reactions stemming from intravenous iron therapy are thought to be mediated by inflammatory substances such as bradykinin in response to iron-catalyzed generation of toxic free radicals. Since ACE inhibitors decrease the breakdown of kinins, it is conceivable that they may potentiate these reactions.", "source": "DDInter", "management_text": "No specific intervention is necessary to avert a potential interaction. However, patients should be closely monitored during and after parenteral iron treatment.", "mechanism_text": "Others", "recommendation": "No specific intervention is necessary to avert a potential interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119358/", "reference_text": "[1] \"Product Information. Ferrlecit (sodium ferric gluconate complex).\" sanofi-aventis, Bridgewater, NJ.[2] Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG \"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.\" Nephrol Dial Transplant 19 (2004): 1576-80[3] \"Product Information. INFeD (iron dextran).\" Schein Pharmaceuticals Inc, Florham Park, NJ.[4] Michael B, Coyne DW, Fishbane S, et al. \"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.\" Kidney Int 61 (2002): 1830-1839[5] Rolla G, Bucca C, Brussino L \"Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor .\" J Allergy Clin Immunol 93 (1994): 1074-5[6] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Simvastatin, Atorvastatin, Lovastatin, More", "alternatives_b": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, More", "updated_at": 1767369485}, {"id": 119221, "ingredient1": "Iron sucrose", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.", "source": "DDInter", "management_text": "Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119359/", "reference_text": "[1] Melhorn DK, Gross S \"Relationships between iron-dextran and vitamin E in iron deficiency anemia in children.\" J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA \"The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction.\" J Pediatr 90 (1977): 282-4", "alternatives_a": "Cyanocobalamin, Folic acid, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119222, "ingredient1": "Isatuximab", "ingredient2": "Human adenovirus e serotype 4 strain cl-68578 antigen", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119360/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119223, "ingredient1": "Isatuximab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119361/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119224, "ingredient1": "Isatuximab", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119362/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119225, "ingredient1": "Isatuximab", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119363/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119226, "ingredient1": "Isatuximab", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119364/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119227, "ingredient1": "Isatuximab", "ingredient2": "Coccidioides immitis spherule", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119365/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119228, "ingredient1": "Isatuximab", "ingredient2": "Cytarabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119366/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine, Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119229, "ingredient1": "Isatuximab", "ingredient2": "Cytarabine (liposomal)", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119367/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine, Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119230, "ingredient1": "Isatuximab", "ingredient2": "Dacarbazine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119368/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119231, "ingredient1": "Isatuximab", "ingredient2": "Doxorubicin (liposomal)", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119369/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119232, "ingredient1": "Isatuximab", "ingredient2": "Efalizumab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119370/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119233, "ingredient1": "Isatuximab", "ingredient2": "Epirubicin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119371/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 119234, "ingredient1": "Isatuximab", "ingredient2": "Etanercept", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119372/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 119235, "ingredient1": "Isatuximab", "ingredient2": "Etoposide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119373/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119236, "ingredient1": "Isatuximab", "ingredient2": "Filgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119374/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119237, "ingredient1": "Isatuximab", "ingredient2": "Fingolimod", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119375/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119238, "ingredient1": "Isatuximab", "ingredient2": "Floxuridine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119376/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119239, "ingredient1": "Isatuximab", "ingredient2": "Fludarabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119377/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119240, "ingredient1": "Isatuximab", "ingredient2": "Fluorouracil", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119378/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 119241, "ingredient1": "Isatuximab", "ingredient2": "Ganciclovir", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119379/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119242, "ingredient1": "Isatuximab", "ingredient2": "Gemcitabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119380/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 119243, "ingredient1": "Isatuximab", "ingredient2": "Golimumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119381/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 119244, "ingredient1": "Isatuximab", "ingredient2": "Hepatitis A Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119382/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119245, "ingredient1": "Isatuximab", "ingredient2": "Hepatitis B Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119383/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119246, "ingredient1": "Isatuximab", "ingredient2": "Human papillomavirus type 11 L1 capsid protein antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119384/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119247, "ingredient1": "Isatuximab", "ingredient2": "Hydroxyurea", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119385/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119248, "ingredient1": "Isatuximab", "ingredient2": "Idarubicin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119386/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 119249, "ingredient1": "Isatuximab", "ingredient2": "Idelalisib", "severity": "Moderate", "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.", "source": "DDInter", "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119387/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Olaratumab, Avelumab, Tafasitamab, Amivantamab, Belantamab mafodotin, Ofatumumab, Pembrolizumab, Rituximab, Cemiplimab", "updated_at": 1767369485}, {"id": 119250, "ingredient1": "Isatuximab", "ingredient2": "Ifosfamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119388/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119251, "ingredient1": "Isatuximab", "ingredient2": "Imatinib", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119389/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119252, "ingredient1": "Isatuximab", "ingredient2": "Infliximab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119390/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 119253, "ingredient1": "Isatuximab", "ingredient2": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119391/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119254, "ingredient1": "Isatuximab", "ingredient2": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119392/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119255, "ingredient1": "Isatuximab", "ingredient2": "Interferon alfa-2a, Recombinant", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119393/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119256, "ingredient1": "Isatuximab", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119394/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119257, "ingredient1": "Isatuximab", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119395/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 119258, "ingredient1": "Isatuximab", "ingredient2": "Lomustine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119396/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119259, "ingredient1": "Isatuximab", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119397/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119260, "ingredient1": "Isatuximab", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119398/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119261, "ingredient1": "Isatuximab", "ingredient2": "Mechlorethamine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119399/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119262, "ingredient1": "Isatuximab", "ingredient2": "Melphalan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119400/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119263, "ingredient1": "Isatuximab", "ingredient2": "Meningococcal polysaccharide vaccine group C", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119401/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119264, "ingredient1": "Isatuximab", "ingredient2": "Mercaptopurine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119402/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119265, "ingredient1": "Isatuximab", "ingredient2": "Mitomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119403/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119266, "ingredient1": "Isatuximab", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119404/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119267, "ingredient1": "Isatuximab", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119405/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119268, "ingredient1": "Isatuximab", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119406/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119269, "ingredient1": "Isatuximab", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119407/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119270, "ingredient1": "Isatuximab", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119408/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119271, "ingredient1": "Isatuximab", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119409/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119272, "ingredient1": "Isatuximab", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.", "source": "DDInter", "management_text": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119410/", "reference_text": "[1] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119273, "ingredient1": "Isatuximab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119411/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119274, "ingredient1": "Isatuximab", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119412/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119275, "ingredient1": "Isatuximab", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119413/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 119276, "ingredient1": "Isatuximab", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119414/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Avelumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, Pembrolizumab, Rituximab, More", "updated_at": 1767369485}, {"id": 119277, "ingredient1": "Isatuximab", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119415/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119278, "ingredient1": "Isatuximab", "ingredient2": "Pegfilgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119416/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119279, "ingredient1": "Isatuximab", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119417/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119280, "ingredient1": "Isatuximab", "ingredient2": "Pentostatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119418/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119281, "ingredient1": "Isatuximab", "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119419/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119282, "ingredient1": "Isatuximab", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119420/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119283, "ingredient1": "Isatuximab", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119421/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119284, "ingredient1": "Isatuximab", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119422/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119285, "ingredient1": "Isatuximab", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119423/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119286, "ingredient1": "Isatuximab", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119424/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 119287, "ingredient1": "Isatuximab", "ingredient2": "Samarium (153Sm) lexidronam", "severity": "Major", "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119425/", "reference_text": "[1] \"Product Information. Quadramet (samarium sm 153 lexidronam)\" Berlex Laboratories, Richmond, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119288, "ingredient1": "Isatuximab", "ingredient2": "Sargramostim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119426/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119289, "ingredient1": "Isatuximab", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119427/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119290, "ingredient1": "Isatuximab", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119428/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119291, "ingredient1": "Isatuximab", "ingredient2": "Sipuleucel-T", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119429/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119292, "ingredient1": "Isatuximab", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119430/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119293, "ingredient1": "Isatuximab", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119431/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119294, "ingredient1": "Isatuximab", "ingredient2": "Streptozocin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119432/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119295, "ingredient1": "Isatuximab", "ingredient2": "Strontium chloride Sr-89", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119433/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119296, "ingredient1": "Isatuximab", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119434/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119297, "ingredient1": "Isatuximab", "ingredient2": "Temozolomide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119435/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119298, "ingredient1": "Isatuximab", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119436/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 119299, "ingredient1": "Isatuximab", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119437/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Trastuzumab deruxtecan, Olaratumab, Panitumumab, Tafasitamab, Obinutuzumab, Amivantamab, Ramucirumab, Belantamab mafodotin, Mogamulizumab, Blinatumomab, More", "updated_at": 1767369485}, {"id": 119300, "ingredient1": "Isatuximab", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119438/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119301, "ingredient1": "Isatuximab", "ingredient2": "Thiotepa", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119439/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119302, "ingredient1": "Isatuximab", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119440/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119303, "ingredient1": "Isatuximab", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119441/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119304, "ingredient1": "Isatuximab", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119442/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119305, "ingredient1": "Isatuximab", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119443/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119306, "ingredient1": "Isatuximab", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119444/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119307, "ingredient1": "Isatuximab", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119445/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119308, "ingredient1": "Isatuximab", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119446/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 119309, "ingredient1": "Isatuximab", "ingredient2": "Ustekinumab", "severity": "Moderate", "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119447/", "reference_text": "[1] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 119310, "ingredient1": "Isatuximab", "ingredient2": "Valganciclovir", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119448/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119311, "ingredient1": "Isatuximab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119449/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119312, "ingredient1": "Isatuximab", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119450/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119313, "ingredient1": "Isatuximab", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119451/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 119314, "ingredient1": "Isatuximab", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119452/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119315, "ingredient1": "Isavuconazonium", "ingredient2": "Aminoglutethimide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119453/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119316, "ingredient1": "Isavuconazonium", "ingredient2": "Amprenavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119454/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119317, "ingredient1": "Isavuconazonium", "ingredient2": "Artesunate", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119455/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119318, "ingredient1": "Isavuconazonium", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119456/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119319, "ingredient1": "Isavuconazonium", "ingredient2": "Belinostat", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119457/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119320, "ingredient1": "Isavuconazonium", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119458/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119321, "ingredient1": "Isavuconazonium", "ingredient2": "Berotralstat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119459/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119322, "ingredient1": "Isavuconazonium", "ingredient2": "Boceprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119460/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119323, "ingredient1": "Isavuconazonium", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119461/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119324, "ingredient1": "Isavuconazonium", "ingredient2": "Cerivastatin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.", "source": "DDInter", "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119462/", "reference_text": "[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE \"Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.\" Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S \"Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.\" Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[4] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J \"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.\" N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M \"Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline.\" Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F \"New insights into the pharmacodynamic and pharmacokinetic properties of statins.\" Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC \"A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.\" J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG \"Rhabdomyolysis in association with simvastatin and amiodarone.\" Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S \"Rhabdomyolysis with simvastatin and nefazodone.\" Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[24] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[25] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995): 1639-45[26] \"Product Information. Baycol (cerivastatin).\" Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S \"Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.\" Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW \"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.\" Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[30] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[32] Westphal JF \"Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin.\" Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL \"Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers.\" J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR \"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.\" Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA \"Amiodarone's role in simvastatin-associated rhabdomyolysis.\" Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS \"Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.\" Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD \"The interaction of diltiazem with simvastatin.\" Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. \"Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.\" Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD \"The interaction of diltiazem with lovastatin and pravastatin.\" Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW \"Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.\" Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[52] Jody DN \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD \"Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.\" Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. \"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\" AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS \"Rhabdomyolysis associated with simvastatin-nefazodone therapy.\" South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H \"Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.\" J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD \"Interaction of diltiazem with lovastatin and pravastatin.\" Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH \"Erythromycin coadministration increases plasma atorvastatin concentrations.\" J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA \"Update on drug interactions with azole antifungal agents.\" Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A \"Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.\" Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[64] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[68] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[69] McMillan K \"Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors.\" Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M \"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved.\" Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119325, "ingredient1": "Isavuconazonium", "ingredient2": "Cisapride", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cisapride, which is primarily metabolized by the isoenzyme. High plasma levels of cisapride have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, protease inhibitors, certain macrolide antibiotics, nefazodone) is considered contraindicated. Use with other agents known to inhibit CYP450 3A4 should generally be avoided if possible.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with potent CYP450 3A4 inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119463/", "reference_text": "[1] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[2] Thomas AR, Chan LN, Bauman JL, Olopade CO \"Prolongation of the QT interval related to cisapride-diltiazem interaction.\" Pharmacotherapy 18 (1998): 381-5[3] Bedford TA, Rowbotham DJ \"Cisapride: drug interactions of clinical significance.\" Drug Saf 15 (1996): 167-75[4] Gray VS \"Syncopal episodes associated with cisapride and concurrent drugs.\" Ann Pharmacother 32 (1998): 648-51[5] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8[6] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[7] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[8] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[9] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[10] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[11] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[12] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[13] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[14] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ \"Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.\" Clin Pharmacol Ther 66 (1999): 448-53[15] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[16] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[17] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8[18] Gross AS, Goh YD, Addison RS, Shenfield GM \"Influence of grapefruit juice on cisapride pharmacokinetics.\" Clin Pharmacol Ther 65 (1999): 395-401[19] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG \"Red wine-cisapride interaction: Comparison with grapefruit juice.\" Clin Pharmacol Ther 70 (2001): 17-23[20] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[21] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[22] Cerner Multum, Inc. \"Australian Product Information.\" O 0[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Metoclopramide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119326, "ingredient1": "Isavuconazonium", "ingredient2": "Clotrimazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119464/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119327, "ingredient1": "Isavuconazonium", "ingredient2": "Conjugated estrogens (topical)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119465/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119328, "ingredient1": "Isavuconazonium", "ingredient2": "Copanlisib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when copanlisib is used with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as nausea, vomiting, diarrhea, stomatitis, hyperglycemia, hypertension, noninfectious pneumonitis, cutaneous reactions (e.g., exfoliative dermatitis, maculopapular rash), anemia, neutropenia, thrombocytopenia, and infections. Dosage adjustments for copanlisib may be necessary and should be done in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when copanlisib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119466/", "reference_text": "[1] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119329, "ingredient1": "Isavuconazonium", "ingredient2": "Dienestrol (topical)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119467/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119330, "ingredient1": "Isavuconazonium", "ingredient2": "Doxorubicin (liposomal)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119468/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119331, "ingredient1": "Isavuconazonium", "ingredient2": "Echinacea", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119469/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119332, "ingredient1": "Isavuconazonium", "ingredient2": "Entrectinib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.", "source": "DDInter", "management_text": "Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the dosage of entrectinib should be reduced to 100 mg once daily for adults and pediatrics patients (12 years and older) with a body surface area (BSA) greater than 1.5 m2. Following discontinuation, and after an appropriate washout period of the CYP450 3A4 inhibitor (i.e., 3 to 5 half-lives), the entrectinib dosage taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119470/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[4] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119333, "ingredient1": "Isavuconazonium", "ingredient2": "Enzalutamide", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119471/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119334, "ingredient1": "Isavuconazonium", "ingredient2": "Epirubicin", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119472/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119335, "ingredient1": "Isavuconazonium", "ingredient2": "Eplerenone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.", "mechanism_text": "Metabolism", "recommendation": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119473/", "reference_text": "[1] \"Product Information. Inspra (eplerenone).\" Searle, Chicago, IL.", "alternatives_a": "Amiloride, Triamterene, Spironolactone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119336, "ingredient1": "Isavuconazonium", "ingredient2": "Ergometrine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119474/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119337, "ingredient1": "Isavuconazonium", "ingredient2": "Ergotamine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119475/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119338, "ingredient1": "Isavuconazonium", "ingredient2": "Erlotinib", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119476/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119339, "ingredient1": "Isavuconazonium", "ingredient2": "Escitalopram", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119477/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119340, "ingredient1": "Isavuconazonium", "ingredient2": "Eslicarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119478/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119341, "ingredient1": "Isavuconazonium", "ingredient2": "Estazolam", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119479/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119342, "ingredient1": "Isavuconazonium", "ingredient2": "Esterified estrogens", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119480/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119343, "ingredient1": "Isavuconazonium", "ingredient2": "Estradiol (topical)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119481/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Dienogest, Etynodiol, Diethylstilbestrol, Bazedoxifene, Prasterone, Methyltestosterone, Ulipristal, Estetrol, Etynodiol, Dienogest, Nafarelin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119344, "ingredient1": "Isavuconazonium", "ingredient2": "Estrone", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119482/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119345, "ingredient1": "Isavuconazonium", "ingredient2": "Estrone sulfate", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119483/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119346, "ingredient1": "Isavuconazonium", "ingredient2": "Estrone sulfate (topical)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119484/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119347, "ingredient1": "Isavuconazonium", "ingredient2": "Eszopiclone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation.", "source": "DDInter", "management_text": "Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119485/", "reference_text": "[1] Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P \"Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism.\" Drug Metab Dispos 27 (1999): 1068-73[2] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[3] \"Product Information. Imovane (zopiclone).\" Rhone-Poulenc Rorer Canada Inc, Laval, IN.[4] Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT \"The effect of erythromycin on the pharmacokinetics and pharmacodymanics of zopiclone.\" Br J Clin Pharmacol 38 (1994): 363-7[5] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Alderman CP, Gebauer MG, Gilbert AL, Condon JT \"Possible interaction of zopiclone and nefazodone.\" Ann Pharmacother 35 (2001): 1378-80[8] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119348, "ingredient1": "Isavuconazonium", "ingredient2": "Ethosuximide", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119486/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119349, "ingredient1": "Isavuconazonium", "ingredient2": "Etonogestrel", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119487/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Ulipristal, Estetrol, Etynodiol, Dienogest", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119350, "ingredient1": "Isavuconazonium", "ingredient2": "Etoposide", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119488/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119351, "ingredient1": "Isavuconazonium", "ingredient2": "Etravirine", "severity": "Moderate", "effect": "Coadministration of etravirine with a drug, such as isavuconazonium sulfate (prodrug of isavuconazole), that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of etravirine and decreased plasma concentrations of isavuconazole. Etravirine itself is a substrate and inducer of CYP450 3A4. Theoretically, etravirine may induce metabolism of isavuconazole while its own metabolism may be inhibited by the isavuconazole.", "source": "DDInter", "management_text": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with isavuconazonium sulfate. In addition, the potential for decreased efficacy of isavuconazole should be considered. Dosage adjustments may be required for one or both drugs.", "mechanism_text": "Metabolism", "recommendation": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with isavuconazonium sulfate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119489/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119352, "ingredient1": "Isavuconazonium", "ingredient2": "Everolimus", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycaemia, and hyperlipidemia may be increased.", "source": "DDInter", "management_text": "Blood trough levels should be closely monitored, and the dosage adjusted accordingly during concomitant administration and after discontinuation of moderate CYP450 3A4 and P-glycoprotein inhibitors. The manufacturer's drug product labeling should be consulted for specific recommendations.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Blood trough levels should be closely monitored, and the dosage adjusted accordingly during concomitant administration and after discontinuation of moderate CYP450 3A4 and P-glycoprotein inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119490/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119353, "ingredient1": "Isavuconazonium", "ingredient2": "Fedratinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119491/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119354, "ingredient1": "Isavuconazonium", "ingredient2": "Felbamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119492/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119355, "ingredient1": "Isavuconazonium", "ingredient2": "Felodipine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119493/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol, Clevidipine, Celecoxib, Enalapril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119356, "ingredient1": "Isavuconazonium", "ingredient2": "Fesoterodine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.", "mechanism_text": "Metabolism", "recommendation": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119494/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119357, "ingredient1": "Isavuconazonium", "ingredient2": "Fexofenadine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119495/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119358, "ingredient1": "Isavuconazonium", "ingredient2": "Fidaxomicin", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119496/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119359, "ingredient1": "Isavuconazonium", "ingredient2": "Flibanserin", "severity": "Major", "effect": "Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.", "source": "DDInter", "management_text": "Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated. When initiating flibanserin following treatment with a moderate or potent CYP450 3A4 inhibitor, the manufacturer recommends waiting until 2 weeks after the last dose of CYP450 3A4 inhibitor. Conversely, if a moderate or potent CYP450 3A4 inhibitor is required during flibanserin therapy, flibanserin should be discontinued at least 2 days before starting the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119497/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119360, "ingredient1": "Isavuconazonium", "ingredient2": "Fluconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119498/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Tetracycline, Norfloxacin, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119361, "ingredient1": "Isavuconazonium", "ingredient2": "Fludrocortisone", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119499/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119362, "ingredient1": "Isavuconazonium", "ingredient2": "Flurazepam", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119500/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119363, "ingredient1": "Isavuconazonium", "ingredient2": "Fluticasone", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. Fluticasone undergoes extensive first-pass and systemic metabolism via CYP450 3A4, thus inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug. However, the extent of interaction may depend on the route of fluticasone administration and the specific formulation.", "source": "DDInter", "management_text": "Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4. Signs and symptoms of hypercorticism include acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma). Systemic glucocorticoids may be necessary until adrenal function recovers.", "mechanism_text": "Metabolism", "recommendation": "Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119501/", "reference_text": "[1] St Clair K, Maguire JD \"Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency.\" Int J STD AIDS 23 (2012): 371-2[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[4] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Hoover WC, Britton LJ, Gardner J, Jackson T, Gutierrez H \"Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor.\" Ann Pharmacother 45 (2011): e38[7] \"Product Information. Bosulif (bosutinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119364, "ingredient1": "Isavuconazonium", "ingredient2": "Fluvoxamine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119502/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119365, "ingredient1": "Isavuconazonium", "ingredient2": "Fosamprenavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119503/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119366, "ingredient1": "Isavuconazonium", "ingredient2": "Fosaprepitant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119504/", "reference_text": "[1] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Company Inc, West Point, PA.[2] \"Product Information. Emend (aprepitant).\" Merck & Company Inc, West Point, PA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119367, "ingredient1": "Isavuconazonium", "ingredient2": "Fosphenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119505/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119368, "ingredient1": "Isavuconazonium", "ingredient2": "Fostamatinib", "severity": "Moderate", "effect": "Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119506/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals, South San Francisco, CA.", "alternatives_a": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119369, "ingredient1": "Isavuconazonium", "ingredient2": "Galantamine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119507/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Rivastigmine, Aducanumab, Memantine, Ginkgo biloba, Tacrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119370, "ingredient1": "Isavuconazonium", "ingredient2": "Gefitinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of gefitinib (250 mg single dose) with the potent inhibitor itraconazole (200 mg once a day for 12 days) increased the mean gefitinib systemic exposure (AUC) by 88% in healthy male volunteers.", "source": "DDInter", "management_text": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119508/", "reference_text": "[1] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[2] \"Product Information. Iressa (gefitinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119371, "ingredient1": "Isavuconazonium", "ingredient2": "Gilteritinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, pancreatitis, liver transaminase and bilirubin elevations, edema, infections and stomatitis, and the gilteritinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119509/", "reference_text": "[1] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119372, "ingredient1": "Isavuconazonium", "ingredient2": "Glasdegib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when glasdegib is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema and mucositis, and the glasdegib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when glasdegib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119510/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119373, "ingredient1": "Isavuconazonium", "ingredient2": "Granisetron", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119511/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Palonosetron", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119374, "ingredient1": "Isavuconazonium", "ingredient2": "Grepafloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119512/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Enoxacin, Gatifloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Levofloxacin, Sparfloxacin, Ofloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119375, "ingredient1": "Isavuconazonium", "ingredient2": "Griseofulvin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119513/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Terbinafine, Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119376, "ingredient1": "Isavuconazonium", "ingredient2": "Guanfacine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme. The risk of adverse reactions such as hypotension, bradycardia, and sedation may increase.", "source": "DDInter", "management_text": "Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors. For extended-release guanfacine, the manufacturers recommend reducing the dosage to half the recommended level during concomitant use . Further dosage adjustments may be required based on patient tolerance and response.", "mechanism_text": "Metabolism", "recommendation": "Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119514/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[3] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119377, "ingredient1": "Isavuconazonium", "ingredient2": "Halofantrine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine. Halofantrine has been associated with QT interval prolongation, ventricular arrhythmias, and sudden death, even at recommended dosages.", "source": "DDInter", "management_text": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119515/", "reference_text": "[1] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002): 514-23[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[4] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[5] Baune B, Flinois JP, Furlan V, et al. \"Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.\" J Pharm Pharmacol 51 (1999): 419-26[6] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[7] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[8] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[9] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002): 514-23[10] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119378, "ingredient1": "Isavuconazonium", "ingredient2": "Haloperidol", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119516/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119379, "ingredient1": "Isavuconazonium", "ingredient2": "Halothane", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119517/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119380, "ingredient1": "Isavuconazonium", "ingredient2": "Hydroxychloroquine", "severity": "Moderate", "effect": "Coadministration with moderate or strong inhibitors of CYP450 2C8 or CYP450 3A4 may increase the plasma concentration of hydroxychloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias.", "source": "DDInter", "management_text": "Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate or strong CYP450 3A4 or 2C8 inhibitor is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119518/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119381, "ingredient1": "Isavuconazonium", "ingredient2": "Idarubicin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119519/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119382, "ingredient1": "Isavuconazonium", "ingredient2": "Idelalisib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119520/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119383, "ingredient1": "Isavuconazonium", "ingredient2": "Ifosfamide", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119521/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119384, "ingredient1": "Isavuconazonium", "ingredient2": "Iloperidone", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119522/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119385, "ingredient1": "Isavuconazonium", "ingredient2": "Imatinib", "severity": "Moderate", "effect": "Imatinib is a substrate of the CYP450 3A4 isoenzyme as well as a potent competitive inhibitor of the CYP450 2C9, 2D6 and 3A4 isoenzymes. Some drugs that are known inhibitors of CYP450 3A4 are also metabolized by one or more of the isoenzymes inhibited by imatinib. Theoretically, coadministration of imatinib with those drugs may result in mutually elevated plasma drug concentrations due to competitive and noncompetitive inhibition of CYP450 activities.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin. In addition, clinical and laboratory monitoring for potentially increased pharmacologic effects of coadministered medications is recommended, especially those with a narrow therapeutic range.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119523/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119386, "ingredient1": "Isavuconazonium", "ingredient2": "Indacaterol", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119524/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Salbutamol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119387, "ingredient1": "Isavuconazonium", "ingredient2": "Indinavir", "severity": "Major", "effect": "Coadministration of isavuconazonium sulfate (prodrug of isavuconazole) and indinavir may increase the plasma concentrations of isavuconazole and decrease the plasma concentrations of indinavir. Both drugs are substrates as well as inhibitors of CYP450 3A4/5. The proposed mechanism for isavuconazole involves indinavir inhibition of CYP450 3A4/5-mediated metabolism of isavuconazole. The reduction in indinavir plasma concentrations occurs by an undetermined mechanism.", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors, such as indinavir, is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors, such as indinavir, is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119525/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8[4] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[5] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119388, "ingredient1": "Isavuconazonium", "ingredient2": "Irinotecan (liposomal)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119526/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119389, "ingredient1": "Istradefylline", "ingredient2": "Isavuconazonium", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.", "source": "DDInter", "management_text": "Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119527/", "reference_text": "[1] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc, Bedminster, NJ.[2] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119390, "ingredient1": "Itraconazole", "ingredient2": "Isavuconazonium", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4, such as itraconazole, may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors, such as itraconazole, is considered contraindicated. Some authorities state that coadministration with isavuconazonium is considered contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors, such as itraconazole, is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119528/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Sporanox oral solution (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[6] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[7] Van Peer A, Woestenborghs R, Heykants J, et al \"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.\" Eur J Clin Pharmacol 36 (1989): 423-6[8] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M \"Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers.\" Ther Drug Monit 21 (1999): 304-9[9] Katz HI \"Drug interactions of the newer oral antifungal agents.\" Br J Dermatol 141 (1999): 26-32[10] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H \"Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects.\" Int J Clin Pharmacol Ther 36 (1998): 306-8[11] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V \"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.\" Antimicrob Agents Chemother 37 (1993): 778-84[12] Wishart JM \"The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection.\" J Am Acad Dermatol 17 (1987): 220-3[13] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A \"Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects.\" Int J Clin Pharmacol Res 14 (1994): 87-93[14] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L \"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.\" Pharmacotherapy 18 (1998): 295-301", "alternatives_a": "Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119391, "ingredient1": "Ivabradine", "ingredient2": "Isavuconazonium", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivabradine with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, some authorities recommend initiating ivabradine at a dosage of 2.5 mg twice daily, provided the resting heart rate is at or above 70 beats per minute and heart rate is closely monitored.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivabradine with moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119529/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[4] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[9] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Adenosine, Regadenoson, Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119392, "ingredient1": "Ivermectin", "ingredient2": "Isavuconazonium", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119530/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Piperazine, Mebendazole, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119393, "ingredient1": "Isavuconazonium", "ingredient2": "Ivosidenib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivosidenib, which is primarily metabolized by the isoenzyme. Increased exposure to ivosidenib may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with ivosidenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, including many of the known moderate inhibitors of the isoenzyme such as amprenavir, aprepitant, crizotinib, darunavir, diltiazem, dronedarone, erythromycin, imatinib, isavuconazonium, mifepristone, netupitant, and verapamil. Ivosidenib is an inducer of CYP450 3A4 and induces its own metabolism following multiple dosing.", "source": "DDInter", "management_text": "Concomitant use of ivosidenib with moderate CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided. If coadministration is required, close monitoring of electrocardiograms and electrolytes is recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivosidenib with moderate CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119531/", "reference_text": "[1] \"Product Information. Tibsovo (ivosidenib).\" Agios Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Tibsovo (ivosidenib).\" Agios Pharmaceuticals, Cambridge, MA.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[5] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119394, "ingredient1": "Isavuconazonium", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when ixabepilone is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ixabepilone should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ixabepilone dosage adjusted as necessary. Frequent monitoring of peripheral blood counts between treatment cycles is recommended, and patients should be advised to contact their physician if they experience signs and symptoms of ixabepilone toxicities such as infection or burning, tingling, or numbness in the hands and feet.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ixabepilone is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119532/", "reference_text": "[1] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119395, "ingredient1": "Isavuconazonium", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119533/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119396, "ingredient1": "Isavuconazonium", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4, such as ketoconazole, may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate (prodrug of isavuconazole) with CYP450 3A4 inhibitors, such as ketoconazole, is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate (prodrug of isavuconazole) with CYP450 3A4 inhibitors, such as ketoconazole, is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119534/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119397, "ingredient1": "Isavuconazonium", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when lapatinib is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to lapatinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the lapatinib dosage adjusted as necessary. Patients should be advised to contact their physician if they experience increased adverse effects of lapatinib such as diarrhea, nausea, vomiting, dyspepsia, and fatigue.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lapatinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119535/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119398, "ingredient1": "Isavuconazonium", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4, P-glycoprotein (P-gp), and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of larotrectinib.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors. Patients should be monitored for adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paraesthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases), and the larotrectinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119536/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.[4] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119399, "ingredient1": "Isavuconazonium", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-gp may increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when lefamulin is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for increased adverse effects and seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lefamulin is used with CYP450 3A4 and/or P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119537/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[3] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[4] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119400, "ingredient1": "Isavuconazonium", "ingredient2": "Lemborexant", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119538/", "reference_text": "[1] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.[2] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119401, "ingredient1": "Isavuconazonium", "ingredient2": "Lenalidomide", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119539/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119402, "ingredient1": "Isavuconazonium", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119540/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119403, "ingredient1": "Isavuconazonium", "ingredient2": "Letrozole", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119541/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119404, "ingredient1": "Isavuconazonium", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119542/", "reference_text": "[1] Sasaki M, Maeda A, Fujimura A \"Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients.\" Eur J Clin Pharmacol 57 (2001): 85-6[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Norvasc (amlodipine).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119405, "ingredient1": "Isavuconazonium", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119543/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119406, "ingredient1": "Isavuconazonium", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and duration of action of levomethadyl acetate, which is a substrate of the isoenzyme. High plasma levels of levomethadyl acetate may increase the risk of QT interval prolongation, which is thought to be associated with serious cardiac events such as ventricular arrhythmias (e.g., torsade de pointes, ventricular tachycardia), cardiac arrest, and sudden death. Cases of QT prolongation and torsade de pointes have been reported with levomethadyl acetate alone during postmarketing use.", "source": "DDInter", "management_text": "Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119544/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119407, "ingredient1": "Isavuconazonium", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119545/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Ulipristal, Estetrol, Etynodiol, Dienogest, Dienogest, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119408, "ingredient1": "Isavuconazonium", "ingredient2": "Lomitapide", "severity": "Major", "effect": "Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated. Some authorities consider concomitant administration of lomitapide and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119546/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119409, "ingredient1": "Isavuconazonium", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lonafarnib.", "source": "DDInter", "management_text": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119547/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119410, "ingredient1": "Isavuconazonium", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119548/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119411, "ingredient1": "Isavuconazonium", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.", "source": "DDInter", "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119549/", "reference_text": "[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE \"Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.\" Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S \"Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.\" Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[4] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J \"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.\" N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M \"Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline.\" Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F \"New insights into the pharmacodynamic and pharmacokinetic properties of statins.\" Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC \"A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.\" J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG \"Rhabdomyolysis in association with simvastatin and amiodarone.\" Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S \"Rhabdomyolysis with simvastatin and nefazodone.\" Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[24] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[25] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995): 1639-45[26] \"Product Information. Baycol (cerivastatin).\" Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S \"Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.\" Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW \"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.\" Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[30] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[32] Westphal JF \"Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin.\" Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL \"Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers.\" J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR \"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.\" Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA \"Amiodarone's role in simvastatin-associated rhabdomyolysis.\" Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS \"Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.\" Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD \"The interaction of diltiazem with simvastatin.\" Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. \"Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.\" Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD \"The interaction of diltiazem with lovastatin and pravastatin.\" Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW \"Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.\" Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[52] Jody DN \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD \"Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.\" Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. \"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\" AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS \"Rhabdomyolysis associated with simvastatin-nefazodone therapy.\" South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H \"Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.\" J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD \"Interaction of diltiazem with lovastatin and pravastatin.\" Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH \"Erythromycin coadministration increases plasma atorvastatin concentrations.\" J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA \"Update on drug interactions with azole antifungal agents.\" Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A \"Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.\" Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[64] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[68] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[69] McMillan K \"Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors.\" Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M \"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved.\" Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119412, "ingredient1": "Isavuconazonium", "ingredient2": "Lumateperone", "severity": "Major", "effect": "Coadministration with strong or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119550/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119413, "ingredient1": "Isavuconazonium", "ingredient2": "Lurasidone", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Lurasidone dosage should start at 20 mg/day and not exceed 80 mg/day when coadministered with moderate CYP450 3A4 inhibitors. If a moderate CYP450 3A4 inhibitor is added to existing lurasidone therapy, the lurasidone dosage should be reduced by half. Patients should be monitored for potentially increased adverse effects such as dizziness, drowsiness, dry mouth, increased appetite, weight gain, extrapyramidal symptoms, tardive dyskinesia, hyperglycaemia, dyslipidemia, hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), orthostatic hypotension, cognitive and motor impairment, seizures, dysphagia, and heat-related illnesses due to disruption of body temperature regulation.", "mechanism_text": "Metabolism", "recommendation": "Lurasidone dosage should start at 20 mg/day and not exceed 80 mg/day when coadministered with moderate CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119551/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119414, "ingredient1": "Isavuconazonium", "ingredient2": "Lurbinectedin", "severity": "Major", "effect": "Coadministration with a moderate CYP450 3A4 inhibitor is predicted to increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity. Concomitant use of lurbinectedin and moderate CYP450 3A4 inhibitors should generally be avoided. If the coadministration of lurbinectedin with a moderate CYP450 3A4 inhibitor cannot be avoided, a dose reduction for lurbinectedin may be considered.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring is advised whenever a moderate inhibitor is added to or withdrawn from therapy. Patients should be advised to contact their physician if they experience symptoms suggestive of myelosuppression or hepatotoxicity, such as fever or any other signs of infection, unusual bruising or bleeding; nausea or vomiting, or pain on the right side of the abdomen.", "mechanism_text": "Metabolism", "recommendation": "Close clinical and laboratory monitoring is advised whenever a moderate inhibitor is added to or withdrawn from therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119552/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119415, "ingredient1": "Isavuconazonium", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.", "source": "DDInter", "management_text": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.", "mechanism_text": "Distribution", "recommendation": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119553/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119416, "ingredient1": "Isavuconazonium", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4. The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole), but no suggestions are given regarding use with less potent inhibitors. It may be reasonable to monitor therapeutic response to macitentan more closely.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119554/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.", "alternatives_a": "Riociguat, Metyrosine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119417, "ingredient1": "Isavuconazonium", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119555/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119418, "ingredient1": "Isavuconazonium", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119556/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Ulipristal, Estetrol, Etynodiol, Dienogest, Dienogest, Etynodiol, Dienogest, Etynodiol, Diethylstilbestrol, Histrelin, Leuprolide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119419, "ingredient1": "Isavuconazonium", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119557/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119420, "ingredient1": "Isavuconazonium", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119558/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Dienogest, Etynodiol, Dienogest, Etynodiol, Ulipristal, Estetrol, Etynodiol, Dienogest, Diethylstilbestrol, Histrelin, Leuprolide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119421, "ingredient1": "Isavuconazonium", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119559/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119422, "ingredient1": "Isavuconazonium", "ingredient2": "Methylergometrine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119560/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119423, "ingredient1": "Isavuconazonium", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119561/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Dapsone, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, Fluorometholone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119424, "ingredient1": "Isavuconazonium", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119562/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119425, "ingredient1": "Isavuconazonium", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119563/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119426, "ingredient1": "Isavuconazonium", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119564/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119427, "ingredient1": "Isavuconazonium", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119565/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119428, "ingredient1": "Isavuconazonium", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when midostaurin is used with CYP450 3A4 inhibitors. Patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when midostaurin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119566/", "reference_text": "[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y \"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.\" Cancer Chemother Pharmacol 72 (2013): 1223-34[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119429, "ingredient1": "Isavuconazonium", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Coadministration of mifepristone with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of both drugs. Mifepristone itself is also a substrate and moderate inhibitor of CYP450 3A4. Theoretically, competitive and/or noncompetitive metabolic inhibition may occur. Because mifepristone is associated with dose-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, caution is advised if mifepristone is prescribed in combination with a CYP450 3A4 inhibitor, particularly when used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome. When the coadministered drug is also a CYP450 3A4 substrate, clinical and/or laboratory monitoring may be appropriate following the addition or withdrawal of mifepristone, and the dosage adjusted as necessary. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Metabolism", "recommendation": "Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, caution is advised if mifepristone is prescribed in combination with a CYP450 3A4 inhibitor, particularly when used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119567/", "reference_text": "[1] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[2] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[3] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[4] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119430, "ingredient1": "Isavuconazonium", "ingredient2": "Mirabegron", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme. However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination. No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119568/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119431, "ingredient1": "Isavuconazonium", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Coadministration of mirtazapine with drugs that inhibit one or more of its metabolic pathways may result in increased plasma concentrations of mirtazapine. In vitro data from human liver microsomes indicate that CYP450 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite, while CYP450 3A4 is primarily responsible for the formation of the N-desmethyl and N-oxide metabolites.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4. Therapeutic response to mirtazapine should be monitored more closely following initiation, discontinuation, or dosing change of CYP450 inhibitors, and the mirtazapine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119569/", "reference_text": "[1] Sitsen JM, Maris FA, Timmer CJ \"Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.\" Eur J Clin Pharmacol 56 (2000): 389-94[2] \"Product Information. Remeron (mirtazapine).\" Organon, West Orange, NJ.[3] Stormer E, von Moltke LL, Shader RI, Greenblatt DJ \"Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4\" Drug Metab Dispos 28 (2000): 1168-75[4] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H \"Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.\" Biochem Pharmacol 93 (2015): 104-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119432, "ingredient1": "Isavuconazonium", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119570/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119433, "ingredient1": "Isavuconazonium", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.", "source": "DDInter", "management_text": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Others", "recommendation": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119571/", "reference_text": "[1] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[4] \"Multum Information Services, Inc. Expert Review Panel\"[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119434, "ingredient1": "Isavuconazonium", "ingredient2": "Modafinil", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119572/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.[3] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[4] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[5] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119435, "ingredient1": "Isavuconazonium", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the bioavailability of mycophenolic acid. The proposed mechanism is isavuconazole inhibition of the UGT-mediated metabolism of mycophenolic acid.", "source": "DDInter", "management_text": "Caution is advised when mycophenolic acid is prescribed with isavuconazonium sulfate. Clinical and laboratory monitoring are recommended following the addition or withdrawal of isavuconazonium sulfate, and the mycophenolic acid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when mycophenolic acid is prescribed with isavuconazonium sulfate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119573/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119436, "ingredient1": "Isavuconazonium", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the bioavailability of mycophenolic acid. The proposed mechanism is isavuconazole inhibition of the UGT-mediated metabolism of mycophenolic acid.", "source": "DDInter", "management_text": "Caution is advised when mycophenolic acid is prescribed with isavuconazonium sulfate. Clinical and laboratory monitoring are recommended following the addition or withdrawal of isavuconazonium sulfate, and the mycophenolic acid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when mycophenolic acid is prescribed with isavuconazonium sulfate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119574/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119437, "ingredient1": "Isavuconazonium", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119575/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119438, "ingredient1": "Isavuconazonium", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp). Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119576/", "reference_text": "[1] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119439, "ingredient1": "Isavuconazonium", "ingredient2": "Naloxegol", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.", "source": "DDInter", "management_text": "Concomitant use of naloxegol with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the dosage of naloxegol should be reduced to 12.5 mg once daily and the patient closely monitored for opioid withdrawal symptoms.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of naloxegol with moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119577/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119440, "ingredient1": "Isavuconazonium", "ingredient2": "Nefazodone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119578/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119441, "ingredient1": "Isavuconazonium", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119579/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119442, "ingredient1": "Isavuconazonium", "ingredient2": "Neratinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119580/", "reference_text": "[1] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[6] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[7] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119443, "ingredient1": "Isavuconazonium", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119581/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119444, "ingredient1": "Isavuconazonium", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119582/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119445, "ingredient1": "Isavuconazonium", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the plasma concentrations of nilotinib, which is a substrate of both the isoenzyme and the efflux transporter. Data are not available for nilotinib in combination with other CYP450 3A4 or P-glycoprotein inhibitors. Theoretically, a reverse interaction may also occur, since many CYP450 3A4 and P-glycoprotein inhibitors are also substrates, and nilotinib is an inhibitor of both.", "source": "DDInter", "management_text": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors. Pharmacologic response to nilotinib should be monitored more closely whenever a CYP450 3A4 or P-glycoprotein inhibitor is added to or withdrawn from therapy, and the nilotinib dosage adjusted as necessary. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 480 msec will require suspension of nilotinib therapy and immediate action to correct any concomitant risk factors before resuming treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Patients should also be monitored for altered efficacy and safety of the concomitant administered drug.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119583/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119446, "ingredient1": "Isavuconazonium", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119584/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119447, "ingredient1": "Isavuconazonium", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and CYP450 3A4 may increase the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors. Pharmacologic response to nintedanib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the nintedanib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for increased adverse effects such as liver enzyme and bilirubin elevations, diarrhea, nausea, vomiting, gastrointestinal perforation, bleeding, and arterial thromboembolic events (e.g., myocardial infarction).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119585/", "reference_text": "[1] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119448, "ingredient1": "Isavuconazonium", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119586/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119449, "ingredient1": "Isavuconazonium", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119587/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119450, "ingredient1": "Isavuconazonium", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119588/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119451, "ingredient1": "Isavuconazonium", "ingredient2": "Olaparib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.", "source": "DDInter", "management_text": "Concomitant use of olaparib with moderate CYP450 3A4 inhibitors should be avoided whenever possible. If coadministration is required, dose reductions are recommended as follows: the olaparib tablet dosage should be reduced to 150 mg twice a day; the olaparib capsule dosage should be reduced to 200 mg twice a day. Specific dose recommendations for each formulation should be followed as the tablet and capsule formulations are not interchangeable due to differences in bioavailability. Once the CYP450 3A4 inhibitor has been discontinued for 3 to 5 elimination half-lives, the usual olaparib dose should be resumed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of olaparib with moderate CYP450 3A4 inhibitors should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119589/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119452, "ingredient1": "Isavuconazonium", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations and adverse opioid effects of oliceridine, which is primarily metabolized by both isoenzymes in vitro. In addition, oliceridine concentrations may decrease following discontinuation of a concomitant moderate or potent CYP450 2D6 or 3A4 inhibitor, possibly resulting in decreased opioid efficacy or withdrawal syndrome. The effect of a CYP450 2D6 inhibitor on the pharmacokinetics of oliceridine has not been studied. However, it may be similar to that reported in CYP450 2D6 poor metabolizers, whose plasma clearance of oliceridine is reduced by approximately 50% compared to those who are nonpoor CYP450 2D6 metabolizers.", "source": "DDInter", "management_text": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4. If concomitant use is considered necessary, patients may require less frequent dosing of oliceridine and should be closely monitored for respiratory depression, sedation, and QT prolongation. If a moderate or potent CYP450 2D6 or 3A4 inhibitor is discontinued, an increase of the oliceridine dosage may be considered while monitoring for signs of opioid withdrawal until stable drug effects are achieved.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119590/", "reference_text": "[1] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[2] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119453, "ingredient1": "Isavuconazonium", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119591/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Palonosetron", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119454, "ingredient1": "Isavuconazonium", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osilodrostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations for signs and symptoms of hypocortisolism such as nausea, vomiting, abdominal pain, loss of appetite, fatigue, dizziness, hypotension, abnormal electrolyte levels, and hypoglycemia. Decrease dosing or temporarily discontinue osilodrostat if patients experience symptoms of hypocortisolism or if urine free cortisol levels fall below the target range or there is a rapid decrease in cortisol levels. Stop osilodrostat and administer exogenous glucocorticoid replacement therapy if patients have symptoms of adrenal insufficiency and serum or plasma cortisol levels are below target range. Osilodrostat therapy may be restarted at a lower dosage when symptoms have resolved and cortisol values are within target range.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119592/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119455, "ingredient1": "Isavuconazonium", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osimertinib is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as diarrhea, QT prolongation, torsade de pointes arrhythmia, and cardiomyopathy (e.g., cardiac failure, pulmonary edema, ejection fraction decreases), and the osimertinib dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osimertinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119593/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119456, "ingredient1": "Isavuconazonium", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119594/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119457, "ingredient1": "Isavuconazonium", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119595/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119458, "ingredient1": "Isavuconazonium", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration with breast cancer resistance protein (BCRP) inhibitors may increase the exposure of the active metabolites of ozanimod and the risk of adverse effects. Coadministration with cyclosporine, a BCRP inhibitor, did not alter the AUC of ozanimod, but it did double the exposure of the minor active metabolites of ozanimod, RP101988 and RP101075 which are direct precursors of the major active metabolite CC112273.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "mechanism_text": "Others", "recommendation": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119596/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119459, "ingredient1": "Isavuconazonium", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "mechanism_text": "Metabolism", "recommendation": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119597/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K \"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma.\" Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J \"Drug interactions of paclitaxel metabolism in human liver microsomes.\" J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D \"Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.\" Drugs 48 (1994): 794-847[5] \"Product Information. Abraxane (paclitaxel protein-bound).\" American Pharmaceutical Partners, Schaumberg, IL.[6] \"Product Information. Taxol (paclitaxel).\" Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM \"Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract).\" Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[9] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119460, "ingredient1": "Isavuconazonium", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119598/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119461, "ingredient1": "Isavuconazonium", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, anorexia, peripheral edema, cardiotoxicity, ECG abnormalities, electrolyte disturbances, bleeding complications, hepatotoxicity and myelosuppression, and the dosage of panobinostat adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119599/", "reference_text": "[1] Hamberg P, Woo MM, Chen LC, et al. \"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\" Cancer Chemother Pharmacol 68 (2011): 805-13[2] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119462, "ingredient1": "Isavuconazonium", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pazopanib, which is primarily metabolized by the isoenzyme. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.", "source": "DDInter", "management_text": "Caution is advised if pazopanib is prescribed in combination with inhibitors of CYP450 3A4. Pharmacologic response to pazopanib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the pazopanib dosage adjusted as necessary. Patients should have liver function tests (ALT, AST, bilirubin), electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. In addition, they should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pazopanib is prescribed in combination with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119600/", "reference_text": "[1] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119463, "ingredient1": "Isavuconazonium", "ingredient2": "Pemigatinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided. If coadministration is required, a reduction in the dosage of pemigatinib is recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119601/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119464, "ingredient1": "Isavuconazonium", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119602/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119465, "ingredient1": "Isavuconazonium", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may significantly increase the plasma concentrations and the incidence and severity of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib.", "source": "DDInter", "management_text": "The use of pexidartinib with a moderate CYP450 3A4 inhibitor should generally be avoided. If concomitant use is required, the dose of pexidartinib should be reduced according to the manufacturer's recommendations. If concomitant use of a moderate CYP450 3A4 inhibitor is discontinued, the dose of pexidartinib may be increased, after 3 plasma half-lives of the moderate CYP450 3A4 inhibitor, to the dose that was used prior to starting the moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of pexidartinib with a moderate CYP450 3A4 inhibitor should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119603/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119466, "ingredient1": "Isavuconazonium", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119604/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119467, "ingredient1": "Isavuconazonium", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119605/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119468, "ingredient1": "Isavuconazonium", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as peripheral edema and QT prolongation, and the pimavanserin dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119606/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119469, "ingredient1": "Isavuconazonium", "ingredient2": "Pimecrolimus (topical)", "severity": "Minor", "effect": "Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119607/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119470, "ingredient1": "Isavuconazonium", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme. The use of pimozide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated. Some authorities consider concomitant administration of lurasidone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. With respect to less potent CYP450 3A4 inhibitors, the manufacturers recommend that they also not be used with pimozide.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119608/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[3] Flockhart DA, Drici MD, Kerbusch T, et al \"Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome.\" J Clin Psychopharmacol 20 (2000): 317-24[4] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[5] Desta Z, Kerbusch T, Flockhart DA \"Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).\" Clin Pharmacol Ther 65 (1999): 10-20[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[8] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[9] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ \"Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.\" Am J Med Sci 309 (1995): 315-6[10] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[11] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119471, "ingredient1": "Isavuconazonium", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119609/", "reference_text": "[1] \"Product Information. Polivy (polatuzumab vedotin).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119472, "ingredient1": "Isavuconazonium", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119610/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119473, "ingredient1": "Isavuconazonium", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ponatinib is used in combination with moderate CYP450 3A4 inhibitors. Patients should be monitored for potentially increased side effects such as thromboembolism, ischemia, congestive heart failure, hypertension, hepatotoxicity, pancreatitis, myelosuppression, hemorrhage, and fluid retention.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ponatinib is used in combination with moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119611/", "reference_text": "[1] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119474, "ingredient1": "Isavuconazonium", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119612/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119475, "ingredient1": "Isavuconazonium", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors. Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119613/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119476, "ingredient1": "Isavuconazonium", "ingredient2": "Praziquantel", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119614/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Triclabendazole, Oxamniquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119477, "ingredient1": "Isavuconazonium", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119615/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluorometholone, Indomethacin, Fluocinolone acetonide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119478, "ingredient1": "Isavuconazonium", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration of isavuconazonium sulfate (prodrug of isavuconazole), a substrate as well as a moderate inhibitor of CYP450 3A4/5, with drugs that are both a substrate as well as inducer of CYP450 3A4/5 may result in decreased plasma concentrations of isavuconazole and increased plasma concentrations of the other drug. Isavuconazole may inhibit the metabolism of the coadministered drug while its own metabolism may be induced by the coadministered drug.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are both a substrate and inducer of CYP450 3A4/5, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever these drugs are added to or withdrawn from combination therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are both a substrate and inducer of CYP450 3A4/5, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119616/", "reference_text": "[1] \"Product Information. Emend (aprepitant).\" Merck & Company Inc, West Point, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Company Inc, West Point, PA.[4] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119479, "ingredient1": "Isavuconazonium", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119617/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119480, "ingredient1": "Isavuconazonium", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119618/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Dienogest, Etynodiol, Dienogest, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119481, "ingredient1": "Isavuconazonium", "ingredient2": "Progesterone (topical)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119619/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119482, "ingredient1": "Isavuconazonium", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of propafenone, which may result in proarrhythmic events and exaggerated beta-adrenergic blocking activity.", "source": "DDInter", "management_text": "Caution is advised when propafenone is administered with CYP450 3A4 inhibitors. Therapeutic response to propafenone as well as clinical and electrocardiographic evidence of toxicity should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the propafenone dosage adjusted as necessary. Patients should be monitored for potential adverse effects such as new or worsening arrhythmias or heart failure, edema, bradycardia, and atrioventricular block. Simultaneous use of propafenone with both a CYP450 3A4 inhibitor and a CYP450 2D6 inhibitor (or in patients with CYP450 2D6 deficiency) should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when propafenone is administered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119620/", "reference_text": "[1] \"Product Information. Rythmol SR (propafenone).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK \"Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.\" Mol Pharmacol 43 (1993): 120-6[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119483, "ingredient1": "Isavuconazonium", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be monitored for potentially increased adverse effects such as dizziness, drowsiness, dry mouth, constipation, increased appetite, weight gain, extrapyramidal symptoms, tardive dyskinesia, hyperglycemia, dyslipidemia, hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), orthostatic hypotension, blood pressure increases (in children and adolescents), QT prolongation, cognitive and motor impairment, dysphagia, and heat-related illnesses due to disruption of body temperature regulation.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119621/", "reference_text": "[1] Spina E, de Leon J \"Metabolic drug interactions with newer antipsychotics: a comparative review.\" Basic Clin Pharmacol Toxicol 100 (2007): 4-22[2] \"Quetiapine for schizophrenia.\" Med Lett Drugs Ther 39 (1997): 117-8[3] DeVane CL, Nemeroff CB \"Clinical pharmacokinetics of quetiapine - An atypical antipsychotic.\" Clin Pharmacokinet 40 (2001): 509-22[4] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB \"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\" Br J Clin Pharmacol 61 (2006): 58-69[5] Hantson P, Di Fazio V, Wallemacq P \"Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose.\" Drug Metab Lett 4 (2010): 7-8[6] Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. \"Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.\" Pharmacopsychiatry 41 (2008): 258-9[7] Spina E, Scordo MG, D'Arrigo C \"Metabolic drug interactions with new psychotropic agents.\" Fundam Clin Pharmacol 17 (2003): 517-38[8] Urichuk L, Prior TI, Dursun S, Baker G \"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.\" Curr Drug Metab 9 (2008): 410-8[9] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[10] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[17] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[19] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[20] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[21] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[22] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[23] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[24] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[25] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[28] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[29] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[32] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[35] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[36] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[39] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[40] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[41] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119484, "ingredient1": "Isavuconazonium", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119622/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119485, "ingredient1": "Isavuconazonium", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119623/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119486, "ingredient1": "Isavuconazonium", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if quinine is used in combination with potent and moderate CYP450 3A4 inhibitors. Patients should be monitored closely for adverse reactions associated with quinine such as hematologic toxicities and cardiac arrhythmias including torsade de pointes and atrial fibrillation. Patients should be advised to contact their physician if they experience increased side effects such as headache, flushing, sweating, nausea, vomiting, diarrhea, abdominal pain, tinnitus, dizziness, vertigo, hearing impairment, blurred vision, vision impairment, and irregular heart rhythm.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if quinine is used in combination with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119624/", "reference_text": "[1] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Wanwimolruk S, Paine MF, Pusek SN, Watkins PB \"Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?\" Br J Clin Pharmacol 54 (2002): 643-51[4] Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L \"Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.\" Eur J Clin Pharmacol 59 (2003): 23-8[5] Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL \"The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.\" Clin Pharmacol Ther 66 (1999): 454-60[6] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[7] Zhao XJ, Ishizaki T \"A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition.\" Eur J Drug Metab Pharm 24 (1999): 272-8[8] Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O \"Metabolism and elimination of quinine in healthy volunteers.\" Eur J Clin Pharmacol (2003):[9] Zhao XJ, Ishizaki T \"Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.\" Br J Clin Pharmacol 44 (1997): 505-11[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[12] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[16] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[17] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[18] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[19] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[21] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[22] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[23] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[24] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[25] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[26] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[27] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[28] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[30] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[31] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[36] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[37] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[38] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[39] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[45] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[46] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[47] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2[48] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119487, "ingredient1": "Isavuconazonium", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119625/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119488, "ingredient1": "Isavuconazonium", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes.", "source": "DDInter", "management_text": "The dosage of ranolazine should not exceed 500 mg twice a day when coadministered with moderate inhibitors of CYP450 3A4, including but not limited to diltiazem, verapamil, aprepitant, erythromycin, fluconazole, and grapefruit juice. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "The dosage of ranolazine should not exceed 500 mg twice a day when coadministered with moderate inhibitors of CYP450 3A4, including but not limited to diltiazem, verapamil, aprepitant, erythromycin, fluconazole, and grapefruit juice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119626/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] European Medicines Agency \"CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine. Procedure No. EMEA/H/C/805. Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/latixa/H-805-en6.pdf.\" ([cited 2008]):[3] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[4] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Adenosine, Regadenoson", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119489, "ingredient1": "Isavuconazonium", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.", "mechanism_text": "Metabolism", "recommendation": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119627/", "reference_text": "[1] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[2] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] Hatorp V, Hansen KT, Thomsen MS \"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.\" J Clin Pharmacol 43 (2003): 649-60[4] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ \"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.\" Diabetologia 46 (2003): 347-51[5] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[6] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT \"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.\" Br J Clin Pharmacol 56 (2003): 305-14[7] Tornio A, Niemi M, Neuvonen M, et al. \"The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.\" Clin Pharmacol Ther 84 (2008): 403-11[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[15] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[16] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[17] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[23] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[24] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[27] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[31] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[32] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[34] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[35] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[36] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[37] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[38] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[39] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119490, "ingredient1": "Isavuconazonium", "ingredient2": "Retapamulin (topical)", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of retapamulin, which is primarily metabolized by the isoenzyme. However, dosage adjustments are not necessary due to the low systemic exposure to retapamulin following topical application.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119628/", "reference_text": "[1] \"Product Information. Altabax (retapamulin topical).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119491, "ingredient1": "Isavuconazonium", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119629/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119492, "ingredient1": "Isavuconazonium", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119630/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119493, "ingredient1": "Isavuconazonium", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119631/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119494, "ingredient1": "Isavuconazonium", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119632/", "reference_text": "[1] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[2] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119495, "ingredient1": "Isavuconazonium", "ingredient2": "Rimegepant", "severity": "Moderate", "effect": "INTERVAL: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of rimegepant, which is primarily metabolized by the isoenzyme. Coadministration with a weak CYP450 3A4 inhibitor is not expected to have a clinically significant effect on rimegepant exposures.", "source": "DDInter", "management_text": "Following concomitant administration with a moderate CYP450 3A4 inhibitor, the manufacturer recommends avoiding another dose of rimegepant within 48 hours.", "mechanism_text": "Metabolism", "recommendation": "Following concomitant administration with a moderate CYP450 3A4 inhibitor, the manufacturer recommends avoiding another dose of rimegepant within 48 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119633/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119496, "ingredient1": "Isavuconazonium", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration of CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119634/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[19] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119497, "ingredient1": "Isavuconazonium", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with weak or moderate dual inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of rivaroxaban, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops. Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.", "mechanism_text": "Metabolism", "recommendation": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119635/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119498, "ingredient1": "Isavuconazonium", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of romidepsin, which is a substrate of the efflux transporter. Although there are no formal drug interaction studies, the interaction may increase the risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.", "source": "DDInter", "management_text": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors. Pharmacologic response to romidepsin should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the romidepsin dosage adjusted as necessary. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119636/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119499, "ingredient1": "Isavuconazonium", "ingredient2": "Ropivacaine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine. Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119637/", "reference_text": "[1] Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT \"The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.\" Anesth Analg 91 (2000): 1207-12[2] Ekstrom G, Gunnarsson UB \"Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.\" Drug Metab Dispos 24 (1996): 955-61[3] Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL \"Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.\" Clin Pharmacol Ther 64 (1998): 484-91[4] McClure JH \"Ropivacaine.\" Br J Anaesth 76 (1996): 300-7[5] \"Product Information. Naropin (ropivacaine).\" Astra USA, Westborough, MA.[6] Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M \"Metabolism and excretion of ropivacaine in humans.\" Drug Metab Dispos 24 (1996): 962-8[7] Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y \"Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.\" Anesthesiology 82 (1995): 214-20", "alternatives_a": "Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119500, "ingredient1": "Isavuconazonium", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119638/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119501, "ingredient1": "Isavuconazonium", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use with CYP450 3A4 inducers; the potential for decreased efficacy of isavuconazonium sulfate should be considered. Caution and clinical monitoring should also be considered during concomitant use of isavuconazonium sulfate and medicines known to shorten the QT interval.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use with CYP450 3A4 inducers; the potential for decreased efficacy of isavuconazonium sulfate should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119639/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[3] \"Product Information. Banzel (rufinamide).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119502, "ingredient1": "Isavuconazonium", "ingredient2": "Ruxolitinib", "severity": "Minor", "effect": "Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme. No dosage adjustment is recommended when ruxolitinib is coadministered with mild or moderate CYP450 3A4 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119640/", "reference_text": "[1] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119503, "ingredient1": "Isavuconazonium", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119641/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119504, "ingredient1": "Isavuconazonium", "ingredient2": "Selpercatinib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme. Increased exposure to selpercatinib may increase the risk of serious adverse effects such as QT interval prolongation, liver transaminase and bilirubin elevations, hypertension, hemorrhage, edema, and hypersensitivity reactions (e.g., fever, rash, arthralgias/myalgias with concurrent decreased platelets or transaminitis).", "source": "DDInter", "management_text": "Concomitant use of selpercatinib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends decreasing the dosage of selpercatinib. Patients receiving selpercatinib 120 mg twice daily should have the dosage reduced to 80 mg twice daily, and those receiving 160 mg twice daily should have the dosage reduced to 120 mg twice daily. Close monitoring for adverse effects is advisable, including more frequent ECGs and laboratory monitoring of liver enzymes, bilirubin, electrolytes, glucose, and blood counts. Selpercatinib treatment should be discontinued, interrupted, or dosage reduced in patients with serious or life-threatening toxicities in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selpercatinib with moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119642/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119505, "ingredient1": "Isavuconazonium", "ingredient2": "Selumetinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3. When coadministered with itraconazole, a potent CYP450 3A4 inhibitor, selumetinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 19% and 49%, respectively.", "source": "DDInter", "management_text": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, a reduction in the dosage of selumetinib is recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119643/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119506, "ingredient1": "Isavuconazonium", "ingredient2": "Sibutramine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme. Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119644/", "reference_text": "[1] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[3] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119507, "ingredient1": "Isavuconazonium", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of sildenafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119645/", "reference_text": "[1] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000): 392-7[4] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001): 239-48[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119508, "ingredient1": "Isavuconazonium", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of silodosin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4. Pharmacologic response to silodosin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the silodosin dosage adjusted as necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119646/", "reference_text": "[1] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Finasteride, Terazosin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119509, "ingredient1": "Isavuconazonium", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.", "source": "DDInter", "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119647/", "reference_text": "[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE \"Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.\" Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S \"Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.\" Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[4] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J \"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.\" N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M \"Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline.\" Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F \"New insights into the pharmacodynamic and pharmacokinetic properties of statins.\" Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC \"A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.\" J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG \"Rhabdomyolysis in association with simvastatin and amiodarone.\" Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S \"Rhabdomyolysis with simvastatin and nefazodone.\" Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[24] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[25] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995): 1639-45[26] \"Product Information. Baycol (cerivastatin).\" Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S \"Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.\" Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW \"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.\" Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[30] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[32] Westphal JF \"Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin.\" Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL \"Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers.\" J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR \"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.\" Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA \"Amiodarone's role in simvastatin-associated rhabdomyolysis.\" Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS \"Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.\" Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD \"The interaction of diltiazem with simvastatin.\" Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. \"Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.\" Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD \"The interaction of diltiazem with lovastatin and pravastatin.\" Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW \"Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.\" Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[52] Jody DN \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD \"Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.\" Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. \"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\" AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS \"Rhabdomyolysis associated with simvastatin-nefazodone therapy.\" South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H \"Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.\" J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD \"Interaction of diltiazem with lovastatin and pravastatin.\" Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH \"Erythromycin coadministration increases plasma atorvastatin concentrations.\" J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA \"Update on drug interactions with azole antifungal agents.\" Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A \"Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.\" Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[64] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[68] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[69] McMillan K \"Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors.\" Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M \"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved.\" Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119510, "ingredient1": "Isavuconazonium", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration with drugs that cause moderate inhibition of CYP450 2C9 and moderate or strong inhibition of CYP450 3A4 may increase the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/3A4 dual inhibitor or a moderate CYP450 2C9 inhibitor in combination with a separate moderate or strong CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Concomitant use of siponimod with a moderate or strong CYP450 2C9/3A4 dual inhibitor (e.g., fluconazole, mifepristone) or a moderate CYP450 2C9 inhibitor (e.g., abiraterone, amiodarone, fenofibrate, gemfibrozil, nitisinone, oxandrolone) in combination with a moderate or strong CYP450 3A4 inhibitor (e.g., amprenavir, aprepitant, atazanavir, boceprevir, ceritinib, chloramphenicol, ciprofloxacin, clarithromycin, cobicistat, conivaptan, crizotinib, dalfopristin-quinupristin, darunavir, delavirdine, diltiazem, dronedarone, erythromycin, fedratinib, fluvoxamine, fosamprenavir, fosaprepitant, fosnetupitant, fusidic acid, idelalisib, imatinib, indinavir, isavuconazole, itraconazole, ketoconazole, letermovir, mibefradil, nefazodone, nelfinavir, netupitant, posaconazole, ribociclib, ritonavir, saquinavir, stiripentol, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole, voxelotor) is not recommended. Caution is advised if siponimod is used in combination with moderate CYP450 2C9 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of siponimod with a moderate or strong CYP450 2C9/3A4 dual inhibitor (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119648/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119511, "ingredient1": "Isavuconazonium", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the blood concentrations of the macrolide immunosuppressants sirolimus and tacrolimus, both of which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119649/", "reference_text": "[1] Christians U, Schmidt G, Bader A, et al \"Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes.\" Br J Clin Pharmacol 41 (1996): 187-90[2] \"Product Information. Parlodel (bromocriptine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119512, "ingredient1": "Isavuconazonium", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of solifenacin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of solifenacin such as severe abdominal pain or constipation for 3 or more days. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119650/", "reference_text": "[1] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119513, "ingredient1": "Isavuconazonium", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119651/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119514, "ingredient1": "Isavuconazonium", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119652/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119515, "ingredient1": "Isavuconazonium", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119653/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119516, "ingredient1": "Isavuconazonium", "ingredient2": "Sonidegib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of sonidegib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends limiting use of the moderate CYP450 3A4 inhibitor to less than 14 days and monitoring for adverse reactions, particularly musculoskeletal toxicity.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of sonidegib with moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119654/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119517, "ingredient1": "Isavuconazonium", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119655/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119518, "ingredient1": "Isavuconazonium", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways. Conversely, many of these inhibitors are also substrates of CYP450 1A2 and/or 3A4, and coadministration with stiripentol may alter their plasma concentrations as well. Stiripentol is both an inhibitor and inducer of CYP450 1A2 and 3A4 in vitro.", "source": "DDInter", "management_text": "Caution is advised when stiripentol is used with inhibitors of CYP450 1A2 and/or 3A4 that are also substrates of these enzymatic pathways. Patients should be monitored for potentially increased adverse effects of stiripentol such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behavior, neutropenia, and thrombocytopenia. In addition, clinical and laboratory monitoring may be appropriate for concomitant drugs whenever stiripentol is added to or withdrawn from therapy. Dosage adjustments or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when stiripentol is used with inhibitors of CYP450 1A2 and/or 3A4 that are also substrates of these enzymatic pathways.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119656/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119519, "ingredient1": "Isavuconazonium", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119657/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119520, "ingredient1": "Isavuconazonium", "ingredient2": "Suvorexant", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The recommended dose of suvorexant is 5 mg when used with moderate CYP450 3A4 inhibitors, and generally should not exceed 10 mg.", "mechanism_text": "Metabolism", "recommendation": "The recommended dose of suvorexant is 5 mg when used with moderate CYP450 3A4 inhibitors, and generally should not exceed 10 mg.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119658/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119521, "ingredient1": "Isavuconazonium", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the blood concentrations of the macrolide immunosuppressants sirolimus and tacrolimus, both of which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119659/", "reference_text": "[1] Christians U, Schmidt G, Bader A, et al \"Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes.\" Br J Clin Pharmacol 41 (1996): 187-90[2] \"Product Information. Parlodel (bromocriptine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Caffeine, Diclofenac, Cromoglicic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119522, "ingredient1": "Isavuconazonium", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tadalafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone. Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119660/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119523, "ingredient1": "Isavuconazonium", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.", "source": "DDInter", "management_text": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Distribution", "recommendation": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119661/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119524, "ingredient1": "Isavuconazonium", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119662/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119525, "ingredient1": "Isavuconazonium", "ingredient2": "Tazemetostat", "severity": "Major", "effect": "Coadministration with moderate or potent CYP450 3A4 inhibitors may significantly increase the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in an increased risk of the frequency or severity of adverse reactions due to tazemetostat such as secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.", "source": "DDInter", "management_text": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided. Alternative therapeutic agents with less inhibitory potential should be considered whenever possible. If coadministration with a moderate CYP450 3A4 inhibitor is required and no other alternatives are possible, the dose of tazemetostat should be reduced as per manufacturer recommendations. After the inhibitor has been discontinued for 3 elimination half-lives, the tazemetostat dose that was taken prior to initiating the inhibitor may be resumed. Patients should be advised to notify their health care professional if they experience signs or symptoms of possible tazemetostat-related adverse effects including secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119663/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119526, "ingredient1": "Isavuconazonium", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119664/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119527, "ingredient1": "Isavuconazonium", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119665/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119528, "ingredient1": "Isavuconazonium", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119666/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119529, "ingredient1": "Isavuconazonium", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of temsirolimus with inhibitors of CYP450 3A4 may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors. Pharmacologic response to temsirolimus should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the temsirolimus dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119667/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119530, "ingredient1": "Isavuconazonium", "ingredient2": "Teniposide", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119668/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119531, "ingredient1": "Isavuconazonium", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119669/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119532, "ingredient1": "Isavuconazonium", "ingredient2": "Testosterone (topical)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119670/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119533, "ingredient1": "Isavuconazonium", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119671/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119534, "ingredient1": "Isavuconazonium", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents. Discontinuation of the concomitant medication may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119672/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119535, "ingredient1": "Isavuconazonium", "ingredient2": "Tinidazole", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119673/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Tetracycline, Norfloxacin, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119536, "ingredient1": "Isavuconazonium", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119674/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119537, "ingredient1": "Isavuconazonium", "ingredient2": "Tofacitinib", "severity": "Moderate", "effect": "Coadministration with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19 may significantly increase the plasma concentrations of tofacitinib, which is primarily metabolized by the former isoenzyme with minor contribution from the latter. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.", "source": "DDInter", "management_text": "The dosage of tofacitinib should be reduced by 50% when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19. For example, the dose for patients receiving 10 mg twice daily should be reduced to 5 mg twice daily and the dose for patients receiving 5 mg twice daily should be reduced to 5 mg once daily. For patients receiving 11 mg once daily of the extended-release formulation, the dose should be reduced to 5 mg once daily of the immediate-release formulation. The dose for patients receiving 3.2 mg twice daily should be reduced to 3.2 mg once daily and the dose for patients receiving 4 mg twice daily should be reduced to 4 mg once daily. Moderate inhibitors of CYP450 3A4 include amiodarone, aprepitant, ciprofloxacin, crizotinib, darunavir, dalfopristin-quinupristin, diltiazem, dronedarone, erythromycin, fluconazole, fusidic acid, grapefruit juice, imatinib, isavuconazonium, netupitant, and verapamil. Potent inhibitors of CYP450 2C19 include fluconazole, fluvoxamine, esomeprazole, lansoprazole, and omeprazole. Inhibitors of CYP450 2C19 alone are unlikely to substantially alter the pharmacokinetics of tofacitinib.", "mechanism_text": "Metabolism", "recommendation": "The dosage of tofacitinib should be reduced by 50% when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119675/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119538, "ingredient1": "Isavuconazonium", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered. Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.", "source": "DDInter", "management_text": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119676/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L \"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.\" Br J Clin Pharmacol 48 (1999): 564-72", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119539, "ingredient1": "Isavuconazonium", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119677/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119540, "ingredient1": "Isavuconazonium", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy. Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should be obtained periodically. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119678/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Abiraterone, Exemestane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119541, "ingredient1": "Isavuconazonium", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119679/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119542, "ingredient1": "Isavuconazonium", "ingredient2": "Trametinib", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119680/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119543, "ingredient1": "Isavuconazonium", "ingredient2": "Tretinoin", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119681/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119544, "ingredient1": "Isavuconazonium", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119682/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119545, "ingredient1": "Isavuconazonium", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119683/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119546, "ingredient1": "Isavuconazonium", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119684/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119547, "ingredient1": "Isavuconazonium", "ingredient2": "Tucatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119685/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119548, "ingredient1": "Isavuconazonium", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with moderate or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors. If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119686/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119549, "ingredient1": "Isavuconazonium", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119687/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119550, "ingredient1": "Isavuconazonium", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119688/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119551, "ingredient1": "Isavuconazonium", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119689/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119552, "ingredient1": "Isavuconazonium", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119690/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119553, "ingredient1": "Isavuconazonium", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV). The possibility of prolonged and/or increased pharmacologic effects of venlafaxine should be considered. Although venlafaxine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of venlafaxine. The interaction may be of greater concern in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119691/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[15] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[16] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[17] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[18] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[23] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[24] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[25] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[26] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[27] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[28] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[35] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[36] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[37] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[38] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[39] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119554, "ingredient1": "Isavuconazonium", "ingredient2": "Vilazodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "mechanism_text": "Metabolism", "recommendation": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119692/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119555, "ingredient1": "Isavuconazonium", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119693/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119556, "ingredient1": "Isavuconazonium", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119694/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119557, "ingredient1": "Isavuconazonium", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119695/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119558, "ingredient1": "Isavuconazonium", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119696/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119559, "ingredient1": "Isavuconazonium", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119697/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119560, "ingredient1": "Isavuconazonium", "ingredient2": "Voxelotor", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the systemic exposure (AUC) to voxelotor, which has been shown to be a substrate of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor. Dose adjustments may be necessary. Patients should be closely monitored for signs of voxelotor-related adverse effects, including headache, diarrhea, abdominal pain, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119698/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc., South San Francisco, CA.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119561, "ingredient1": "Isavuconazonium", "ingredient2": "Zanubrutinib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme. Increased zanubrutinib exposure may potentiate the risk of toxicities such as hemorrhage, infection, cytopenias, malignancies, and atrial fibrillation or flutter.", "source": "DDInter", "management_text": "The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors. Patients should be closely monitored for development of zanubrutinib-related toxicities, and further dosage adjustments made or treatment withheld as needed in accordance with the product labeling. Following discontinuation of the CYP450 3A4 inhibitor, the previous dosage of zanubrutinib should be resumed.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119699/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119562, "ingredient1": "Isavuconazonium", "ingredient2": "Ziprasidone", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119700/", "reference_text": "[1] Miceli JJ, Smith M, Robarge L, Morse T, Laurent A \"The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.\" Br J Clin Pharmacol 49(suppl 1) (2000): s71-6[2] Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D \"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.\" Br J Clin Pharmacol 49(Suppl 1) (2000): 35S-42S[3] Wilner KD, Hansen RA, Folger CJ, Geoffroy P \"The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.\" Br J Clin Pharmacol 49(Suppl 1) (2000): 57S-60S[4] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119563, "ingredient1": "Isavuconazonium", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119701/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119564, "ingredient1": "Isavuconazonium", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme. While clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of zonisamide should be considered.", "source": "DDInter", "management_text": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119702/", "reference_text": "[1] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M \"Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.\" Eur J Clin Pharmacol 54 (1998): 177-83[2] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119565, "ingredient1": "Isocarboxazid", "ingredient2": "Oxitriptan", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119703/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Esketamine", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119566, "ingredient1": "Isocarboxazid", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119704/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "updated_at": 1767369485}, {"id": 119567, "ingredient1": "Isocarboxazid", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119705/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 119568, "ingredient1": "Isocarboxazid", "ingredient2": "Amoxapine", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119706/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Amoxapine, Viloxazine", "updated_at": 1767369485}, {"id": 119569, "ingredient1": "Isocarboxazid", "ingredient2": "Amyl Nitrite", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119707/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 119570, "ingredient1": "Isocarboxazid", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119708/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119571, "ingredient1": "Isocarboxazid", "ingredient2": "Belladonna", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119709/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119572, "ingredient1": "Isocarboxazid", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119710/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 119573, "ingredient1": "Isocarboxazid", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119711/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Nortriptyline, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 119574, "ingredient1": "Isocarboxazid", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119712/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Paroxetine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119575, "ingredient1": "Isocarboxazid", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.", "source": "DDInter", "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119713/", "reference_text": "[1] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[2] Domino EF, Sullivan TS, Luby ED \"Barbiturate intoxication in a patient treated with a MAO inhibitor.\" Am J Psychiatry 118 (1962): 941-3[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 119576, "ingredient1": "Isocarboxazid", "ingredient2": "Pentoxyverine", "severity": "Major", "effect": "Labelings for products containing carbetapentane state that the drug should not be used in combination with monoamine oxidase inhibitors (MAOIs). No data are available regarding a potential interaction. However, serious and fatal reactions have been associated with another cough suppressant, dextromethorphan, during coadministration with MAOIs. Dextromethorphan is a weak serotonin reuptake inhibitor whose serotonergic activity may be enhanced by MAOIs. The result is an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A receptors and characterized by symptoms such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.", "source": "DDInter", "management_text": "Products containing carbetapentane should not be used concurrently with MAOIs or for 14 days after stopping treatment with an MAOI.", "mechanism_text": "Synergism", "recommendation": "Products containing carbetapentane should not be used concurrently with MAOIs or for 14 days after stopping treatment with an MAOI.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119714/", "reference_text": "[1] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[2] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[3] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[4] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[5] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[6] Magurno JA, Board AW \"MAOIs, OTC drugs, and hypertensive crisis.\" J Clin Psychiatry 51 (1990): 212-3[7] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[8] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[9] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[10] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[11] \"Product Information. solotuss (carbetapentane).\" Hawthorn Pharmaceuticals, Madison, MS.[12] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[13] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[14] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[15] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[16] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[17] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[18] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[19] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[20] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[21] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[22] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[23] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[24] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[25] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[26] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[27] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[28] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[29] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[30] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[31] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[32] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[33] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[34] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[35] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 119577, "ingredient1": "Isocarboxazid", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119715/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 119578, "ingredient1": "Isocarboxazid", "ingredient2": "Clofedanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119716/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 119579, "ingredient1": "Isocarboxazid", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119717/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119580, "ingredient1": "Isocarboxazid", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119718/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Duloxetine, Vilazodone, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, More", "alternatives_b": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 119581, "ingredient1": "Isocarboxazid", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119719/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Doxepin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119582, "ingredient1": "Isocarboxazid", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119720/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119583, "ingredient1": "Isocarboxazid", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119721/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119584, "ingredient1": "Isocarboxazid", "ingredient2": "Cyclandelate", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119722/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Pentoxifylline, Niacin", "updated_at": 1767369485}, {"id": 119585, "ingredient1": "Isocarboxazid", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119723/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119586, "ingredient1": "Isocarboxazid", "ingredient2": "Cyproheptadine", "severity": "Moderate", "effect": "Cyproheptadine may antagonize the therapeutic effect of monoamine oxidase inhibitors (MAOIs). This interaction was reported in one patient treated with phenelzine for chronic depression. Another patient developed visual hallucinations following the addition of cyproheptadine to a stabilized regimen of phenelzine. Causality has not been definitely established. The mechanism is unknown but may be related to the antiserotonergic activity of cyproheptadine. MAOIs may also potentiate the sedative and anticholinergic effects of cyproheptadine.", "source": "DDInter", "management_text": "Patients should be monitored for potentially diminished therapeutic response to MAOIs and increased antihistaminic effects of cyproheptadine during coadministration. Discontinuation of cyproheptadine may be necessary if an interaction is suspected.", "mechanism_text": "Antagonism", "recommendation": "Patients should be monitored for potentially diminished therapeutic response to MAOIs and increased antihistaminic effects of cyproheptadine during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119724/", "reference_text": "[1] Katz RJ, Rosenthal M \"Adverse interaction of cyproheptadine with serotonergic antidepressants.\" J Clin Psychiatry 55 (1994): 314-5[2] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[3] Zubieta JK, Demitrack MA \"Depression after cyproheptadine: MAO treatment .\" Biol Psychiatry 31 (1992): 1177-8[4] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[6] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[8] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[9] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[10] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[11] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[12] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[13] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[14] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[17] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[18] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[19] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[20] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[21] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[22] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[23] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[24] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[25] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[26] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[27] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Bupropion, Viloxazine", "updated_at": 1767369485}, {"id": 119587, "ingredient1": "Isocarboxazid", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "The addition of a rauwolfia alkaloid to existing monoamine oxidase inhibitor (MAOI) therapy may result in profound excitation and/or a hypertensive reaction. The proposed mechanism is increased norepinephrine levels at adrenergic receptors due to both the inhibition of catecholamine metabolism by MAOIs and the release of catecholamines induced by rauwolfia alkaloids.", "source": "DDInter", "management_text": "In general, rauwolfia alkaloids should not be administered to patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with rauwolfia alkaloids.", "mechanism_text": "Synergism", "recommendation": "In general, rauwolfia alkaloids should not be administered to patients treated with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119725/", "reference_text": "[1] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975): 86-90[2] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Trimipramine, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119588, "ingredient1": "Isocarboxazid", "ingredient2": "Desflurane", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119726/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119589, "ingredient1": "Isocarboxazid", "ingredient2": "Dexbrompheniramine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119727/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119590, "ingredient1": "Isocarboxazid", "ingredient2": "Dexfenfluramine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119728/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Orlistat, Naltrexone", "alternatives_b": "Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 119591, "ingredient1": "Isocarboxazid", "ingredient2": "Dezocine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119729/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119592, "ingredient1": "Isocarboxazid", "ingredient2": "Dimenhydrinate", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119730/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119593, "ingredient1": "Isocarboxazid", "ingredient2": "Dobutamine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119731/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 119594, "ingredient1": "Isocarboxazid", "ingredient2": "Enflurane", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119732/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119595, "ingredient1": "Isocarboxazid", "ingredient2": "Entacapone", "severity": "Major", "effect": "Theoretically, coadministration of monoamine oxidase (MAO) inhibitors and catechol-O-methyltransferase (COMT) inhibitors may potentiate the risk of hypertensive crisis and serotonin syndrome, the latter of which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. MAO and COMT are the two major enzymatic pathways involved in the metabolism of catecholamines, thus inhibition of both systems may lead to excessive levels of norepinephrine and serotonin. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, COMT inhibitors should not be used concurrently with nonselective MAO inhibitors or other agents that possess MAO inhibiting activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAO inhibitor therapy and initiation of treatment with COMT inhibitors.", "mechanism_text": "Synergism", "recommendation": "In general, COMT inhibitors should not be used concurrently with nonselective MAO inhibitors or other agents that possess MAO inhibiting activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119733/", "reference_text": "[1] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[3] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[6] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[7] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[8] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[9] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[10] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[14] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[15] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[16] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[17] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[18] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[19] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[20] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[21] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[22] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[23] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[24] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[25] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[26] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[29] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[30] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[31] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[32] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[33] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[34] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119596, "ingredient1": "Isocarboxazid", "ingredient2": "Ephedrine", "severity": "Major", "effect": "Indirect- or mixed-acting sympathomimetic amines may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Death has occurred in some reported cases. The mechanism involves a synergistic sympathomimetic effect due to enhanced norepinephrine storage in adrenergic neurons (MAOI activity) and increased liberation of catecholamines (indirect sympathomimetic activity).", "source": "DDInter", "management_text": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119734/", "reference_text": "[1] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[2] Davies B, Bannister R, Sever P \"Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards.\" Lancet 1 (1978): 172-5[3] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[4] Mason AM, Buckle RM \"\"Cold\" cures and monoamine-oxidase inhibitors.\" Br Med J 1 (1969): 845-6[5] Cuthbert MF, Greenberg MP, Morley SW \"Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.\" Br Med J 1 (1969): 404-6[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[7] Horler AR, Wynne NA \"Hypertensive crisis due to pargyline and metaraminol.\" Br Med J 5459 (1965): 460-1[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[10] Humberstone PM \"Hypertension from cold remedies.\" Br Med J 1 (1969): 846[11] Kraft KE, Dore FH \"Computerized drug interaction programs: how reliable?.\" JAMA 275 (1996): 1087[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[13] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[14] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[15] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[18] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[21] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[22] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[23] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[24] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[25] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[26] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[27] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[28] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[29] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[30] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[31] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[32] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[33] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[34] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[35] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[36] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[37] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[38] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[39] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[40] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[41] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[42] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[43] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Trazodone, More", "alternatives_b": "Tropicamide, Ketorolac, Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 119597, "ingredient1": "Isocarboxazid", "ingredient2": "Ephedrine (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119735/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, Desipramine, More", "alternatives_b": "Tropicamide, Ketorolac, Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 119598, "ingredient1": "Isocarboxazid", "ingredient2": "Epinephrine (ophthalmic)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119736/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Hydrocortisone, Metronidazole, Clotrimazole, Prednisolone, Triamcinolone, Acetylsalicylic acid, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 119599, "ingredient1": "Isocarboxazid", "ingredient2": "Epinephrine (topical)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119737/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Hydrocortisone, Metronidazole, Clotrimazole, Prednisolone, Triamcinolone, Acetylsalicylic acid, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 119600, "ingredient1": "Isocarboxazid", "ingredient2": "Eplerenone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119738/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Finerenone", "alternatives_b": "Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "updated_at": 1767369485}, {"id": 119601, "ingredient1": "Isocarboxazid", "ingredient2": "Epoprostenol", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119739/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Desipramine, Trimipramine, Maprotiline, St. John's Wort, Oxitriptan, Mirtazapine, Bupropion, Viloxazine, Trazodone, Nortriptyline, Tryptophan, More", "updated_at": 1767369485}, {"id": 119602, "ingredient1": "Isocarboxazid", "ingredient2": "Eprosartan", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119740/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sacubitril", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 119603, "ingredient1": "Isocarboxazid", "ingredient2": "Ergotamine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119741/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Desipramine, Esketamine", "updated_at": 1767369485}, {"id": 119604, "ingredient1": "Isocarboxazid", "ingredient2": "Escitalopram", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119742/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 119605, "ingredient1": "Isocarboxazid", "ingredient2": "Esketamine", "severity": "Major", "effect": "Coadministration with psychostimulants (e.g., amphetamines) or monoamine oxidase inhibitors (MAOIs) may potentiate the hypertensive effects of esketamine.", "source": "DDInter", "management_text": "Caution is advised and blood pressure should be closely monitored during concomitant use of esketamine with psychostimulants or MAOIs. All patients receiving esketamine should have BP assessed prior to administration. If BP is elevated (e.g., >140 mmHg systolic, >90 mmHg diastolic), a delay in esketamine treatment may be necessary, taking into consideration the benefits versus risks in individual patients. BP should be monitored for at least 2 hours after esketamine administration, starting at approximately 40 minutes post-dose and subsequently as clinically warranted. In patients with a history of hypertensive encephalopathy, more intensive monitoring is warranted due to increased risk for developing encephalopathy with even small increases in BP. If at any point BP is elevated and remains high, promptly seek assistance from practitioners experienced in BP management. Patients experiencing symptoms of a hypertensive crisis (e.g., chest pain, shortness of breath) or hypertensive encephalopathy (e.g., sudden severe headache, visual disturbances, seizures, diminished consciousness or focal neurological deficits) should be immediately referred for emergency care.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and blood pressure should be closely monitored during concomitant use of esketamine with psychostimulants or MAOIs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119743/", "reference_text": "[1] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119606, "ingredient1": "Isocarboxazid", "ingredient2": "Eslicarbazepine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119744/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119607, "ingredient1": "Isocarboxazid", "ingredient2": "Esmolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119745/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119608, "ingredient1": "Isocarboxazid", "ingredient2": "Estazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119746/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119609, "ingredient1": "Isocarboxazid", "ingredient2": "Eszopiclone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119747/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119610, "ingredient1": "Isocarboxazid", "ingredient2": "Etacrynic acid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119748/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119611, "ingredient1": "Isocarboxazid", "ingredient2": "Ethosuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119749/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Tryptophan", "updated_at": 1767369485}, {"id": 119612, "ingredient1": "Isocarboxazid", "ingredient2": "Ethotoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119750/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119613, "ingredient1": "Isocarboxazid", "ingredient2": "Etomidate", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119751/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119614, "ingredient1": "Isocarboxazid", "ingredient2": "Ezogabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119752/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119615, "ingredient1": "Isocarboxazid", "ingredient2": "Felbamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119753/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119616, "ingredient1": "Isocarboxazid", "ingredient2": "Felodipine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119754/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Mibefradil, Celecoxib", "alternatives_b": "Desipramine, Vilazodone, Desvenlafaxine, Maprotiline, Oxitriptan, Trazodone, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Amoxapine, More", "updated_at": 1767369485}, {"id": 119617, "ingredient1": "Isocarboxazid", "ingredient2": "Fenfluramine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119755/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Orlistat, Naltrexone, Lacosamide", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119618, "ingredient1": "Isocarboxazid", "ingredient2": "Fenoldopam", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119756/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 119619, "ingredient1": "Isocarboxazid", "ingredient2": "Flavoxate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119757/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119620, "ingredient1": "Isocarboxazid", "ingredient2": "Flibanserin", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119758/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Tryptophan", "alternatives_b": "Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 119621, "ingredient1": "Isocarboxazid", "ingredient2": "Fluphenazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119759/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119622, "ingredient1": "Isocarboxazid", "ingredient2": "Flurazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119760/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119623, "ingredient1": "Isocarboxazid", "ingredient2": "Fluvoxamine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119761/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Viloxazine, Fluvoxamine, Esketamine", "updated_at": 1767369485}, {"id": 119624, "ingredient1": "Isocarboxazid", "ingredient2": "Fosinopril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119762/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119625, "ingredient1": "Isocarboxazid", "ingredient2": "Fosphenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119763/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119626, "ingredient1": "Isocarboxazid", "ingredient2": "Fospropofol", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119764/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Vilazodone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119627, "ingredient1": "Isocarboxazid", "ingredient2": "Frovatriptan", "severity": "Major", "effect": "The 5-HT1 receptor agonists used to treat migraine headaches exhibit modest 5-HT1A activity. Theoretically, MAOIs may potentiate the serotonergic activity of 5-HT1 receptor agonists and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of serotonin metabolism. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "Concomitant use of 5-HT1 receptor agonists with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) should generally be avoided. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with 5-HT1 receptor agonists. Otherwise, patients should be closely monitored for adverse effects related to excessive serotonergic activity.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of 5-HT1 receptor agonists with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119765/", "reference_text": "[1] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[2] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[3] Fleishaker JC, Ryan KK, Jansat JM, et al. \"Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.\" Br J Clin Pharmacol 51 (2001): 437-41[4] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[5] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[9] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Bupropion, Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 119628, "ingredient1": "Isocarboxazid", "ingredient2": "Furosemide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119766/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 119629, "ingredient1": "Isocarboxazid", "ingredient2": "Gabapentin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119767/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119630, "ingredient1": "Isocarboxazid", "ingredient2": "Ginkgo biloba", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119768/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "updated_at": 1767369485}, {"id": 119631, "ingredient1": "Isocarboxazid", "ingredient2": "Ginseng", "severity": "Moderate", "effect": "Ginseng may potentiate the effects of monoamine oxidase inhibitors (MAOIs). Headaches, tremors, insomnia, and/or manic episodes have been reported rarely in patients receiving phenelzine concurrently with or following the addition of ginseng. An inadvertent rechallenge in one case led to similar reactions. The mechanism of interaction is unknown, although ginseng reportedly may have central nervous system stimulating and psychoactive properties.", "source": "DDInter", "management_text": "In general, patients should consult a healthcare provider before taking any herbal or alternative medicine. While data are limited, it may be prudent to avoid the use of ginseng in patients receiving MAOIs or other agents which possess MAOI activity (e.g., furazolidone, linezolid, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with agents that may interact with MAOIs.", "mechanism_text": "Synergism", "recommendation": "In general, patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119769/", "reference_text": "[1] Jones BD, Runikis AM \"Interaction of ginseng with phenelzine.\" J Clin Psychopharmacol 7 (1987): 201-2[2] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[3] Shader RI, Greenblatt DJ \"Bees, ginseng and MAOIs revisited.\" J Clin Psychopharmacol 8 (1988): 235[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[6] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[8] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[9] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[10] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[11] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[12] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[13] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[14] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[17] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[18] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[19] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[20] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[21] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[22] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[23] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119632, "ingredient1": "Isocarboxazid", "ingredient2": "Glipizide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119770/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Esketamine", "updated_at": 1767369485}, {"id": 119633, "ingredient1": "Isocarboxazid", "ingredient2": "Glyburide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119771/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Desvenlafaxine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Esketamine", "updated_at": 1767369485}, {"id": 119634, "ingredient1": "Isocarboxazid", "ingredient2": "Glycopyrronium", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119772/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 119635, "ingredient1": "Isocarboxazid", "ingredient2": "Granisetron", "severity": "Major", "effect": "Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), 5-HT1 receptor agonists (triptans), ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John's wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome.", "source": "DDInter", "management_text": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is typically recommended following use of fluoxetine and 2 weeks following use of MAOIs before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119773/", "reference_text": "[1] \"Product Information. Akynzeo (netupitant-palonosetron).\" Eisai Inc, Woodcliff Lake, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Sancuso (granisetron).\" ProStrakan Group, Bedminster, NJ.[6] \"Product Information. Aloxi (palonosetron).\" MGI Pharma Inc, Minnetonka, MN.[7] \"Product Information. Anzemet (dolasetron).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Rolapitant, Aprepitant", "alternatives_b": "Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 119636, "ingredient1": "Isocarboxazid", "ingredient2": "Guanabenz", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119774/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119637, "ingredient1": "Isocarboxazid", "ingredient2": "Guanadrel", "severity": "Moderate", "effect": "Theoretically, monoamine oxidase inhibitors (MAOIs) may antagonize the hypotensive effect of peripherally-acting antiadrenergic agents like guanadrel and guanethidine that work by depleting catecholamine stores from adrenergic nerve endings. MAOIs inhibit the breakdown of catecholamines and enhance storage in adrenergic neurons.", "source": "DDInter", "management_text": "While clinical data are lacking, guanadrel and guanethidine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). The manufacturer of phenelzine considers the combination contraindicated. At least 7 to 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with guanadrel or guanethidine. If they have been used together, clinicians should be aware that significant hypotension may occur following withdrawal of MAOI therapy.", "mechanism_text": "Antagonism", "recommendation": "While clinical data are lacking, guanadrel and guanethidine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119775/", "reference_text": "[1] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[2] Iversen LL \"Inhibition of noradrenaline uptake by drugs.\" J Pharm Pharmacol 17 (1965): 62-4[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[6] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[7] Lee CH, Strosberg AM, Warren LA \"The importance of catecholamine uptake in the reversal of guenethidine blockade of adrenergic neurons.\" Res Commun Chem Pathol Pharmacol 30 (1980): 3-14[8] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966): 510-4[9] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[14] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[15] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[16] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[17] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[18] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[19] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[20] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[21] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[22] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[23] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[24] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[25] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[26] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[27] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119638, "ingredient1": "Isocarboxazid", "ingredient2": "Guanethidine", "severity": "Moderate", "effect": "Theoretically, monoamine oxidase inhibitors (MAOIs) may antagonize the hypotensive effect of peripherally-acting antiadrenergic agents like guanadrel and guanethidine that work by depleting catecholamine stores from adrenergic nerve endings. MAOIs inhibit the breakdown of catecholamines and enhance storage in adrenergic neurons.", "source": "DDInter", "management_text": "While clinical data are lacking, guanadrel and guanethidine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). The manufacturer of phenelzine considers the combination contraindicated. At least 7 to 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with guanadrel or guanethidine. If they have been used together, clinicians should be aware that significant hypotension may occur following withdrawal of MAOI therapy.", "mechanism_text": "Antagonism", "recommendation": "While clinical data are lacking, guanadrel and guanethidine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119776/", "reference_text": "[1] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[2] Iversen LL \"Inhibition of noradrenaline uptake by drugs.\" J Pharm Pharmacol 17 (1965): 62-4[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[6] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[7] Lee CH, Strosberg AM, Warren LA \"The importance of catecholamine uptake in the reversal of guenethidine blockade of adrenergic neurons.\" Res Commun Chem Pathol Pharmacol 30 (1980): 3-14[8] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966): 510-4[9] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[14] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[15] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[16] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[17] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[18] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[19] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[20] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[21] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[22] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[23] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[24] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[25] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[26] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[27] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 119639, "ingredient1": "Isocarboxazid", "ingredient2": "Guanfacine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119777/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Sertraline, Desvenlafaxine, Fluoxetine, Oxitriptan, Tryptophan, Milnacipran, Vortioxetine, Levomilnacipran, Vilazodone, Paroxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119640, "ingredient1": "Isocarboxazid", "ingredient2": "Halazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119778/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119641, "ingredient1": "Isocarboxazid", "ingredient2": "Haloperidol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119779/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119642, "ingredient1": "Isocarboxazid", "ingredient2": "Halothane", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119780/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119643, "ingredient1": "Isocarboxazid", "ingredient2": "Diamorphine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119781/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 119644, "ingredient1": "Isocarboxazid", "ingredient2": "Hydralazine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119782/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119645, "ingredient1": "Isocarboxazid", "ingredient2": "Hydroflumethiazide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119783/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Nortriptyline, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 119646, "ingredient1": "Isocarboxazid", "ingredient2": "Hydromorphone", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119784/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119647, "ingredient1": "Isocarboxazid", "ingredient2": "Hydroxyzine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119785/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119648, "ingredient1": "Isocarboxazid", "ingredient2": "Ifosfamide", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119786/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993): 2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119649, "ingredient1": "Isocarboxazid", "ingredient2": "Iloperidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119787/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 119650, "ingredient1": "Isocarboxazid", "ingredient2": "Iloprost", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119788/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Desipramine, Trimipramine, Maprotiline, St. John's Wort, Oxitriptan, Viloxazine, Trazodone, Amitriptyline, Tryptophan, Amoxapine, Imipramine, More", "updated_at": 1767369485}, {"id": 119651, "ingredient1": "Isocarboxazid", "ingredient2": "Imipramine", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119789/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Imipramine", "updated_at": 1767369485}, {"id": 119652, "ingredient1": "Isocarboxazid", "ingredient2": "Amrinone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119790/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Arbutamine, Angiotensin II", "updated_at": 1767369485}, {"id": 119653, "ingredient1": "Isocarboxazid", "ingredient2": "Indacaterol", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119791/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "St. John's Wort, Oxitriptan, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Paroxetine", "alternatives_b": "Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 119654, "ingredient1": "Isocarboxazid", "ingredient2": "Indapamide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119792/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 119655, "ingredient1": "Isocarboxazid", "ingredient2": "Insulin human", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119793/", "reference_text": "[1] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[36] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[45] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[48] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[52] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[53] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[54] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[56] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[60] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[70] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[78] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[79] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[83] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[84] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[85] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, Desipramine, More", "updated_at": 1767369485}, {"id": 119656, "ingredient1": "Isocarboxazid", "ingredient2": "Insulin aspart (aspart protamine)", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119794/", "reference_text": "[1] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[36] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[45] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[48] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[52] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[53] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[54] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[56] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[60] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[70] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[78] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[79] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[83] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[84] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[85] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Maprotiline, St. John's Wort, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, Desipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119657, "ingredient1": "Isocarboxazid", "ingredient2": "Insulin lispro", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119795/", "reference_text": "[1] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[36] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[45] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[48] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[52] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[53] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[54] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[56] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[60] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[70] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[78] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[79] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[83] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[84] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[85] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, Desipramine, More", "updated_at": 1767369485}, {"id": 119658, "ingredient1": "Isocarboxazid", "ingredient2": "Insulin lispro (protamine)", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119796/", "reference_text": "[1] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[36] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[45] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[48] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[52] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[53] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[54] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[56] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[60] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[70] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[78] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[79] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[83] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[84] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[85] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Maprotiline, St. John's Wort, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, Desipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119659, "ingredient1": "Isocarboxazid", "ingredient2": "Insulin human (zinc)", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119797/", "reference_text": "[1] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[36] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[45] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[48] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[52] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[53] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[54] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[56] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[60] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[70] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[78] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[79] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[83] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[84] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[85] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, Desipramine, More", "updated_at": 1767369485}, {"id": 119660, "ingredient1": "Isocarboxazid", "ingredient2": "Insulin human (zinc extended)", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119798/", "reference_text": "[1] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[36] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[45] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[48] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[52] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[53] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[54] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[56] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[60] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[70] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[78] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[79] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[83] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[84] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[85] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, Desipramine, More", "updated_at": 1767369485}, {"id": 119661, "ingredient1": "Isocarboxazid", "ingredient2": "Iohexol", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119799/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 119662, "ingredient1": "Isocarboxazid", "ingredient2": "Iopamidol", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119800/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 119663, "ingredient1": "Isocarboxazid", "ingredient2": "Irbesartan", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119801/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sacubitril", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 119664, "ingredient1": "Isoetharine", "ingredient2": "Isocarboxazid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119802/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119665, "ingredient1": "Isoflurane", "ingredient2": "Isocarboxazid", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119803/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119666, "ingredient1": "Isoprenaline", "ingredient2": "Isocarboxazid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119804/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "alternatives_b": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119667, "ingredient1": "Isosorbide", "ingredient2": "Isocarboxazid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119805/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119668, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Isocarboxazid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119806/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 119669, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Isocarboxazid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119807/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Vericiguat", "alternatives_b": "Desipramine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More", "updated_at": 1767369485}, {"id": 119670, "ingredient1": "Isoxsuprine", "ingredient2": "Isocarboxazid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119808/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Pentoxifylline, Niacin", "updated_at": 1767369485}, {"id": 119671, "ingredient1": "Isocarboxazid", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119809/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119672, "ingredient1": "Isocarboxazid", "ingredient2": "Ketamine", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119810/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119673, "ingredient1": "Isocarboxazid", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119811/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Duloxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119674, "ingredient1": "Isocarboxazid", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119812/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Viloxazine, St. John's Wort, Tryptophan", "updated_at": 1767369485}, {"id": 119675, "ingredient1": "Isocarboxazid", "ingredient2": "Lasmiditan", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119813/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Viloxazine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 119676, "ingredient1": "Isocarboxazid", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119814/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119677, "ingredient1": "Isocarboxazid", "ingredient2": "Levosalbutamol", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119815/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119678, "ingredient1": "Isocarboxazid", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119816/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, More", "alternatives_b": "Mibefradil, Celecoxib", "updated_at": 1767369485}, {"id": 119679, "ingredient1": "Isocarboxazid", "ingredient2": "Levmetamfetamine (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119817/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119680, "ingredient1": "Isocarboxazid", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119818/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119681, "ingredient1": "Isocarboxazid", "ingredient2": "Levobunolol (ophthalmic)", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119819/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "updated_at": 1767369485}, {"id": 119682, "ingredient1": "Isocarboxazid", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119820/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer US Pharmaceuticals, New York, NY.[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc, Smyrna, GA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 119683, "ingredient1": "Isocarboxazid", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119821/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119684, "ingredient1": "Isocarboxazid", "ingredient2": "Levomilnacipran", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119822/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Viloxazine, Esketamine, Levomilnacipran", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119685, "ingredient1": "Isocarboxazid", "ingredient2": "Levorphanol", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119823/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119686, "ingredient1": "Isocarboxazid", "ingredient2": "Licorice", "severity": "Minor", "effect": "Some phenolic components of licorice may have monoamine oxidase inhibitor (MAOI) activity, in vitro. The clinical significance is unknown. Until more information is available, the concomitant use with other MAOIs should be approached cautiously.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119824/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119687, "ingredient1": "Isocarboxazid", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119825/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119688, "ingredient1": "Isocarboxazid", "ingredient2": "Linezolid", "severity": "Major", "effect": "Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and may have additive pharmacologic effects with other monoamine oxidase inhibitors (MAOIs). Theoretically, coadministration may increase the risk of a hypertensive crisis. Concomitant use of linezolid with other MAOIs may also increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Rare cases of serotonin syndrome have been reported in association with linezolid when used with other serotonergic agents.", "source": "DDInter", "management_text": "The use of linezolid concurrently or within two weeks of taking any drug that inhibits monoamine oxidase A or B is generally considered contraindicated. In emergency situations requiring urgent treatment with linezolid (e.g., vancomycin-resistant Enterococcus faecium (VRE) infections; nosocomial pneumonia and complicated skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus), the availability of alternative interventions should be considered in patients already receiving a MAOI and the benefit of linezolid treatment should be weighed against the risk of serotonin toxicity. If linezolid is required, the MAOI must be immediately stopped, and the patient closely monitored for emergent symptoms of CNS toxicity for two weeks (five weeks if fluoxetine was taken) or until 24 hours after the last dose of linezolid, whichever comes first. Patients and/or their caregivers should be advised to seek medical attention if potential symptoms of serotonin syndrome develop. Treatment with the MAOI may be resumed 24 hours after the last dose of linezolid.", "mechanism_text": "Synergism", "recommendation": "The use of linezolid concurrently or within two weeks of taking any drug that inhibits monoamine oxidase A or B is generally considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119826/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Ayvox) is given to patients taking certain psychiatric medications. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm#table.\" ([2011 July 26]):[2] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[3] Paladino JA \"Linezolid: an oxazolidinone antimicrobial agent.\" Am J Health Syst Pharm 59 (2002): 2413-25[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[6] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[8] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[9] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[10] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[11] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[12] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[13] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[14] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[17] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[18] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[19] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[20] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[21] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[22] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[23] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[24] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[25] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[26] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[27] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[28] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[29] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[30] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[31] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[32] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[33] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[34] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[35] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[36] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[37] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[38] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[39] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[40] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[41] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[42] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119689, "ingredient1": "Isocarboxazid", "ingredient2": "Lisdexamfetamine", "severity": "Major", "effect": "Centrally-acting sympathomimetic agents (i.e., CNS stimulants), particularly the amphetamines and amphetamine derivatives, may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). MAOIs also slow amphetamine metabolism, which may potentiate amphetamine effect on the release of norepinephrine and other monoamines from adrenergic nerve endings.", "source": "DDInter", "management_text": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119827/", "reference_text": "[1] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[2] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[3] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[4] Krisko I, Lewis E, Johnson JE \"Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity.\" Ann Intern Med 70 (1969): 559-64[5] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[6] \"Product Information. Vyvanse (lisdexamfetamine).\" Shire US Inc, Florence, KY.[7] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[10] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[11] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[12] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Dally PJ \"Fatal reaction associated with tranylcypromine and methylamphetamine.\" Lancet 1 (1962): 1235-6[15] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[16] \"Product Information. Dexedrine (dextroamphetamine)\" SmithKline Beecham, Philadelphia, PA.[17] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[18] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[19] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[20] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals, East Hanover, NJ.[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[42] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[43] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[44] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 119690, "ingredient1": "Isocarboxazid", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119828/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 119691, "ingredient1": "Isocarboxazid", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119829/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119692, "ingredient1": "Isocarboxazid", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119830/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 119693, "ingredient1": "Isocarboxazid", "ingredient2": "Lorazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119831/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119694, "ingredient1": "Isocarboxazid", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119832/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sacubitril", "alternatives_b": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 119695, "ingredient1": "Isocarboxazid", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119833/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119696, "ingredient1": "Isocarboxazid", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119834/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 119697, "ingredient1": "Isocarboxazid", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119835/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 119698, "ingredient1": "Isocarboxazid", "ingredient2": "Maprotiline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119836/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Maprotiline, Viloxazine", "updated_at": 1767369485}, {"id": 119699, "ingredient1": "Isocarboxazid", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119837/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Amoxapine, Imipramine, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 119700, "ingredient1": "Isocarboxazid", "ingredient2": "Mazindol", "severity": "Major", "effect": "Centrally-acting sympathomimetic agents (i.e., CNS stimulants), particularly the amphetamines and amphetamine derivatives, may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). MAOIs also slow amphetamine metabolism, which may potentiate amphetamine effect on the release of norepinephrine and other monoamines from adrenergic nerve endings.", "source": "DDInter", "management_text": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119838/", "reference_text": "[1] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[2] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[3] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[4] Krisko I, Lewis E, Johnson JE \"Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity.\" Ann Intern Med 70 (1969): 559-64[5] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[6] \"Product Information. Vyvanse (lisdexamfetamine).\" Shire US Inc, Florence, KY.[7] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[10] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[11] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[12] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Dally PJ \"Fatal reaction associated with tranylcypromine and methylamphetamine.\" Lancet 1 (1962): 1235-6[15] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[16] \"Product Information. Dexedrine (dextroamphetamine)\" SmithKline Beecham, Philadelphia, PA.[17] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[18] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[19] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[20] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals, East Hanover, NJ.[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[42] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[43] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[44] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Orlistat, Naltrexone", "alternatives_b": "Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "updated_at": 1767369485}, {"id": 119701, "ingredient1": "Isocarboxazid", "ingredient2": "Mecamylamine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119839/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119702, "ingredient1": "Isocarboxazid", "ingredient2": "Meclizine", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119840/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Sertraline, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More", "updated_at": 1767369485}, {"id": 119703, "ingredient1": "Isocarboxazid", "ingredient2": "Meperidine", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe and fatal adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome). The interaction is unpredictable and has been reported primarily with meperidine or fentanyl and various MAOIs including phenelzine, tranylcypromine, linezolid, moclobemide, and selegiline. Fatal hyperpyrexia and hypertension have also been observed in animal studies with meperidine and phenelzine or furazolidone. In contrast, symptoms of the depressive reaction probably stem from potentiation of CNS effects by MAOIs and include respiratory depression, cyanosis, hypotension, and coma.", "source": "DDInter", "management_text": "Meperidine and fentanyl should not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Some manufacturers of MAOIs also contraindicate the concomitant use of propoxyphene and methadone due to their possible serotonergic effects. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with these opioids. Although morphine may also have significant CNS interactions with MAOIs, it is generally considered a safer alternative in patients treated with MAOIs who require a narcotic analgesic.", "mechanism_text": "Others", "recommendation": "Meperidine and fentanyl should not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119841/", "reference_text": "[1] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[2] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[3] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[4] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[5] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[6] Upton R, Graff A, Williamson E, et al. \"American Herbal Pharmacopoeia and Therapeutic Compendium. Monograph printed in Herbalgram.\" Herbalgram 40 (1997): 1-38(monograph)[7] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[8] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[9] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[10] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[15] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[16] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[17] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[18] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[19] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[20] Youssef MS, Wilkinson PA \"Epidural fentanyl and monoamine oxidase inhibitors.\" Anaesthesia 43 (1988): 210-2[21] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[22] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[23] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Actiq (fentanyl).\" Abbott Pharmaceutical, Abbott Park, IL.[25] Vigran IM \"Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride.\" JAMA 187 (1964): 953-4[26] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[27] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[28] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[29] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[30] Starr C \"Interaction between pethidine and selegiline.\" Lancet 337 (1991): 554[31] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[32] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Meperidine Hydrochloride Injection, USP (meperidine)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[35] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[36] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[37] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[38] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[39] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[40] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[41] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[42] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[43] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[44] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[45] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[46] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[47] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[48] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[49] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[50] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[51] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[52] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[53] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[54] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[55] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[56] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[57] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[58] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[59] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119704, "ingredient1": "Isocarboxazid", "ingredient2": "Mephentermine", "severity": "Major", "effect": "Indirect- or mixed-acting sympathomimetic amines may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Death has occurred in some reported cases. The mechanism involves a synergistic sympathomimetic effect due to enhanced norepinephrine storage in adrenergic neurons (MAOI activity) and increased liberation of catecholamines (indirect sympathomimetic activity).", "source": "DDInter", "management_text": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119842/", "reference_text": "[1] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[2] Davies B, Bannister R, Sever P \"Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards.\" Lancet 1 (1978): 172-5[3] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[4] Mason AM, Buckle RM \"\"Cold\" cures and monoamine-oxidase inhibitors.\" Br Med J 1 (1969): 845-6[5] Cuthbert MF, Greenberg MP, Morley SW \"Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.\" Br Med J 1 (1969): 404-6[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[7] Horler AR, Wynne NA \"Hypertensive crisis due to pargyline and metaraminol.\" Br Med J 5459 (1965): 460-1[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[10] Humberstone PM \"Hypertension from cold remedies.\" Br Med J 1 (1969): 846[11] Kraft KE, Dore FH \"Computerized drug interaction programs: how reliable?.\" JAMA 275 (1996): 1087[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[13] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[14] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[15] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[18] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[21] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[22] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[23] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[24] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[25] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[26] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[27] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[28] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[29] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[30] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[31] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[32] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[33] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[34] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[35] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[36] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[37] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[38] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[39] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[40] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[41] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[42] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[43] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, Fluvoxamine, More", "alternatives_b": "Arbutamine, Angiotensin II", "updated_at": 1767369485}, {"id": 119705, "ingredient1": "Isocarboxazid", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119843/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119706, "ingredient1": "Isocarboxazid", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.", "source": "DDInter", "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119844/", "reference_text": "[1] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[2] Domino EF, Sullivan TS, Luby ED \"Barbiturate intoxication in a patient treated with a MAO inhibitor.\" Am J Psychiatry 118 (1962): 941-3[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Lacosamide, Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119707, "ingredient1": "Isocarboxazid", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119845/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Doxepin", "updated_at": 1767369485}, {"id": 119708, "ingredient1": "Isocarboxazid", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119846/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Fluvoxamine", "updated_at": 1767369485}, {"id": 119709, "ingredient1": "Isocarboxazid", "ingredient2": "Orciprenaline", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119847/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "alternatives_b": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119710, "ingredient1": "Isocarboxazid", "ingredient2": "Metaraminol", "severity": "Major", "effect": "Indirect- or mixed-acting sympathomimetic amines may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Death has occurred in some reported cases. The mechanism involves a synergistic sympathomimetic effect due to enhanced norepinephrine storage in adrenergic neurons (MAOI activity) and increased liberation of catecholamines (indirect sympathomimetic activity).", "source": "DDInter", "management_text": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119848/", "reference_text": "[1] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[2] Davies B, Bannister R, Sever P \"Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards.\" Lancet 1 (1978): 172-5[3] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[4] Mason AM, Buckle RM \"\"Cold\" cures and monoamine-oxidase inhibitors.\" Br Med J 1 (1969): 845-6[5] Cuthbert MF, Greenberg MP, Morley SW \"Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.\" Br Med J 1 (1969): 404-6[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[7] Horler AR, Wynne NA \"Hypertensive crisis due to pargyline and metaraminol.\" Br Med J 5459 (1965): 460-1[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[10] Humberstone PM \"Hypertension from cold remedies.\" Br Med J 1 (1969): 846[11] Kraft KE, Dore FH \"Computerized drug interaction programs: how reliable?.\" JAMA 275 (1996): 1087[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[13] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[14] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[15] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[18] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[21] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[22] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[23] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[24] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[25] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[26] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[27] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[28] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[29] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[30] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[31] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[32] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[33] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[34] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[35] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[36] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[37] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[38] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[39] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[40] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[41] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[42] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[43] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Trazodone, More", "updated_at": 1767369485}, {"id": 119711, "ingredient1": "Isocarboxazid", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119849/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119712, "ingredient1": "Isocarboxazid", "ingredient2": "Metamfetamine", "severity": "Major", "effect": "Centrally-acting sympathomimetic agents (i.e., CNS stimulants), particularly the amphetamines and amphetamine derivatives, may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). MAOIs also slow amphetamine metabolism, which may potentiate amphetamine effect on the release of norepinephrine and other monoamines from adrenergic nerve endings.", "source": "DDInter", "management_text": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119850/", "reference_text": "[1] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[2] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[3] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[4] Krisko I, Lewis E, Johnson JE \"Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity.\" Ann Intern Med 70 (1969): 559-64[5] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[6] \"Product Information. Vyvanse (lisdexamfetamine).\" Shire US Inc, Florence, KY.[7] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[10] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[11] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[12] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Dally PJ \"Fatal reaction associated with tranylcypromine and methylamphetamine.\" Lancet 1 (1962): 1235-6[15] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[16] \"Product Information. Dexedrine (dextroamphetamine)\" SmithKline Beecham, Philadelphia, PA.[17] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[18] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[19] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[20] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals, East Hanover, NJ.[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[42] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[43] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[44] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Desipramine, Trimipramine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Trazodone, Tryptophan, Amitriptyline, Nortriptyline, More", "alternatives_b": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 119713, "ingredient1": "Isocarboxazid", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119851/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Sertraline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "updated_at": 1767369485}, {"id": 119714, "ingredient1": "Isocarboxazid", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119852/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119715, "ingredient1": "Isocarboxazid", "ingredient2": "Methohexital", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119853/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119716, "ingredient1": "Isocarboxazid", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119854/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Fluvoxamine", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 119717, "ingredient1": "Isocarboxazid", "ingredient2": "Methoxamine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119855/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 119718, "ingredient1": "Isocarboxazid", "ingredient2": "Methoxyflurane", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119856/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "updated_at": 1767369485}, {"id": 119719, "ingredient1": "Isocarboxazid", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119857/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119720, "ingredient1": "Isocarboxazid", "ingredient2": "Metipranolol (ophthalmic)", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119858/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "updated_at": 1767369485}, {"id": 119721, "ingredient1": "Isocarboxazid", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Theoretically, metoclopramide may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Metoclopramide has been shown to induce the release of catecholamines in patients with essential hypertension. This action could produce a synergistic sympathomimetic effect with MAOIs, which enhance norepinephrine storage in adrenergic neurons.", "source": "DDInter", "management_text": "While clinical data are lacking, metoclopramide should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with metoclopramide.", "mechanism_text": "Synergism", "recommendation": "While clinical data are lacking, metoclopramide should preferably not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119859/", "reference_text": "[1] \"Product Information. Reglan (metoclopramide).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Filibeck DJ, Grimm D, Forman WB, Leidner BA \"Metoclopramide-induced hypertensive crisis.\" Clin Pharm 3 (1984): 548-9[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[22] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[23] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[24] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[25] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Cisapride", "alternatives_b": "Oxitriptan, St. John's Wort, Tryptophan", "updated_at": 1767369485}, {"id": 119722, "ingredient1": "Isocarboxazid", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119860/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 119723, "ingredient1": "Isocarboxazid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119861/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 119724, "ingredient1": "Isocarboxazid", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119862/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Bosentan, Riociguat, Ambrisentan, Macitentan", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119725, "ingredient1": "Isocarboxazid", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119863/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119726, "ingredient1": "Isocarboxazid", "ingredient2": "Midodrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119864/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Trazodone, Tryptophan, Clomipramine, More", "updated_at": 1767369485}, {"id": 119727, "ingredient1": "Isocarboxazid", "ingredient2": "Milnacipran", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119865/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Viloxazine, Milnacipran, Esketamine", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119728, "ingredient1": "Isocarboxazid", "ingredient2": "Mirtazapine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119866/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Mirtazapine", "updated_at": 1767369485}, {"id": 119729, "ingredient1": "Isocarboxazid", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119867/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Desipramine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119730, "ingredient1": "Isocarboxazid", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119868/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 119731, "ingredient1": "Isocarboxazid", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) markedly potentiate the action of morphine. Coadministration of narcotic analgesics including morphine in patients treated with MAOIs has rarely resulted in hypotension, respiratory depression, or coma. The mechanism is unknown but may be related to additive central nervous system and respiratory depressant effects.", "source": "DDInter", "management_text": "Morphine liposomal preparations should not be used in patients taking MAOIs or other agents which possess MAOI activity (e.g., furazolidone, procarbazine, selegiline), or within 14 days of stopping such treatment.", "mechanism_text": "Synergism", "recommendation": "Morphine liposomal preparations should not be used in patients taking MAOIs or other agents which possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119869/", "reference_text": "[1] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[4] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[5] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[6] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC, Chadds Ford, PA.[7] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[8] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[10] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[11] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[14] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[15] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[16] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[17] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[18] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[19] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[20] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[21] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[22] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[23] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[24] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[25] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119732, "ingredient1": "Isocarboxazid", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119870/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Rolapitant, Aprepitant", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119733, "ingredient1": "Isocarboxazid", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119871/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119734, "ingredient1": "Isocarboxazid", "ingredient2": "Nalbuphine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119872/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119735, "ingredient1": "Isocarboxazid", "ingredient2": "Naphazoline (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119873/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119736, "ingredient1": "Isocarboxazid", "ingredient2": "Naphazoline (ophthalmic)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119874/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119737, "ingredient1": "Isocarboxazid", "ingredient2": "Naratriptan", "severity": "Major", "effect": "The 5-HT1 receptor agonists used to treat migraine headaches exhibit modest 5-HT1A activity. Theoretically, MAOIs may potentiate the serotonergic activity of 5-HT1 receptor agonists and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of serotonin metabolism. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "Concomitant use of 5-HT1 receptor agonists with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) should generally be avoided. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with 5-HT1 receptor agonists. Otherwise, patients should be closely monitored for adverse effects related to excessive serotonergic activity.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of 5-HT1 receptor agonists with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119875/", "reference_text": "[1] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[2] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[3] Fleishaker JC, Ryan KK, Jansat JM, et al. \"Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.\" Br J Clin Pharmacol 51 (2001): 437-41[4] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[5] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[9] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 119738, "ingredient1": "Isocarboxazid", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119876/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Desipramine, Trimipramine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Amitriptyline, More", "updated_at": 1767369485}, {"id": 119739, "ingredient1": "Isocarboxazid", "ingredient2": "Nefazodone", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119877/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Viloxazine, Nefazodone", "updated_at": 1767369485}, {"id": 119740, "ingredient1": "Isocarboxazid", "ingredient2": "Nesiritide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119878/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Vericiguat", "updated_at": 1767369485}, {"id": 119741, "ingredient1": "Isocarboxazid", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119879/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mibefradil, Celecoxib", "alternatives_b": "Sertraline, Maprotiline, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 119742, "ingredient1": "Isocarboxazid", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119880/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mibefradil, Celecoxib", "alternatives_b": "Duloxetine, Sertraline, Desvenlafaxine, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 119743, "ingredient1": "Isocarboxazid", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119881/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mibefradil, Celecoxib", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Amoxapine, Imipramine, Esketamine, Desipramine, Trimipramine, More", "updated_at": 1767369485}, {"id": 119744, "ingredient1": "Isocarboxazid", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119882/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More", "alternatives_b": "Desipramine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More", "updated_at": 1767369485}, {"id": 119745, "ingredient1": "Isocarboxazid", "ingredient2": "Nitrous oxide", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119883/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119746, "ingredient1": "Isocarboxazid", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119884/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 119747, "ingredient1": "Isocarboxazid", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119885/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 119748, "ingredient1": "Isocarboxazid", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119886/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119749, "ingredient1": "Isocarboxazid", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119887/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119750, "ingredient1": "Isocarboxazid", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119888/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sacubitril", "alternatives_b": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 119751, "ingredient1": "Isocarboxazid", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119889/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119752, "ingredient1": "Isocarboxazid", "ingredient2": "Ondansetron", "severity": "Major", "effect": "Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), 5-HT1 receptor agonists (triptans), ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John's wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome.", "source": "DDInter", "management_text": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is typically recommended following use of fluoxetine and 2 weeks following use of MAOIs before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119890/", "reference_text": "[1] \"Product Information. Akynzeo (netupitant-palonosetron).\" Eisai Inc, Woodcliff Lake, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Sancuso (granisetron).\" ProStrakan Group, Bedminster, NJ.[6] \"Product Information. Aloxi (palonosetron).\" MGI Pharma Inc, Minnetonka, MN.[7] \"Product Information. Anzemet (dolasetron).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Rolapitant, Aprepitant", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 119753, "ingredient1": "Isocarboxazid", "ingredient2": "Opicapone", "severity": "Major", "effect": "Theoretically, coadministration of monoamine oxidase (MAO) inhibitors and catechol-O-methyltransferase (COMT) inhibitors may potentiate the risk of hypertensive crisis and serotonin syndrome, the latter of which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. MAO and COMT are the two major enzymatic pathways involved in the metabolism of catecholamines, thus inhibition of both systems may lead to excessive levels of norepinephrine and serotonin. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, COMT inhibitors should not be used concurrently with nonselective MAO inhibitors or other agents that possess MAO inhibiting activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAO inhibitor therapy and initiation of treatment with COMT inhibitors.", "mechanism_text": "Synergism", "recommendation": "In general, COMT inhibitors should not be used concurrently with nonselective MAO inhibitors or other agents that possess MAO inhibiting activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119891/", "reference_text": "[1] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[3] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[6] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[7] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[8] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[9] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[10] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[14] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[15] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[16] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[17] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[18] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[19] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[20] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[21] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[22] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[23] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[24] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[25] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[26] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[29] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[30] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[31] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[32] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[33] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[34] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 119754, "ingredient1": "Isocarboxazid", "ingredient2": "Opium", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119892/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 119755, "ingredient1": "Isocarboxazid", "ingredient2": "Oxazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119893/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119756, "ingredient1": "Isocarboxazid", "ingredient2": "Oxcarbazepine", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119894/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119757, "ingredient1": "Isocarboxazid", "ingredient2": "Oxymetazoline (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119895/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119758, "ingredient1": "Isocarboxazid", "ingredient2": "Oxymetazoline (ophthalmic)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119896/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119759, "ingredient1": "Isocarboxazid", "ingredient2": "Oxymetazoline (topical)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119897/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119760, "ingredient1": "Isocarboxazid", "ingredient2": "Oxymorphone", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119898/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 119761, "ingredient1": "Isocarboxazid", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with monoamine oxidase inhibitors (MAOIs) may increase the risk of hypertensive crisis. The proposed mechanism may involve inhibition of monoamine oxidase by the metabolites of ozanimod. In addition, MAO-B inhibitors may decrease exposure of the active metabolites of ozanimod which may lead to loss of ozanimod efficacy. This interaction has not been studied in a clinical setting.", "source": "DDInter", "management_text": "Coadministration of ozanimod with MAOIs is considered contraindicated. At least 14 days should elapse between discontinuation of ozanimod and initiation of treatment with MAOIs.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ozanimod with MAOIs is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119899/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[21] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 119762, "ingredient1": "Isocarboxazid", "ingredient2": "Papaverine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119900/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide, Alosetron", "alternatives_b": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 119763, "ingredient1": "Isocarboxazid", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119901/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119764, "ingredient1": "Isocarboxazid", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119902/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119765, "ingredient1": "Isocarboxazid", "ingredient2": "Paroxetine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119903/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Esketamine, Paroxetine", "updated_at": 1767369485}, {"id": 119766, "ingredient1": "Isocarboxazid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119904/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119767, "ingredient1": "Isocarboxazid", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.", "source": "DDInter", "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119905/", "reference_text": "[1] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[2] Domino EF, Sullivan TS, Luby ED \"Barbiturate intoxication in a patient treated with a MAO inhibitor.\" Am J Psychiatry 118 (1962): 941-3[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 119768, "ingredient1": "Isocarboxazid", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119906/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119769, "ingredient1": "Isocarboxazid", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119907/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119770, "ingredient1": "Isocarboxazid", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119908/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 119771, "ingredient1": "Isocarboxazid", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119909/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119772, "ingredient1": "Isocarboxazid", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119910/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119773, "ingredient1": "Isocarboxazid", "ingredient2": "Phendimetrazine", "severity": "Major", "effect": "Centrally-acting sympathomimetic agents (i.e., CNS stimulants), particularly the amphetamines and amphetamine derivatives, may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). MAOIs also slow amphetamine metabolism, which may potentiate amphetamine effect on the release of norepinephrine and other monoamines from adrenergic nerve endings.", "source": "DDInter", "management_text": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119911/", "reference_text": "[1] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[2] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[3] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[4] Krisko I, Lewis E, Johnson JE \"Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity.\" Ann Intern Med 70 (1969): 559-64[5] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[6] \"Product Information. Vyvanse (lisdexamfetamine).\" Shire US Inc, Florence, KY.[7] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[10] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[11] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[12] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Dally PJ \"Fatal reaction associated with tranylcypromine and methylamphetamine.\" Lancet 1 (1962): 1235-6[15] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[16] \"Product Information. Dexedrine (dextroamphetamine)\" SmithKline Beecham, Philadelphia, PA.[17] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[18] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[19] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[20] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals, East Hanover, NJ.[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[42] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[43] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[44] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119774, "ingredient1": "Isocarboxazid", "ingredient2": "Phenelzine", "severity": "Major", "effect": "The concomitant use of monoamine oxidase inhibitors (MAOIs) with other MAOIs may result in hypertensive crisis, convulsions, fever, delirium, coma, and circulatory collapse. Cases of hypertension with fatal and nonfatal stroke have been reported in patients who were switched from phenelzine or isocarboxazid to tranylcypromine. The mechanism is unknown.", "source": "DDInter", "management_text": "Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated. A washout period of at least 7 to 10 days is recommended when switching from one MAOI to another.", "mechanism_text": "Synergism", "recommendation": "Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119912/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Bazire SR \"Sudden death associated with switching monoamine oxidase inhibitors.\" Drug Intell Clin Pharm 20 (1986): 954-6[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Phenelzine", "updated_at": 1767369485}, {"id": 119775, "ingredient1": "Isocarboxazid", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119913/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Vilazodone, Sertraline, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More", "alternatives_b": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 119776, "ingredient1": "Isocarboxazid", "ingredient2": "Phenoxybenzamine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119914/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Pentoxifylline, Niacin", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 119777, "ingredient1": "Isocarboxazid", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119915/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119778, "ingredient1": "Isocarboxazid", "ingredient2": "Phenylephrine (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119916/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119779, "ingredient1": "Isocarboxazid", "ingredient2": "Phenylephrine (topical)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119917/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119780, "ingredient1": "Isocarboxazid", "ingredient2": "Phenylpropanolamine", "severity": "Major", "effect": "Indirect- or mixed-acting sympathomimetic amines may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Death has occurred in some reported cases. The mechanism involves a synergistic sympathomimetic effect due to enhanced norepinephrine storage in adrenergic neurons (MAOI activity) and increased liberation of catecholamines (indirect sympathomimetic activity).", "source": "DDInter", "management_text": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "In general, indirect- and mixed-acting sympathomimetic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119918/", "reference_text": "[1] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[2] Davies B, Bannister R, Sever P \"Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards.\" Lancet 1 (1978): 172-5[3] Harrison WM, McGrath PJ, Stewart JW, Quitkin F \"MAOIs and hypertensive crises: the role of OTC drugs.\" J Clin Psychiatry 50 (1989): 64-5[4] Mason AM, Buckle RM \"\"Cold\" cures and monoamine-oxidase inhibitors.\" Br Med J 1 (1969): 845-6[5] Cuthbert MF, Greenberg MP, Morley SW \"Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.\" Br Med J 1 (1969): 404-6[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[7] Horler AR, Wynne NA \"Hypertensive crisis due to pargyline and metaraminol.\" Br Med J 5459 (1965): 460-1[8] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[9] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[10] Humberstone PM \"Hypertension from cold remedies.\" Br Med J 1 (1969): 846[11] Kraft KE, Dore FH \"Computerized drug interaction programs: how reliable?.\" JAMA 275 (1996): 1087[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[13] Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M \"Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs.\" Ann N Y Acad Sci 107 (1963): 1005-15[14] Smookler S, Bermudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant.\" Ann Intern Med 11 (1982): 482-4[15] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[18] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[21] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[22] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[23] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[24] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[25] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[26] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[27] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[28] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[29] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[30] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[31] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[32] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[33] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[34] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[35] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[36] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[37] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[38] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[39] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[40] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[41] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[42] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[43] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, Nefazodone, St. John's Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119781, "ingredient1": "Isocarboxazid", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119919/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran", "updated_at": 1767369485}, {"id": 119782, "ingredient1": "Isocarboxazid", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119920/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119783, "ingredient1": "Isocarboxazid", "ingredient2": "Pindolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119921/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Sertraline, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, Nortriptyline, Levomilnacipran, Tryptophan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119784, "ingredient1": "Isocarboxazid", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119922/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Nortriptyline, Tryptophan, Protriptyline, Esketamine", "alternatives_b": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 119785, "ingredient1": "Isocarboxazid", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119923/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119786, "ingredient1": "Isocarboxazid", "ingredient2": "Prazosin", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119924/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, Desipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119787, "ingredient1": "Isocarboxazid", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.", "source": "DDInter", "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119925/", "reference_text": "[1] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[2] Domino EF, Sullivan TS, Luby ED \"Barbiturate intoxication in a patient treated with a MAO inhibitor.\" Am J Psychiatry 118 (1962): 941-3[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone, Lacosamide", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 119788, "ingredient1": "Isocarboxazid", "ingredient2": "Procarbazine", "severity": "Major", "effect": "The concomitant use of monoamine oxidase inhibitors (MAOIs) with other MAOIs may result in hypertensive crisis, convulsions, fever, delirium, coma, and circulatory collapse. Cases of hypertension with fatal and nonfatal stroke have been reported in patients who were switched from phenelzine or isocarboxazid to tranylcypromine. The mechanism is unknown.", "source": "DDInter", "management_text": "Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated. A washout period of at least 7 to 10 days is recommended when switching from one MAOI to another.", "mechanism_text": "Synergism", "recommendation": "Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119926/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Bazire SR \"Sudden death associated with switching monoamine oxidase inhibitors.\" Drug Intell Clin Pharm 20 (1986): 954-6[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 119789, "ingredient1": "Isocarboxazid", "ingredient2": "Procyclidine", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and antiparkinsonian agents may have additive anticholinergic effects. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119927/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119790, "ingredient1": "Isocarboxazid", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119928/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119791, "ingredient1": "Isocarboxazid", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119929/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine, Hydroxocobalamin, Fomepizole, More", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119792, "ingredient1": "Isocarboxazid", "ingredient2": "Propantheline", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119930/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Alosetron", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 119793, "ingredient1": "Isocarboxazid", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119931/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119794, "ingredient1": "Isocarboxazid", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119932/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 119795, "ingredient1": "Isocarboxazid", "ingredient2": "Propylhexedrine (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119933/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119796, "ingredient1": "Isocarboxazid", "ingredient2": "Protriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119934/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Protriptyline, Viloxazine", "updated_at": 1767369485}, {"id": 119797, "ingredient1": "Isocarboxazid", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119935/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 119798, "ingredient1": "Isocarboxazid", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119936/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119799, "ingredient1": "Isocarboxazid", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119937/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119800, "ingredient1": "Isocarboxazid", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119938/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119801, "ingredient1": "Isocarboxazid", "ingredient2": "Racepinephrine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119939/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119802, "ingredient1": "Isocarboxazid", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119940/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119803, "ingredient1": "Isocarboxazid", "ingredient2": "Ramipril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119941/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "Desipramine, Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, Esketamine, More", "updated_at": 1767369485}, {"id": 119804, "ingredient1": "Isocarboxazid", "ingredient2": "Rasagiline", "severity": "Major", "effect": "Coadministration of a selective monoamine oxidase B (MAO-B) inhibitor with other MAO inhibitors, selective or nonselective, may increase the risk of a hypertensive crisis. Although selective inhibitors of MAO-B presumably have minimal effect on intestinal and hepatic MAO-A that catabolizes exogenous amines like tyramine, the selectivity may not be absolute even at recommended doses and may diminish with increasing doses. Coadministration of a selective MAO-B inhibitor with other MAO inhibitors may increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Concurrent use of selective MAO-B inhibitors with other MAO inhibitors is considered contraindicated. At least 14 days should elapse between discontinuation of a nonselective MAO inhibitor and initiation of treatment with a selective MAO inhibitor, and vice versa. The recommended dosages of selective MAO-B inhibitors should not be exceeded, as it can increase the risk of nonselective MAO inhibition and precipitation of a hypertensive crisis.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of selective MAO-B inhibitors with other MAO inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119942/", "reference_text": "[1] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[3] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[4] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[5] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[8] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[9] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[14] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[15] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[16] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[17] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[18] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[19] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[20] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[21] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[22] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[23] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[24] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[25] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[26] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[27] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[28] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[29] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[30] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[31] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[32] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[33] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[34] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[35] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[36] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[37] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[38] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[39] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119805, "ingredient1": "Isocarboxazid", "ingredient2": "Remifentanil", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Others", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119943/", "reference_text": "[1] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals, Raritan, NJ.[2] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993): 1270-1[3] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[4] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984): 1041-4[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968): 279-82[6] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc, New York, NY.[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceutical, Richmond, VA.[9] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories, Texarkana, TX.[10] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc, Columbus, OH.[11] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company, Norwalk, CT.[13] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987): 251-2[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987): 210-2[17] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119806, "ingredient1": "Isocarboxazid", "ingredient2": "Remimazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119944/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119807, "ingredient1": "Isocarboxazid", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "The addition of a rauwolfia alkaloid to existing monoamine oxidase inhibitor (MAOI) therapy may result in profound excitation and/or a hypertensive reaction. The proposed mechanism is increased norepinephrine levels at adrenergic receptors due to both the inhibition of catecholamine metabolism by MAOIs and the release of catecholamines induced by rauwolfia alkaloids.", "source": "DDInter", "management_text": "In general, rauwolfia alkaloids should not be administered to patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with rauwolfia alkaloids.", "mechanism_text": "Synergism", "recommendation": "In general, rauwolfia alkaloids should not be administered to patients treated with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119945/", "reference_text": "[1] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975): 86-90[2] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119808, "ingredient1": "Isocarboxazid", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119946/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119809, "ingredient1": "Isocarboxazid", "ingredient2": "Rizatriptan", "severity": "Major", "effect": "Monoamine oxidase inhibitors (MAOIs) may significantly elevate the plasma concentrations of certain 5-HT1 receptor agonists (namely rizatriptan, sumatriptan, and zolmitriptan) and their active metabolites by inhibiting their metabolic clearance via monoamine oxidase, subtype A. Clinically, this interaction may increase the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, associated with the use of 5-HT1 receptor agonists.", "source": "DDInter", "management_text": "Concomitant use of rizatriptan, sumatriptan, or zolmitriptan with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with 5-HT1 receptor agonists. If concurrent therapy is necessary, almotriptan, frovatriptan and naratriptan may be preferred due to the lack of a significant pharmacokinetic interaction with MAOIs. However, patients should be closely monitored for adverse effects related to excessive serotonergic activity.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of rizatriptan, sumatriptan, or zolmitriptan with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119947/", "reference_text": "[1] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[2] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Fleishaker JC, Ryan KK, Jansat JM, et al. \"Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.\" Br J Clin Pharmacol 51 (2001): 437-41[6] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[7] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[10] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[11] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[12] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[13] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[33] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[35] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Viloxazine, Esketamine", "updated_at": 1767369485}, {"id": 119810, "ingredient1": "Isocarboxazid", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119948/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 119811, "ingredient1": "Isocarboxazid", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119949/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119812, "ingredient1": "Isocarboxazid", "ingredient2": "Safinamide", "severity": "Major", "effect": "Coadministration of a selective monoamine oxidase B (MAO-B) inhibitor with other MAO inhibitors, selective or nonselective, may increase the risk of a hypertensive crisis. Although selective inhibitors of MAO-B presumably have minimal effect on intestinal and hepatic MAO-A that catabolizes exogenous amines like tyramine, the selectivity may not be absolute even at recommended doses and may diminish with increasing doses. Coadministration of a selective MAO-B inhibitor with other MAO inhibitors may increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Concurrent use of selective MAO-B inhibitors with other MAO inhibitors is considered contraindicated. At least 14 days should elapse between discontinuation of a nonselective MAO inhibitor and initiation of treatment with a selective MAO inhibitor, and vice versa. The recommended dosages of selective MAO-B inhibitors should not be exceeded, as it can increase the risk of nonselective MAO inhibition and precipitation of a hypertensive crisis.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of selective MAO-B inhibitors with other MAO inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119950/", "reference_text": "[1] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[3] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[4] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[5] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[8] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[9] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[14] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[15] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[16] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[17] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[18] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[19] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[20] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[21] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[22] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[23] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[24] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[25] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[26] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[27] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[28] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[29] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[30] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[31] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[32] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[33] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[34] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[35] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[36] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[37] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[38] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[39] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119813, "ingredient1": "Isocarboxazid", "ingredient2": "Salmeterol", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119951/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "alternatives_b": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119814, "ingredient1": "Isocarboxazid", "ingredient2": "Scopolamine", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119952/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone, Tropicamide, Ketorolac, Rolapitant, Aprepitant", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119815, "ingredient1": "Isocarboxazid", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.", "source": "DDInter", "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119953/", "reference_text": "[1] Sjoqvist F \"Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances.\" Proc R Soc Med 58 (1965): 967-78[2] Domino EF, Sullivan TS, Luby ED \"Barbiturate intoxication in a patient treated with a MAO inhibitor.\" Am J Psychiatry 118 (1962): 941-3[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 119816, "ingredient1": "Isocarboxazid", "ingredient2": "Selegiline", "severity": "Major", "effect": "Coadministration of a selective monoamine oxidase B (MAO-B) inhibitor with other MAO inhibitors, selective or nonselective, may increase the risk of a hypertensive crisis. Although selective inhibitors of MAO-B presumably have minimal effect on intestinal and hepatic MAO-A that catabolizes exogenous amines like tyramine, the selectivity may not be absolute even at recommended doses and may diminish with increasing doses. Coadministration of a selective MAO-B inhibitor with other MAO inhibitors may increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Concurrent use of selective MAO-B inhibitors with other MAO inhibitors is considered contraindicated. At least 14 days should elapse between discontinuation of a nonselective MAO inhibitor and initiation of treatment with a selective MAO inhibitor, and vice versa. The recommended dosages of selective MAO-B inhibitors should not be exceeded, as it can increase the risk of nonselective MAO inhibition and precipitation of a hypertensive crisis.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of selective MAO-B inhibitors with other MAO inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119954/", "reference_text": "[1] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[3] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[4] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[5] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[8] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[9] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[14] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[15] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[16] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[17] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[18] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[19] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[20] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[21] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[22] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[23] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[24] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[25] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[26] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[27] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[28] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[29] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[30] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[31] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[32] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[33] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[34] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[35] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[36] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[37] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[38] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[39] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119817, "ingredient1": "Isocarboxazid", "ingredient2": "Selexipag", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119955/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 119818, "ingredient1": "Isocarboxazid", "ingredient2": "Sertraline", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119956/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Viloxazine, Sertraline, Esketamine", "updated_at": 1767369485}, {"id": 119819, "ingredient1": "Isocarboxazid", "ingredient2": "Sevoflurane", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119957/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Fluvoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119820, "ingredient1": "Isocarboxazid", "ingredient2": "Sibutramine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119958/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Orlistat, Naltrexone", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 119821, "ingredient1": "Isocarboxazid", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119959/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, Vilazodone, Trimipramine, Desvenlafaxine, Maprotiline, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Amoxapine, More", "updated_at": 1767369485}, {"id": 119822, "ingredient1": "Isocarboxazid", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119960/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Desvenlafaxine, Fluoxetine, Oxitriptan, Tryptophan, Milnacipran, Vortioxetine, Levomilnacipran, Vilazodone, More", "alternatives_b": "Finasteride, Dutasteride", "updated_at": 1767369485}, {"id": 119823, "ingredient1": "Isocarboxazid", "ingredient2": "Solifenacin", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and anticholinergic agents may have additive anticholinergic and/or CNS-depressant effects.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119961/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[7] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[10] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[11] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[12] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[13] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[14] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[15] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[16] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[17] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[20] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[21] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine, Paroxetine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide, Finasteride, Dutasteride", "updated_at": 1767369485}, {"id": 119824, "ingredient1": "Isocarboxazid", "ingredient2": "Solriamfetol", "severity": "Major", "effect": "Coadministration of solriamfetol with other drugs that also inhibit the reuptake of dopamine or norepinephrine, including monoamine oxidase inhibitors (MAOIs), may increase the risk of hypertensive reactions including death, stroke, myocardial infarction, aortic dissection, pulmonary edema, and renal failure. Additionally, MAOIs can increase dopaminergic and noradrenergic activity by inhibiting the metabolism of dopamine and norepinephrine.", "source": "DDInter", "management_text": "Concomitant use of solriamfetol with MAOIs is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with solriamfetol.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Concomitant use of solriamfetol with MAOIs is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119962/", "reference_text": "[1] \"Product Information. Sunosi (solriamfetol).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 119825, "ingredient1": "Isocarboxazid", "ingredient2": "Sotalol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119963/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119826, "ingredient1": "Isocarboxazid", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119964/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Viloxazine, Bupropion, St. John's Wort, Esketamine", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119827, "ingredient1": "Isocarboxazid", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119965/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 119828, "ingredient1": "Isocarboxazid", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119966/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119829, "ingredient1": "Isocarboxazid", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119967/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide, Bosentan, More", "alternatives_b": "Desipramine, Vilazodone, Trimipramine, Escitalopram, Maprotiline, Desvenlafaxine, Oxitriptan, Trazodone, Vortioxetine, Milnacipran, Tryptophan, More", "updated_at": 1767369485}, {"id": 119830, "ingredient1": "Isocarboxazid", "ingredient2": "Tapentadol", "severity": "Major", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the noradrenergic and serotonergic activities of tapentadol. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of norepinephrine and serotonin metabolism and tapentadol inhibition of their reuptake. Theoretically, coadministration may increase the risk of adverse cardiovascular effects such as hypotension, hypertension, and arrhythmias due to elevated norepinephrine levels. In addition, an increased risk of seizure may occur due to additive lowering of seizure threshold. The interaction may also cause serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "The use of tapentadol in patients currently receiving or within 14 days of receiving a monoamine oxidase inhibitor (MAOI) is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of tapentadol in patients currently receiving or within 14 days of receiving a monoamine oxidase inhibitor (MAOI) is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119968/", "reference_text": "[1] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[3] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[5] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[6] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[7] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[8] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[12] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[33] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[35] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 119831, "ingredient1": "Isocarboxazid", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119969/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119832, "ingredient1": "Isocarboxazid", "ingredient2": "Telmisartan", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119970/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sacubitril", "alternatives_b": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "updated_at": 1767369485}, {"id": 119833, "ingredient1": "Isocarboxazid", "ingredient2": "Temazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119971/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119834, "ingredient1": "Isocarboxazid", "ingredient2": "Terazosin", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119972/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Finasteride, Dutasteride", "alternatives_b": "Desipramine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More", "updated_at": 1767369485}, {"id": 119835, "ingredient1": "Isocarboxazid", "ingredient2": "Terbutaline", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.", "source": "DDInter", "management_text": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.", "mechanism_text": "Synergism", "recommendation": "Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119973/", "reference_text": "[1] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[4] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS \"Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial.\" Ann Allergy 47 (1981): 402-4[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[12] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[13] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[14] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[15] \"Product Information. S2 Inhalant (racepinephrine).\" Nephron Pharmaceuticals, Orlando, FL.[16] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[17] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[18] \"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology.\" J Allergy Clin Immunol 75 (1985): 443-9[19] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[20] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[22] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[27] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[30] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[31] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[36] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "alternatives_b": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119836, "ingredient1": "Isocarboxazid", "ingredient2": "Tetrabenazine", "severity": "Major", "effect": "Tetrabenazine may cause excitation and hypertension in patients treated with monoamine oxidase inhibitors (MAOIs). The proposed mechanism has not been fully established but may be related to interference with biogenic amine storage. In addition, tetrabenazine may have depressant effects and may exacerbate depression.", "source": "DDInter", "management_text": "Concurrent administration of tetrabenazine and deutetrabenazine with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with either tetrabenazine or deutetrabenazine, and vice versa.", "mechanism_text": "Synergism", "recommendation": "Concurrent administration of tetrabenazine and deutetrabenazine with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119974/", "reference_text": "[1] \"Product Information. Xenazine (tetrabenazine).\" Prestwick Pharmaceuticals Inc, Washington DC, VA.[2] \"Product Information. Austedo (deutetrabenazine).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Nitoman (tetrabenazine).\" Cambridge Laboratories Ltd, Wallsend, Tyne & Wear, .[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Pitolisant, Tafamidis", "updated_at": 1767369485}, {"id": 119837, "ingredient1": "Isocarboxazid", "ingredient2": "Tetryzoline (nasal)", "severity": "Major", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors). However, the interaction has not been reported extensively in the medical literature.", "source": "DDInter", "management_text": "Concomitant use of tetrahydrozoline nasal formulations with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated by the manufacturers.", "mechanism_text": "Others", "recommendation": "Concomitant use of tetrahydrozoline nasal formulations with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119975/", "reference_text": "[1] \"Product Information. Tyzine (tetrahydrozoline).\" Kenwood Laboratories, Fairfield, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119838, "ingredient1": "Isocarboxazid", "ingredient2": "Tetryzoline (ophthalmic)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119976/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Vortioxetine, Doxepin, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119839, "ingredient1": "Isocarboxazid", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119977/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119840, "ingredient1": "Isocarboxazid", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119978/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Sertraline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "updated_at": 1767369485}, {"id": 119841, "ingredient1": "Isocarboxazid", "ingredient2": "Thiopental", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119979/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Vilazodone, Sertraline, Maprotiline, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Trazodone, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 119842, "ingredient1": "Isocarboxazid", "ingredient2": "Thioridazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119980/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119843, "ingredient1": "Isocarboxazid", "ingredient2": "Thiothixene", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119981/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 119844, "ingredient1": "Isocarboxazid", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119982/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119845, "ingredient1": "Isocarboxazid", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119983/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 119846, "ingredient1": "Isocarboxazid", "ingredient2": "Tizanidine", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119984/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119847, "ingredient1": "Isocarboxazid", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119985/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "updated_at": 1767369485}, {"id": 119848, "ingredient1": "Isocarboxazid", "ingredient2": "Tolazoline", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119986/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More", "updated_at": 1767369485}, {"id": 119849, "ingredient1": "Isocarboxazid", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119987/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "alternatives_b": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "updated_at": 1767369485}, {"id": 119850, "ingredient1": "Isocarboxazid", "ingredient2": "Tolcapone", "severity": "Major", "effect": "Theoretically, coadministration of monoamine oxidase (MAO) inhibitors and catechol-O-methyltransferase (COMT) inhibitors may potentiate the risk of hypertensive crisis and serotonin syndrome, the latter of which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. MAO and COMT are the two major enzymatic pathways involved in the metabolism of catecholamines, thus inhibition of both systems may lead to excessive levels of norepinephrine and serotonin. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, COMT inhibitors should not be used concurrently with nonselective MAO inhibitors or other agents that possess MAO inhibiting activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAO inhibitor therapy and initiation of treatment with COMT inhibitors.", "mechanism_text": "Synergism", "recommendation": "In general, COMT inhibitors should not be used concurrently with nonselective MAO inhibitors or other agents that possess MAO inhibiting activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119988/", "reference_text": "[1] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[3] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[6] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[7] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[8] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[9] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[10] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[14] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[15] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[16] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[17] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[18] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[19] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[20] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[21] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[22] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[23] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[24] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[25] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[26] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[29] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[30] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[31] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[32] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[33] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[34] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Vilazodone, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119851, "ingredient1": "Isocarboxazid", "ingredient2": "Topiramate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119989/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Viloxazine, St. John's Wort, Tryptophan", "updated_at": 1767369485}, {"id": 119852, "ingredient1": "Isocarboxazid", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119990/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 119853, "ingredient1": "Isocarboxazid", "ingredient2": "Trandolapril", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119991/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119854, "ingredient1": "Isocarboxazid", "ingredient2": "Tranylcypromine", "severity": "Major", "effect": "The concomitant use of monoamine oxidase inhibitors (MAOIs) with other MAOIs may result in hypertensive crisis, convulsions, fever, delirium, coma, and circulatory collapse. Cases of hypertension with fatal and nonfatal stroke have been reported in patients who were switched from phenelzine or isocarboxazid to tranylcypromine. The mechanism is unknown.", "source": "DDInter", "management_text": "Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated. A washout period of at least 7 to 10 days is recommended when switching from one MAOI to another.", "mechanism_text": "Synergism", "recommendation": "Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119992/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Bazire SR \"Sudden death associated with switching monoamine oxidase inhibitors.\" Drug Intell Clin Pharm 20 (1986): 954-6[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[6] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[7] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[8] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[9] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[10] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[11] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[12] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[13] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[16] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[17] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[18] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[19] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[20] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[21] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[22] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[23] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[25] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[26] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[27] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[28] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[29] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[30] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[31] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[32] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[33] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[34] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[35] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[36] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[37] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[38] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[39] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[40] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[41] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Tranylcypromine", "updated_at": 1767369485}, {"id": 119855, "ingredient1": "Isocarboxazid", "ingredient2": "Treprostinil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119993/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Desipramine, Trimipramine, Maprotiline, Oxitriptan, Mirtazapine, Bupropion, Viloxazine, Trazodone, Tryptophan, Amitriptyline, Nortriptyline, More", "updated_at": 1767369485}, {"id": 119856, "ingredient1": "Isocarboxazid", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119994/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Finerenone", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 119857, "ingredient1": "Isocarboxazid", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119995/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119858, "ingredient1": "Isocarboxazid", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119996/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 119859, "ingredient1": "Isocarboxazid", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119997/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119860, "ingredient1": "Isocarboxazid", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119998/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119861, "ingredient1": "Isocarboxazid", "ingredient2": "Trihexyphenidyl", "severity": "Minor", "effect": "Monoamine oxidase inhibitors and antiparkinsonian agents may have additive anticholinergic effects. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/119999/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119862, "ingredient1": "Isocarboxazid", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and phenothiazines may result in additive hypotensive effects and central nervous system effects such as dizziness, drowsiness, confusion, disorientation, memory loss, and seizures. Phenothiazines can also cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly during initiation of treatment with parenteral doses. Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration. Tolerance to the hypotensive effects often develops after a few doses. An increased incidence of extrapyramidal effects has been reported when some MAOIs and phenothiazines are used concomitantly. Data are limited, and the mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Ambulatory patients should also be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Alcohol should be avoided, since it may increase hypotensive and CNS effects.", "mechanism_text": "Synergism", "recommendation": "Although often safe and effective, caution is advised during coadministration of MAOIs and phenothiazines, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120000/", "reference_text": "[1] \"Product Information. Tacaryl (methdilazine).\" Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[5] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[6] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[7] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[8] Jones EM, Dawson A \"Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.\" J Neurol Neurosurg Psychiatry 52 (1989): 1006-9[9] Poster DS \"Procarbazine-prochlorperazine interaction: an underreported phenomenon.\" J Med 9 (1978): 519-24[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Barsa JA, Saunders JC \"A comparative study of tranylcypromine and paragyline.\" Psychopharmacologia 6 (1964): 295-8[12] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[13] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[14] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[15] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119863, "ingredient1": "Isocarboxazid", "ingredient2": "Trimethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120001/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119864, "ingredient1": "Isocarboxazid", "ingredient2": "Trimethaphan", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120002/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119865, "ingredient1": "Isocarboxazid", "ingredient2": "Trimethobenzamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120003/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119866, "ingredient1": "Isocarboxazid", "ingredient2": "Trimipramine", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120004/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Isocarboxazid", "alternatives_b": "Trimipramine", "updated_at": 1767369485}, {"id": 119867, "ingredient1": "Isocarboxazid", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120005/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "alternatives_b": "Duloxetine, Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119868, "ingredient1": "Isocarboxazid", "ingredient2": "Triprolidine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120006/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987): 1242-3[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005): 151-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004): 62-5[7] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis, Morris Plains, NJ.[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Periactin (cyproheptadine).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[13] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[14] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[17] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[20] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[21] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[22] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[23] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[24] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[26] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[27] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[28] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Vilazodone, Trimipramine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 119869, "ingredient1": "Isocarboxazid", "ingredient2": "Tryptophan", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120007/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Bupropion, Viloxazine, Esketamine, Tryptophan", "updated_at": 1767369485}, {"id": 119870, "ingredient1": "Isocarboxazid", "ingredient2": "Valbenazine", "severity": "Major", "effect": "Coadministration of valbenazine with monoamine oxidase inhibitors (MAOIs) may increase the risk of adverse effects such as serotonin syndrome or reduce the therapeutic effects of valbenazine. The mechanism for this interaction has not been delineated; however, concomitant use of these drugs may increase the concentration of monoamine neurotransmitters in synapses.", "source": "DDInter", "management_text": "The use of valbenazine with MAOIs should generally be avoided. If concomitant use is required, caution and close clinical and laboratory monitoring are recommended. Alternative treatment may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The use of valbenazine with MAOIs should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120008/", "reference_text": "[1] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[21] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Pitolisant, Tafamidis", "updated_at": 1767369485}, {"id": 119871, "ingredient1": "Isocarboxazid", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120009/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 119872, "ingredient1": "Isocarboxazid", "ingredient2": "Venlafaxine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120010/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Isocarboxazid", "alternatives_b": "Esketamine, Venlafaxine", "updated_at": 1767369485}, {"id": 119873, "ingredient1": "Isocarboxazid", "ingredient2": "Vigabatrin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120011/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 119874, "ingredient1": "Isocarboxazid", "ingredient2": "Vilazodone", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents.", "mechanism_text": "Synergism", "recommendation": "In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120012/", "reference_text": "[1] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[4] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[7] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[8] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[9] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[10] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[12] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[13] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[14] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[15] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[16] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[19] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[20] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[21] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[26] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[27] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[28] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[29] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[30] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[33] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[34] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[35] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[36] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[37] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[38] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[41] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[42] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[45] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[48] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[49] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[50] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[51] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[52] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[53] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[54] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[55] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[56] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[58] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[59] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[60] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[61] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[62] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[63] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[64] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[67] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[68] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[69] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[70] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[71] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[72] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[73] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[74] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Vilazodone, Esketamine", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119875, "ingredient1": "Isocarboxazid", "ingredient2": "Vortioxetine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120013/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine, Vortioxetine, Esketamine", "alternatives_b": "Isocarboxazid", "updated_at": 1767369485}, {"id": 119876, "ingredient1": "Isocarboxazid", "ingredient2": "Xylometazoline (nasal)", "severity": "Moderate", "effect": "By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).", "source": "DDInter", "management_text": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120014/", "reference_text": "[1] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[2] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[3] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[5] Fenwick MJ, Muwanga CL \"Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.\" J Accid Emerg Med 17 (2000): 143-4[6] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[9] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[10] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[11] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[12] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[13] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[14] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[15] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[16] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[17] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[19] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[20] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[21] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[22] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[23] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[24] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[25] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[26] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[27] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[28] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[29] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[30] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[31] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[32] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[33] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[34] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Trazodone, Tryptophan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119877, "ingredient1": "Isocarboxazid", "ingredient2": "Yohimbine", "severity": "Moderate", "effect": "Theoretically, yohimbine may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Yohimbine has been shown to induce the release of norepinephrine in patients with essential hypertension. This action could produce a synergistic sympathomimetic effect with MAOIs, which enhance norepinephrine storage in adrenergic neurons.", "source": "DDInter", "management_text": "While clinical data are lacking, yohimbine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with yohimbine.", "mechanism_text": "Others", "recommendation": "While clinical data are lacking, yohimbine should preferably not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120015/", "reference_text": "[1] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[5] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[6] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[7] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[8] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[9] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[10] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[11] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[12] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[13] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[14] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[15] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[16] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[17] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[18] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[19] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[20] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Phenyl salicylate, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 119878, "ingredient1": "Isocarboxazid", "ingredient2": "Zaleplon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120016/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 119879, "ingredient1": "Isocarboxazid", "ingredient2": "Ziconotide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120017/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 119880, "ingredient1": "Isocarboxazid", "ingredient2": "Ziprasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120018/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "updated_at": 1767369485}, {"id": 119881, "ingredient1": "Isocarboxazid", "ingredient2": "Zolmitriptan", "severity": "Major", "effect": "Monoamine oxidase inhibitors (MAOIs) may significantly elevate the plasma concentrations of certain 5-HT1 receptor agonists (namely rizatriptan, sumatriptan, and zolmitriptan) and their active metabolites by inhibiting their metabolic clearance via monoamine oxidase, subtype A. Clinically, this interaction may increase the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, associated with the use of 5-HT1 receptor agonists.", "source": "DDInter", "management_text": "Concomitant use of rizatriptan, sumatriptan, or zolmitriptan with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with 5-HT1 receptor agonists. If concurrent therapy is necessary, almotriptan, frovatriptan and naratriptan may be preferred due to the lack of a significant pharmacokinetic interaction with MAOIs. However, patients should be closely monitored for adverse effects related to excessive serotonergic activity.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of rizatriptan, sumatriptan, or zolmitriptan with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120019/", "reference_text": "[1] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[2] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Fleishaker JC, Ryan KK, Jansat JM, et al. \"Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.\" Br J Clin Pharmacol 51 (2001): 437-41[6] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[7] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[10] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[11] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[12] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[13] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[33] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[35] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Esketamine", "updated_at": 1767369485}, {"id": 119882, "ingredient1": "Isocarboxazid", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120020/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 119883, "ingredient1": "Isocarboxazid", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120021/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Oxitriptan, Tryptophan", "updated_at": 1767369485}, {"id": 119884, "ingredient1": "Isoflurane", "ingredient2": "Amoxapine", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120022/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 119885, "ingredient1": "Isoflurane", "ingredient2": "Atracurium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120023/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119886, "ingredient1": "Isoflurane", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.", "source": "DDInter", "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120024/", "reference_text": "[1] \"Product Information. Cardizem (diltiazem).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Hantler CB, Wilton N, Learned DM, et al \"Impaired myocardial conduction in patients receiving diltiazem therapy during enflurane anesthesia.\" Anesthesiology 67 (1987): 94-6[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Thiopental, Nitrous oxide, Methohexital, Esketamine, Etomidate, Ketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119887, "ingredient1": "Isoflurane", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "Rauwolfia alkaloids may accentuate the hypotensive effects of general anesthetics by depleting catecholamine neurotransmitters.", "source": "DDInter", "management_text": "Patients should be closely monitored. If profound hypotension occurs, a direct-acting sympathomimetic agent, such as dobutamine or epinephrine, may be required.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120025/", "reference_text": "[1] Jahr JS, Weber S \"Ventricular dysrhythmias following an alfentanil anesthetic in a patient on reserpine for hypertension.\" Acta Anaesthesiol Scand 35 (1991): 788-9[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961): 114-7", "alternatives_a": "Alfentanil, Remifentanil, Fentanyl, Sufentanil, Esketamine, Sevoflurane", "alternatives_b": "Prazosin, Guanethidine, Hydralazine, Guanfacine", "updated_at": 1767369485}, {"id": 119888, "ingredient1": "Isoflurane", "ingredient2": "Dezocine", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120026/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 119889, "ingredient1": "Isoflurane", "ingredient2": "Doxacurium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120027/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119890, "ingredient1": "Isoflurane", "ingredient2": "Estazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120028/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Etomidate, Nitrous oxide", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 119891, "ingredient1": "Isoflurane", "ingredient2": "Felodipine", "severity": "Moderate", "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.", "source": "DDInter", "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120029/", "reference_text": "[1] \"Product Information. Cardizem (diltiazem).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Hantler CB, Wilton N, Learned DM, et al \"Impaired myocardial conduction in patients receiving diltiazem therapy during enflurane anesthesia.\" Anesthesiology 67 (1987): 94-6[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Thiopental, Remifentanil, Nitrous oxide, Methohexital, Esketamine, Etomidate, Ketamine", "alternatives_b": "Propranolol, Carvedilol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Atenolol, Clevidipine, Celecoxib, Moexipril, Perindopril, More", "updated_at": 1767369485}, {"id": 119892, "ingredient1": "Isoflurane", "ingredient2": "Flurazepam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120030/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "alternatives_b": "Etomidate, Thiopental, Nitrous oxide", "updated_at": 1767369485}, {"id": 119893, "ingredient1": "Isoflurane", "ingredient2": "Fospropofol", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120031/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992): 240-5[2] \"Product Information. Lusedra (fospropofol).\" Eisai Inc, Teaneck, NJ.[3] \"Product Information. Diprivan (propofol).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] Pavlin DJ, Coda B, Shen DD, et al \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996): 23-37[5] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990): 760-5[6] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999): 110-7", "alternatives_a": "Propofol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119894, "ingredient1": "Isoflurane", "ingredient2": "Halazepam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120032/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Etomidate, Nitrous oxide", "alternatives_b": "Meprobamate, Buspirone", "updated_at": 1767369485}, {"id": 119895, "ingredient1": "Isoflurane", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120033/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 119896, "ingredient1": "Isoflurane", "ingredient2": "Hydromorphone", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120034/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119897, "ingredient1": "Isoflurane", "ingredient2": "Imipramine", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120035/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 119898, "ingredient1": "Isoflurane", "ingredient2": "Isoniazid", "severity": "Moderate", "effect": "Nephrotoxic concentrations of inorganic fluoride may occur in patients receiving enflurane anesthesia while on isoniazid therapy. A similar effect has been noted for isoflurane, in vitro. The isoniazid metabolite, hydrazine, facilitates defluorination of the anesthetic . Hydrazine concentrations are highest in fast acetylators of isoniazid.", "source": "DDInter", "management_text": "Renal function should be monitored postsurgically, especially in fast acetylators of isoniazid.", "mechanism_text": "Synergism", "recommendation": "Renal function should be monitored postsurgically, especially in fast acetylators of isoniazid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120036/", "reference_text": "[1] Dale O, Brown BR \"Clinical pharmacokinetics of the inhalational anaesthetics.\" Clin Pharmacokinet 12 (1987): 145-67[2] Gauntlett IS, Koblin DD, Fahey MR, et al. \"Metabolism of isoflurane in patients receiving isoniazid.\" Anesth Analg 69 (1989): 245-9[3] Mazze RI, Woodruff RE, Heerdt ME \"Isoniazid-induced enflurane defluorination in humans.\" Anesthesiology 57 (1982): 5-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Self TH, Chrisman CR, Baciewicz AM, Bronze MS \"Isoniazid drug and food interactions.\" Am J Med Sci 317 (1999): 304-11[6] Uragoda CG, Kottegoda SR \"Adverse reactions to isoniazid on ingestion of fish with a high histamine content.\" Tubercle 58 (1977): 83-9[7] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[8] Smith CK, Durack DT \"Isoniazid and reaction to cheese.\" Ann Intern Med 88 (1978): 520-1[9] Dimartini A \"Isoniazid, tricyclics and the ''cheese reaction''.\" Int Clin Psychopharmacol 10 (1995): 197-8", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Propofol, Esketamine, Sevoflurane, Etomidate, Ketamine", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, More", "updated_at": 1767369485}, {"id": 119899, "ingredient1": "Isoflurane", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.", "source": "DDInter", "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120037/", "reference_text": "[1] \"Product Information. Cardizem (diltiazem).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Hantler CB, Wilton N, Learned DM, et al \"Impaired myocardial conduction in patients receiving diltiazem therapy during enflurane anesthesia.\" Anesthesiology 67 (1987): 94-6[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine", "alternatives_b": "Clevidipine, Celecoxib", "updated_at": 1767369485}, {"id": 119900, "ingredient1": "Isoflurane", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120038/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 119901, "ingredient1": "Isoflurane", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120039/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119902, "ingredient1": "Isoflurane", "ingredient2": "Lorazepam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120040/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone", "alternatives_b": "Thiopental, Nitrous oxide", "updated_at": 1767369485}, {"id": 119903, "ingredient1": "Isoflurane", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120041/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "alternatives_b": "Etomidate", "updated_at": 1767369485}, {"id": 119904, "ingredient1": "Isoflurane", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120042/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119905, "ingredient1": "Isoflurane", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120043/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "alternatives_b": "Nitrous oxide", "updated_at": 1767369485}, {"id": 119906, "ingredient1": "Isoflurane", "ingredient2": "Mivacurium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120044/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119907, "ingredient1": "Isoflurane", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120045/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 119908, "ingredient1": "Isoflurane", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "There are no data on the safety of administering general anesthetics to patients concurrently on nefazodone.", "source": "DDInter", "management_text": "The manufacturer recommends discontinuing nefazodone for as long as possible before elective surgery.", "mechanism_text": "Others", "recommendation": "The manufacturer recommends discontinuing nefazodone for as long as possible before elective surgery.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120046/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiopental, Propofol", "alternatives_b": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "updated_at": 1767369485}, {"id": 119909, "ingredient1": "Isoflurane", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.", "source": "DDInter", "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120047/", "reference_text": "[1] \"Product Information. Cardizem (diltiazem).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Hantler CB, Wilton N, Learned DM, et al \"Impaired myocardial conduction in patients receiving diltiazem therapy during enflurane anesthesia.\" Anesthesiology 67 (1987): 94-6[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "Remifentanil, Nitrous oxide, Esketamine, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 119910, "ingredient1": "Isoflurane", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.", "source": "DDInter", "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120048/", "reference_text": "[1] \"Product Information. Cardizem (diltiazem).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Hantler CB, Wilton N, Learned DM, et al \"Impaired myocardial conduction in patients receiving diltiazem therapy during enflurane anesthesia.\" Anesthesiology 67 (1987): 94-6[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "Esketamine, Etomidate, Ketamine, Nitrous oxide", "updated_at": 1767369485}, {"id": 119911, "ingredient1": "Isoflurane", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.", "source": "DDInter", "management_text": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120049/", "reference_text": "[1] \"Product Information. Cardizem (diltiazem).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Hantler CB, Wilton N, Learned DM, et al \"Impaired myocardial conduction in patients receiving diltiazem therapy during enflurane anesthesia.\" Anesthesiology 67 (1987): 94-6[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "Remifentanil, Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 119912, "ingredient1": "Isoflurane", "ingredient2": "Nitrous oxide", "severity": "Minor", "effect": "Coadministration of 70% nitrous oxide reduces the dosage requirements for halogenated inhalation anesthetics. Minimum alveolar concentration (MAC) values can be reduced from 0.75% to 0.29% for halothane, from 1.68% to 0.6% for enflurane, and from 1.15% to 0.5% for isoflurane. The MAC equivalent dose for sevoflurane is reduced by approximately 50% in the presence of 50% nitrous oxide.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120050/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Thiopental, Nitrous oxide, Methohexital, Etomidate, Ketamine", "alternatives_b": "Thiopental, Isoflurane, Methohexital, Desflurane, Enflurane, Halothane, Ketamine", "updated_at": 1767369485}, {"id": 119913, "ingredient1": "Isoflurane", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient's hemodynamic status should be closely monitored.", "mechanism_text": "Others", "recommendation": "This combination should be avoided or used very cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120051/", "reference_text": "[1] Cooke JE \"Drug interactions in anesthesia.\" Clin Plast Surg 12 (1985): 83-9[2] Smith RB \"Drug interactions and drug reactions.\" Otolaryngol Clin North Am 14 (1981): 615-29[3] \"Product Information. Fluothane (halothane).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Kainuma M, Suzuki A \"Convulsions after adrenaline administration during enflurane anaesthesia.\" Anaesthesia 41 (1986): 874-5[5] Horrigan RW, Eger EI, Wilson C \"Epinephrine-induced arrhythmias during enflurane anesthesia in man: a nonlinear dose-response relationship and dose-dependent protection from lidocaine.\" Anesth Analg 57 (1978): 547-50[6] Gold MI \"Profound hypotension associated with preoperative use of phenothiazines.\" Anesth Analg 53 (1974): 844-8[7] Mostello L, Stueber K, Lake CR \"Is topical application of epinephrine at skin graft donor sites during halothane anesthesia safe?\" Ann Plast Surg 20 (1988): 313-6[8] Johnston RR, Eger EI II, Wilson C \"A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.\" Anesth Analg 55 (1976): 709-12[9] Reisner LS, Lippmann M \"Ventricular arrhythmias after epinephrine injection in enflurane and in halothane anesthesia.\" Anesth Analg 54 (1975): 468-70[10] Cullen BF, Miller MG \"Drug interactions and anesthesia: a review.\" Anesth Analg 58 (1979): 413-23[11] Hirshom WI, Taylor RG, Sheehan JC \"Arrhythmias produced by combinations of halothane and small amounts of vasopressor.\" Br J Oral Surg 2 (1964): 131-6[12] Pepple J \"Epinephrine-halothane interaction in children versus adults.\" Anesthesiology 60 (1984): 76-8[13] Bennett JA, Eltringham RJ \"Possible dangers of anaesthesia in patients receiving fenfluramine. Results of animal studies following a case of human cardiac arrest.\" Anaesthesia 32 (1977): 8-13[14] Ueda W, Hirakawa M, Mae O \"Appraisal of epinephrine administration to patients under halothane anesthesia for closure of cleft palate.\" Anesthesiology 58 (1983): 574-6[15] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Konchigeri HN, Shaker MH, Winnie AP \"Effect of epinephrine during enflurane anesthesia.\" Anesth Analg 53 (1974): 894-7[17] Forbes AM \"Halothane, adrenaline and cardiac arrest.\" Anaesthesia 21 (1966): 22-7[18] Karl HW, Swedlow DB, Lee KW, Downes JJ \"Epinephrine-halothane interactions in children.\" Anesthesiology 58 (1983): 142-5[19] Snow JC, Shamsai J, Sakarya I \"Effects of epinephrine during halothane anesthesia in mastoidotympanoplastic surgery.\" Anesth Analg 47 (1968): 252-6[20] Reisner LS, Lippmann M \"Further data on epinephrine interactions.\" Anesth Analg 56 (1977): 468[21] Ghoneim MM \"Drug interaction in anaesthesia. A review.\" Can Anaesth Soc J 18 (1971): 353-75", "alternatives_a": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate", "updated_at": 1767369485}, {"id": 119914, "ingredient1": "Isoflurane", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120052/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 119915, "ingredient1": "Isoflurane", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120053/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 119916, "ingredient1": "Isoflurane", "ingredient2": "Opium", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120054/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate, Thiopental, Methohexital", "alternatives_b": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Celecoxib, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 119917, "ingredient1": "Isoflurane", "ingredient2": "Oxazepam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120055/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Etomidate, Thiopental, Nitrous oxide", "alternatives_b": "Meprobamate, Buspirone", "updated_at": 1767369485}, {"id": 119918, "ingredient1": "Isoflurane", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120056/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Etomidate", "alternatives_b": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 119919, "ingredient1": "Isoflurane", "ingredient2": "Pancuronium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120057/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Esketamine, Sodium oxybate, Thiopental, Methohexital", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119920, "ingredient1": "Isoflurane", "ingredient2": "Phenelzine", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120058/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119921, "ingredient1": "Isoflurane", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120059/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119922, "ingredient1": "Isoflurane", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120060/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 119923, "ingredient1": "Isoflurane", "ingredient2": "Quazepam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120061/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Etomidate, Nitrous oxide", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 119924, "ingredient1": "Isoflurane", "ingredient2": "Rapacuronium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120062/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119925, "ingredient1": "Isoflurane", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120063/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997): 100-5[3] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Remifentanil, Etomidate", "alternatives_b": "Thiopental, Isoflurane, Methohexital, Desflurane, Enflurane, Halothane, Ketamine", "updated_at": 1767369485}, {"id": 119926, "ingredient1": "Isoflurane", "ingredient2": "Remimazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120064/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Etomidate, Nitrous oxide", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 119927, "ingredient1": "Isoflurane", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Rauwolfia alkaloids may accentuate the hypotensive effects of general anesthetics by depleting catecholamine neurotransmitters.", "source": "DDInter", "management_text": "Patients should be closely monitored. If profound hypotension occurs, a direct-acting sympathomimetic agent, such as dobutamine or epinephrine, may be required.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120065/", "reference_text": "[1] Jahr JS, Weber S \"Ventricular dysrhythmias following an alfentanil anesthetic in a patient on reserpine for hypertension.\" Acta Anaesthesiol Scand 35 (1991): 788-9[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961): 114-7", "alternatives_a": "Prazosin, Guanethidine, Hydralazine, Guanfacine", "alternatives_b": "Esketamine, Sevoflurane", "updated_at": 1767369485}, {"id": 119928, "ingredient1": "Isoflurane", "ingredient2": "Rocuronium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120066/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "Esketamine, Sodium oxybate, Thiopental, Methohexital", "updated_at": 1767369485}, {"id": 119929, "ingredient1": "Isoflurane", "ingredient2": "Selegiline", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120067/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sodium oxybate", "alternatives_b": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More", "updated_at": 1767369485}, {"id": 119930, "ingredient1": "Isoflurane", "ingredient2": "Temazepam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120068/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "alternatives_b": "Thiopental, Nitrous oxide", "updated_at": 1767369485}, {"id": 119931, "ingredient1": "Isoflurane", "ingredient2": "Tranylcypromine", "severity": "Major", "effect": "Anecdotal reports have implicated the concomitant use of general anesthesia and nonselective monoamine oxidase inhibitors (MAOIs) as causing hypotension or hypertension. Analysis of these cases suggests that other contributing factors may have been involved (e.g., meperidine and sympathomimetic agents).", "source": "DDInter", "management_text": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "mechanism_text": "Others", "recommendation": "The makers of MAOIs, both selective and nonselective, consider general anesthesia to be contraindicated in patients treated with MAOIs and recommend discontinuing MAOI therapy 10 to 14 days before elective surgery.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120069/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[3] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[9] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[10] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[13] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[14] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[15] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[16] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[17] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[18] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[19] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[20] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[21] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[22] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[23] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[24] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119932, "ingredient1": "Isoflurane", "ingredient2": "Triazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120070/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Etomidate, Nitrous oxide", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 119933, "ingredient1": "Isoflurane", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120071/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Oxitriptan, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 119934, "ingredient1": "Isoflurane", "ingredient2": "Tubocurarine", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120072/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Methohexital, Propofol, Esketamine, Etomidate", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119935, "ingredient1": "Isoflurane", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120073/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Esketamine, Sodium oxybate, Thiopental, Methohexital", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 119936, "ingredient1": "Isoprenaline", "ingredient2": "Abarelix", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120074/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119937, "ingredient1": "Isoprenaline", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120075/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine, Umeclidinium, More", "updated_at": 1767369485}, {"id": 119938, "ingredient1": "Isoprenaline", "ingredient2": "Aminophylline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120076/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Droxidopa, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 119939, "ingredient1": "Isoprenaline", "ingredient2": "Amoxapine", "severity": "Moderate", "effect": "The concomitant use of isoproterenol and tricyclic antidepressants may increase the risk of arrhythmias, especially at high doses. The mechanism has not been delineated. Tachycardia has been reported in clinical studies.", "source": "DDInter", "management_text": "Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias. Patients receiving this combination should be monitored and advised to notify their physician if they experience a fast or irregular pulse.", "mechanism_text": "Synergism", "recommendation": "Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120077/", "reference_text": "[1] Kadar D \"Letter: Amitriptyline and isoproterenol: fatal drug combination.\" Can Med Assoc J 112 (1975): 556-7[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine, Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 119940, "ingredient1": "Isoprenaline", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120078/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119941, "ingredient1": "Isoprenaline", "ingredient2": "Bedaquiline", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120079/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More", "updated_at": 1767369485}, {"id": 119942, "ingredient1": "Isoprenaline", "ingredient2": "Bepridil", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120080/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119943, "ingredient1": "Isoprenaline", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.", "source": "DDInter", "management_text": "This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.", "mechanism_text": "Antagonism", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120081/", "reference_text": "[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR \"The effect of propranolol on catecholamine clearance.\" Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A \"Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.\" Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC \"Isoproterenol-induced bradyarrhythmias.\" Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[7] Vlay SC \"Catecholamine-sensitive ventricular tachycardia.\" Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J \"Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man.\" Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ \"Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report.\" J Electrocardiol 24 (1991): 191-5", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine, Mometasone furoate, Umeclidinium, Aclidinium, More", "updated_at": 1767369485}, {"id": 119944, "ingredient1": "Isoprenaline", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120082/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More", "updated_at": 1767369485}, {"id": 119945, "ingredient1": "Isoprenaline", "ingredient2": "Cisapride", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120083/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Metoclopramide", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119946, "ingredient1": "Isoprenaline", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120084/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine, Formoterol, Cromoglicic acid, Ipratropium, More", "alternatives_b": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine, Methyldopa", "updated_at": 1767369485}, {"id": 119947, "ingredient1": "Isoprenaline", "ingredient2": "Digitoxin", "severity": "Moderate", "effect": "The concomitant use of sympathomimetic agents and cardiac glycosides may increase the risk of cardiac arrhythmias. The mechanism of this interaction is not known. Increased ectopic pacemaker activity has been reported to occur in patients taking digoxin in combination with pseudoephedrine.", "source": "DDInter", "management_text": "Caution should be exercised if these two drugs are coadministered. Electrocardiogram monitoring (ECG) is recommended. The use of epinephrine (adrenaline) with high doses of digitalis glycosides is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution should be exercised if these two drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120085/", "reference_text": "[1] \"Product Information. Claritin-D (loratadine-pseudoephedrine).\" Schering-Plough, Liberty Corner, NJ.[2] \"Product Information. Epinephrine Hydrochloride Injection (epinephrine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Lanoxin (digoxin).\" Glaxo Wellcome, Research Triangle Park, NC.[4] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Allegra-D (fexofenadine-pseudoephedrine).\" Chattem Consumer Products, Chattanooga, TN.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[9] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[10] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine, Formoterol, Cromoglicic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119948, "ingredient1": "Isoprenaline", "ingredient2": "Dobutamine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120086/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Angiotensin II, Ephedrine, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Dopamine, Methoxamine, More", "updated_at": 1767369485}, {"id": 119949, "ingredient1": "Isoprenaline", "ingredient2": "Doxorubicin (liposomal)", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120087/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119950, "ingredient1": "Isoprenaline", "ingredient2": "Entacapone", "severity": "Moderate", "effect": "COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.", "source": "DDInter", "management_text": "The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that caution be exercised when these drugs are given together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120088/", "reference_text": "[1] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A \"The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.\" Clin Pharmacol Ther 58 (1995): 221-7[4] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, More", "updated_at": 1767369485}, {"id": 119951, "ingredient1": "Isoprenaline", "ingredient2": "Entrectinib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120089/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 119952, "ingredient1": "Isoprenaline", "ingredient2": "Enzalutamide", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120090/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "updated_at": 1767369485}, {"id": 119953, "ingredient1": "Isoprenaline", "ingredient2": "Ephedrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120091/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 119954, "ingredient1": "Isoprenaline", "ingredient2": "Ephedrine (nasal)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120092/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 119955, "ingredient1": "Isoprenaline", "ingredient2": "Epinephrine (ophthalmic)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120093/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Mometasone furoate, More", "alternatives_b": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "updated_at": 1767369485}, {"id": 119956, "ingredient1": "Isoprenaline", "ingredient2": "Epinephrine (topical)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120094/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Acetylsalicylic acid, Chlorhexidine, Neomycin, Mometasone furoate, More", "alternatives_b": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "updated_at": 1767369485}, {"id": 119957, "ingredient1": "Isoprenaline", "ingredient2": "Epirubicin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120095/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119958, "ingredient1": "Isoprenaline", "ingredient2": "Eribulin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120096/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 119959, "ingredient1": "Isoprenaline", "ingredient2": "Ertugliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120097/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 119960, "ingredient1": "Isoprenaline", "ingredient2": "Escitalopram", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120098/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 119961, "ingredient1": "Isoprenaline", "ingredient2": "Esmolol", "severity": "Moderate", "effect": "Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.", "source": "DDInter", "management_text": "This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.", "mechanism_text": "Antagonism", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120099/", "reference_text": "[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR \"The effect of propranolol on catecholamine clearance.\" Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A \"Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.\" Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC \"Isoproterenol-induced bradyarrhythmias.\" Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[7] Vlay SC \"Catecholamine-sensitive ventricular tachycardia.\" Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J \"Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man.\" Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ \"Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report.\" J Electrocardiol 24 (1991): 191-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119962, "ingredient1": "Isoprenaline", "ingredient2": "Exenatide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120100/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 119963, "ingredient1": "Isoprenaline", "ingredient2": "Ezogabine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120101/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 119964, "ingredient1": "Isoprenaline", "ingredient2": "Fenfluramine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120102/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Dexfenfluramine, Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, More", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "updated_at": 1767369485}, {"id": 119965, "ingredient1": "Isoprenaline", "ingredient2": "Fingolimod", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120103/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 119966, "ingredient1": "Isoprenaline", "ingredient2": "Flecainide", "severity": "Moderate", "effect": "Flecainide suppression of anterograde conduction through an accessory AV pathway was reversed after an isoproterenol infusion, according to one case report. The proposed mechanism is counteractive pharmacologic effects on the AV-conductive tissue. Patients who have underlying arrhythmias may suffer recurrent or new arrhythmias when isoproterenol is added to their medical regimens, even if antiarrhythmic therapy was previously adequate.", "source": "DDInter", "management_text": "Patients should be monitored for altered antiarrhythmic efficacy during concurrent administration.", "mechanism_text": "Antagonism", "recommendation": "Patients should be monitored for altered antiarrhythmic efficacy during concurrent administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120104/", "reference_text": "[1] Brembilla-Perrot B, Admant P, Le Helloco A, Pernot C \"Loss of efficacy of flecainide in the Wolff-Parkinson-White syndrome after isoproterenol administration.\" Eur Heart J 6 (1985): 1074-8", "alternatives_a": "Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine", "updated_at": 1767369485}, {"id": 119967, "ingredient1": "Isoprenaline", "ingredient2": "Fluconazole", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120105/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, More", "alternatives_b": "Droxidopa, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "updated_at": 1767369485}, {"id": 119968, "ingredient1": "Isoprenaline", "ingredient2": "Fludrocortisone", "severity": "Minor", "effect": "Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120106/", "reference_text": "[1] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac, Deflazacort", "alternatives_b": "Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Epinephrine, More", "updated_at": 1767369485}, {"id": 119969, "ingredient1": "Isoprenaline", "ingredient2": "Fluphenazine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120107/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More", "updated_at": 1767369485}, {"id": 119970, "ingredient1": "Isoprenaline", "ingredient2": "Flutamide", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120108/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119971, "ingredient1": "Isoprenaline", "ingredient2": "Fluticasone", "severity": "Minor", "effect": "Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120109/", "reference_text": "[1] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Droxidopa, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Tiotropium, Mometasone furoate, Amcinonide, More", "updated_at": 1767369485}, {"id": 119972, "ingredient1": "Isoprenaline", "ingredient2": "Foscarnet", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120110/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119973, "ingredient1": "Isoprenaline", "ingredient2": "Fostemsavir", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120111/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 119974, "ingredient1": "Isoprenaline", "ingredient2": "Gatifloxacin", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120112/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119975, "ingredient1": "Isoprenaline", "ingredient2": "Gemifloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120113/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 119976, "ingredient1": "Isoprenaline", "ingredient2": "Gilteritinib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120114/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 119977, "ingredient1": "Isoprenaline", "ingredient2": "Glasdegib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120115/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 119978, "ingredient1": "Isoprenaline", "ingredient2": "Glipizide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120116/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 119979, "ingredient1": "Isoprenaline", "ingredient2": "Glyburide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120117/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More", "updated_at": 1767369485}, {"id": 119980, "ingredient1": "Isoprenaline", "ingredient2": "Goserelin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120118/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119981, "ingredient1": "Isoprenaline", "ingredient2": "Granisetron", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120119/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119982, "ingredient1": "Isoprenaline", "ingredient2": "Grepafloxacin", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120120/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119983, "ingredient1": "Isoprenaline", "ingredient2": "Guanadrel", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120121/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Formoterol, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Terbutaline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119984, "ingredient1": "Isoprenaline", "ingredient2": "Guanethidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120122/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Formoterol, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Terbutaline, More", "alternatives_b": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "updated_at": 1767369485}, {"id": 119985, "ingredient1": "Isoprenaline", "ingredient2": "Halofantrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120123/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 119986, "ingredient1": "Isoprenaline", "ingredient2": "Haloperidol", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120124/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More", "updated_at": 1767369485}, {"id": 119987, "ingredient1": "Isoprenaline", "ingredient2": "Halothane", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120125/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Dopamine, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More", "updated_at": 1767369485}, {"id": 119988, "ingredient1": "Isoprenaline", "ingredient2": "Histrelin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120126/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 119989, "ingredient1": "Isoprenaline", "ingredient2": "Hydroxyamphetamine (ophthalmic)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120127/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119990, "ingredient1": "Isoprenaline", "ingredient2": "Hydroxychloroquine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120128/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 119991, "ingredient1": "Isoprenaline", "ingredient2": "Hydroxyzine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120129/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More", "updated_at": 1767369485}, {"id": 119992, "ingredient1": "Isoprenaline", "ingredient2": "Ibutilide", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120130/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "updated_at": 1767369485}, {"id": 119993, "ingredient1": "Isoprenaline", "ingredient2": "Idarubicin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120131/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 119994, "ingredient1": "Isoprenaline", "ingredient2": "Iloperidone", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120132/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 119995, "ingredient1": "Isoprenaline", "ingredient2": "Imipramine", "severity": "Moderate", "effect": "The concomitant use of isoproterenol and tricyclic antidepressants may increase the risk of arrhythmias, especially at high doses. The mechanism has not been delineated. Tachycardia has been reported in clinical studies.", "source": "DDInter", "management_text": "Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias. Patients receiving this combination should be monitored and advised to notify their physician if they experience a fast or irregular pulse.", "mechanism_text": "Synergism", "recommendation": "Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120133/", "reference_text": "[1] Kadar D \"Letter: Amitriptyline and isoproterenol: fatal drug combination.\" Can Med Assoc J 112 (1975): 556-7[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Fenoldopam, Mephentermine, Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 119996, "ingredient1": "Isoprenaline", "ingredient2": "Indacaterol", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120134/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium", "updated_at": 1767369485}, {"id": 119997, "ingredient1": "Isoprenaline", "ingredient2": "Insulin human", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120135/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119998, "ingredient1": "Isoprenaline", "ingredient2": "Insulin aspart (aspart protamine)", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120136/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 119999, "ingredient1": "Isoprenaline", "ingredient2": "Insulin lispro", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120137/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 120000, "ingredient1": "Isoprenaline", "ingredient2": "Insulin lispro (protamine)", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/120138/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More", "alternatives_b": "", "updated_at": 1767369485}]